Heteroaromatic derivative regulators, their preparation methods and applications

Abstract

The present invention relates to modulators of heteroaryl derivatives, their preparation methods and uses. In particular, the present invention relates to compounds of general formula (I), their preparation methods and pharmaceutical compositions containing the compounds, and their use as Janus kinase inhibitors in the treatment of inflammation-related diseases and tumor-related diseases, wherein each substituent in general formula (VIII) is the same as defined in the specification.

Description

Technical Field

[0001] The present invention belongs to the field of drug synthesis, and particularly relates to a JAK inhibitor, a preparation method thereof, and an application thereof. Background Art

[0002] Janus kinase (JAK) is an intracellular non-receptor tyrosine kinase that mediates the signal transduction and activation of various cytokines. The JAK kinase family contains four subfamily members, namely JAK1, JAK2, JAK3, and TYK2. Each subfamily member mediates different types of cytokine signal pathways. JAK1, JAK2, and TYK2 are expressed in various tissue cells of the human body, and JAK3 is mainly expressed in various hematopoietic tissue cells. The common feature of cytokine receptors is that the receptor itself does not have kinase activity, but the intracellular segment of the receptor has a binding site for tyrosine kinase JAK. When a cytokine receptor binds to its ligand, the JAKs coupled to the receptor are activated, and then the receptor is phosphorylated. The phosphorylated tyrosine site can bind to the STAT protein containing an SH2 domain, so that STAT is recruited to the receptor and phosphorylated by JAKs. Subsequently, phosphotyrosine mediates the dimerization of STAT, and the activated STAT dimer transfers to the nucleus and activates the transcription of its target genes, thereby regulating various functions such as the growth, activation, and differentiation of various cells.

[0003] The JAK / STAT signaling pathway mediates the signal transduction of most cytokines in cells and plays a key role in biological processes such as immune regulation and immune cell proliferation. The JAK / STAT signaling pathway has a wide range of functions and is involved in many important biological processes such as cell proliferation, differentiation, apoptosis, and immune regulation, and is closely related to various inflammatory diseases such as rheumatoid arthritis, dermatitis, psoriasis, and inflammatory bowel disease (ulcerative colitis and Crohn's disease); at the same time, the JAK / STAT signaling pathway is closely related to neoplastic diseases such as myelofibrosis, polycythemia vera, and essential thrombocythemia. Mutations in the JAK molecule itself can also lead to neoplastic diseases such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), ductal carcinoma of the breast, and non-small cell lung cancer (NSCLC).

[0004] Inflammatory bowel disease is a chronic intestinal inflammatory disease, including ulcerative colitis (UC) and Crohn's disease (CD). Currently, the drugs for treating inflammatory bowel disease mainly include aminosalicylate preparations, glucocorticoids, immunosuppressants, antibiotics, etc. The treatment of UC mainly follows the principles of regulating immune response and inhibiting inflammation. Currently, in clinical practice, sulfasalazine is mainly used to treat mild to moderate UC. For moderate to severe UC, commonly used drugs currently include glucocorticoids, but because the risks are greater than the benefits, they are not used as long-term treatment methods. Monoclonal antibodies have problems such as high drug costs, generation of drug antibodies affecting drug safety and effectiveness, and inconvenient intravenous administration methods. There is still a far unmet medical need in this field. Many treated patients have not achieved remission, and up to 80% of Crohn's disease patients and 30% of UC patients ultimately need to undergo surgery.

[0005] Tofacitinib (Xeljanz) is the first oral JAK inhibitor for treating adult patients with moderate to severe active UC. It has significant inhibitory activity against JAK1, 2, and 3 subtypes, which increases the efficacy of tofacitinib but also brings relatively serious side effects. Adverse reactions include infections, tuberculosis, tumors, anemia, liver damage, and increased cholesterol, etc. There are many black box warnings in the tofacitinib instruction manual: severe infections (pulmonary tuberculosis, bacteria, fungi, viruses) and malignancies (lymphoma, etc.). Due to the wide range of functions mediated by each JAK, these side effects are caused by the drug simultaneously inhibiting multiple JAKs. Since JAK is widely involved in the regulation of immune cells, JAK inhibitors will inevitably cause side effects related to immunosuppression, such as severe infections and even the occurrence of tumors. Even among the many highly selective inhibitors currently under research, this kind of side effect caused by inhibiting the target cannot be avoided.

[0006] Given the good efficacy of JAK inhibitors and the serious side effects related to multiple targets, developing a JAK inhibitor drug with higher safety has become an urgent problem to be solved currently. Since inflammatory bowel disease occurs on the luminal surface of the gastrointestinal tract and the drug can play a role without entering the blood system, developing a drug that reduces the systemic exposure of the drug in the blood circulation and increases the local exposure of the drug at the inflammatory site has become a good strategy to improve safety. International application WO2016191524A1 reported that Theravance synthesized a series of compounds. These compounds have extremely low systemic exposure and form enrichment at the intestinal inflammatory site, which can effectively treat intestinal inflammation without causing serious side effects, indicating that this strategy has great feasibility and may have significant clinical application value. Summary of the Invention

[0007] The technical problem to be solved by the present invention is to overcome the defect that existing JAK inhibitors have serious side effects while exerting therapeutic effects, and to provide a heteroaryl derivative regulator, a preparation method and an application thereof. The heteroaryl derivative of the present invention has a good inhibitory effect on JAK kinase, can significantly increase the local exposure amount at the treatment site, and has good targeting properties.

[0008] The present invention solves the above technical problems through the following technical solutions.

[0009] A compound represented by the general formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof:

[0010]

[0011] Wherein:

[0012] L 1 is selected from a bond, an alkylene group, an alkenylene group, an alkynyl group, a cycloalkyl group, a heterocyclic group, -(CH 2 ) n1 C(O)(CH 2 ) m1 -, -(CH 2 ) n1 C(O)(CH 2 ) m1 NR aa (CH 2 ) m2 -, -NR aa (CH 2 ) n1 -, -(CH 2 ) n1 S(O) m1 -, or -(CH 2 ) n1 S(O) m1 NR aa -;

[0013] L 2 is selected from a bond, an oxygen atom, a sulfur atom, -CR aa R bb -, -(CH 2 ) n1 C(O)-, -NR 4 -, or -(CH 2 ) n1 S(O) m1 -;

[0014] L 3 is selected from a bond, -NR aa -, or -C(O)NR aa -;

[0015] Ring A is a 6- to 14-membered heteroaryl, wherein the 6- to 14-membered heteroaryl is selected from 6- to 14-membered fused heteroaryls; preferably a 5-fused 5-membered heteroaryl, a 5-fused 6-membered heteroaryl or a 6-fused 6-membered heteroaryl;

[0016] Ring B is selected from a 3- to 10-membered monocyclic heteroalkyl, a 6- to 14-membered bridged heteroalkyl, a 6- to 14-membered fused heteroalkyl or a 6- to 14-membered spiro heteroalkyl;

[0017] Ring C is a heteroaryl;

[0018] R 1 is selected from a hydrogen atom, a deuterium atom, an oxo group, an alkyl group, a deuterated alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a halogen, an amino group, a nitro group, a hydroxy group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclic group, an oxo heterocyclic group, a thio heterocyclic group, an aryl group, a heteroaryl group, -(CH 2 ) n1 R aa 、-(CH 2 ) n1 OR aa 、-NR aa C(O)(CH 2 ) n1 OR aa 、-NR aa C(=S)(CH 2 ) n1 OR bb 、-(CH 2 ) n1 SR aa 、-(CH 2 ) n1 C(O)R aa 、-(CH 2 ) n1 C(O)OR aa 、-(CH 2 ) n1 S(O) m1 R aa 、-(CH 2 ) n1 NR aa R bb 、-(CH 2 ) n1 C(O)NR aa R bb 、-(CH 2 ) n1 NR aa C(O)R bb or -(CH 2 ) n1 NR aa S(O)m1 R bb , wherein the alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, amino, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl and heteroaryl are optionally further selected from a hydrogen atom, a deuterium atom, an alkyl, a haloalkyl, a halogen, an amino, an oxo group, a nitro group, a cyano group, a hydroxy group, an alkenyl, an alkynyl, an alkoxy, a haloalkoxy, a hydroxyalkyl, a cycloalkyl, a heterocyclic group, an aryl, a heteroaryl, -(CH 2 ) n1 -, -(CH 2 ) n1 R cc , -(CH 2 ) n1 OR cc , -(CH 2 ) n1 SR cc , -(CH 2 ) n1 C(O)R cc , -(CH 2 ) n1 C(O)OR cc , -(CH 2 ) n1 S(O) m1 R cc , -(CH 2 ) n1 NR cc R dd , -(CH 2 ) n1 C(O)NR cc R dd , -(CH 2 ) n1 NR cc C(O)R dd or -(CH 2 ) n1 NR cc S(O) m1 R dd and substituted by one or more substituents selected therefrom;

[0019] R 2 is selected from a hydrogen atom, a deuterium atom, an alkyl, a deuterated alkyl, a haloalkyl, an alkoxy, a haloalkoxy, a halogen, an amino, a nitro group, a hydroxy group, a cyano group, an alkenyl, an alkynyl, a cycloalkyl, a hydroxyalkyl, a heterocyclic group, an oxo heterocyclic group, a thio heterocyclic group, an aryl, a heteroaryl, -(CH 2 ) n1 R aa , -(CH 2 ) n1 O(CH 2 )m1 R aa 、 -(CH 2 ) n1 OR aa 、 -(CH 2 ) n1 NR aa (CH 2 ) m1 R aa 、 -NR aa C(O)(CH 2 ) n1 OR aa 、 -NR aa C(=S)(CH 2 ) n1 OR bb 、 -(CH 2 ) n1 SR aa 、 -(CH 2 ) n1 C(O)R aa 、 -(CH 2 ) n1 C(O)OR aa 、 -(CH 2 ) n1 S(O) m1 R aa 、 -(CH 2 ) n1 S(O) m1 NR aa R bb 、 -(CH 2 ) n1 P(O) m2 R aa R bb 、 -(CH 2 ) n1 NR aa R bb 、 -(CH 2 ) n1 S-、 -(CH 2 ) n1 C(O)NR aa R bb 、 -(CH 2 ) n1 NR aa C(O)R bb or -(CH 2 ) n1 NR aa S(O) m1 R bb, wherein the alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, amino, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl and heteroaryl are optionally further selected from a hydrogen atom, a deuterium atom, a substituted or unsubstituted alkyl, a halogen, a hydroxy group, a substituted or unsubstituted amino group, an oxo group, a nitro group, a cyano group, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, a substituted or unsubstituted alkoxy, a substituted or unsubstituted hydroxyalkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aryl and a substituted or unsubstituted heteroaryl, -(CH 2 ) n1 -, -(CH 2 ) n1 R cc , -(CH 2 ) n1 OR cc , -(CH 2 ) n1 SR cc , -(CH 2 ) n1 C(O)R cc , -(CH 2 ) n1 C(O)OR cc , -(CH 2 ) n1 S(O) m1 R cc , -(CH 2 ) n1 S(O) m1 NR cc R dd , -(CH 2 ) n1 NR cc R dd , -(CH 2 ) n1 C(O)NR cc R dd , -(CH 2 ) n1 C(O)NR cc S(O) m1 R dd , -(CH 2 ) n1 NR cc S(O) m1 R dd or -(CH 2 ) n1 NR cc S(O) m1 R dd ; and is substituted by one or more substituents selected from the group consisting of;

[0020] R 3 selected from a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a hydroxyalkyl group, a heterocyclic group, an oxo heterocyclic group, a thioheterocyclic group, an aryl group, a heteroaryl group, -(CH 2 ) n1 R aa 、-(CH 2 ) n1 OR aa 、-NR aa C(O)(CH 2 ) n1 OR aa 、-NR aa C(=S)(CH 2 ) n1 OR bb 、-(CH 2 ) n1 SR aa 、-(CH 2 ) n1 C(O)R aa 、-(CH 2 ) n1 C(O)OR aa 、-(CH 2 ) n1 S(O) m1 R aa 、-(CH 2 ) n1 S(O) m1 NR aa R bb 、-(CH 2 ) n1 P(O) m2 R aa R bb 、-(CH 2 ) n1 NR aa R bb 、-(CH 2 ) n1 C(O)NR aa R bb 、-(CH 2 ) n1 NR aa C(O)R bb or -(CH 2 ) n1 NR aa S(O) m1 R bb, wherein the alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, amino, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl and heteroaryl are optionally further selected from a hydrogen atom, a deuterium atom, a substituted or unsubstituted alkyl, a halogen, a hydroxyl group, a substituted or unsubstituted amino, an oxo group, a nitro group, a cyano group, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, a substituted or unsubstituted alkoxy, a substituted or unsubstituted hydroxyalkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aryl and a substituted or unsubstituted heteroaryl, -(CH 2 ) n1 -, -(CH 2 ) n1 R cc , -(CH 2 ) n1 OR cc , -(CH 2 ) n1 SR cc , -(CH 2 ) n1 C(O)R cc , -(CH 2 ) n1 C(O)OR cc , -(CH 2 ) n1 S(O) m1 R cc , -(CH 2 ) n1 S(O) m1 NR cc R dd , -(CH 2 ) n1 NR cc R dd , -(CH 2 ) n1 C(O)NR cc R dd , -(CH 2 ) n1 C(O)NR cc S(O) m1 R dd , -(CH 2 ) n1 NR cc S(O) m1 R dd or -(CH 2 ) n1 NR cc S(O) m1 R dd and is substituted by one or more substituents selected therefrom;

[0021] R 4 is selected from a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a haloalkyl group, an alkoxy group, a hydroxyalkyl group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxy group, a cyano group, an alkenyl group, and an alkynyl group;

[0022] R aa 、R bb 、R cc and R dd are the same or different and each independently selected from a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a haloalkyl group, an alkoxy group, a hydroxyalkyl group, a haloalkoxy group, a halogen, a cyano group, a nitro group, a hydroxy group, an amino group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group, wherein the alkyl group, deuterated alkyl group, haloalkyl group, alkoxy group, hydroxyalkyl group, haloalkoxy group, alkenyl group, alkynyl group, cycloalkyl group, heterocyclic group, aryl group, and heteroaryl group are optionally further substituted by one or more substituents selected from a hydrogen atom, a deuterium atom, a substituted or unsubstituted alkyl group, a halogen, a hydroxy group, a substituted or unsubstituted amino group, an oxo group, a nitro group, a cyano group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heteroaryl group;

[0023] x is an integer of 0, 1, 2, or 3;

[0024] y is an integer of 0, 1, 2, 3, 4, or 5;

[0025] m 1 is an integer of 0, 1, or 2;

[0026] m 2 is an integer of 0, 1, or 2; and

[0027] n 1 is an integer of 0, 1, 2, 3, 4, or 5.

[0028] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above):

[0029] L 1 is selected from a bond, an alkylene group, a cycloalkyl group, a heterocyclic group, -(CH 2 ) n1 C(O)(CH 2 ) m1 -, -(CH 2 ) n1 C(O)(CH 2 ) m1 NR aa (CH 2 )m2 -、-NR aa (CH 2 ) n1 -、-(CH 2 ) n1 S(O) m1 -, or -(CH 2 ) n1 S(O) m1 NR aa -;

[0030] L 2 Selected from bonds, oxygen atoms, -CR aa R bb -、-(CH 2 ) n1 C(O)-、-NR 4 -, or -(CH 2 ) n1 S(O) m1 -;

[0031] R 4 is selected from a hydrogen atom or an alkyl group;

[0032] L 3 Select from bond, -NR aa -, or -C(O)NR aa -;

[0033] Ring A is a 6-14-membered fused heteroaryl group;

[0034] Ring B is selected from a 3-10 membered monoheterocyclic group, a 6-14 membered bridged heterocyclic group, a 6-14 membered fused heterocyclic group or a 6-14 membered spiroheterocyclic group;

[0035] Ring C is heteroaryl;

[0036] R 1 is selected from hydrogen, alkyl, haloalkyl, alkoxy, halogen, amino, hydroxy, cyano, cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein the alkyl, amino, heterocyclic, aryl, or heteroaryl is optionally further substituted by one or more substituents selected from halogen, cyano, alkyl, or alkoxy;

[0037] R 2 is selected from hydrogen, alkyl, alkoxy, halogen, amino, hydroxy, cyano, cycloalkyl, heterocyclic, aryl, heteroaryl, -(CH 2 ) n1 C(O)R cc 、-(CH 2 ) n1 SR aa , or -(CH 2 ) n1 NRaa R bb ; wherein the alkyl, alkoxy, amino, cycloalkyl, heterocyclic group, aryl, or heteroaryl is optionally further substituted by one or more substituents selected from substituted or unsubstituted alkyl, unsubstituted alkoxy, unsubstituted cycloalkyl, substituted or unsubstituted amino, substituted or unsubstituted heterocyclic group, or unsubstituted heteroaryl; wherein "substituted" means substituted by alkyl or halogen;

[0038] R cc is a heterocyclic group; the heterocyclic group is optionally substituted by unsubstituted alkyl;

[0039] R 3 is selected from a hydrogen atom, alkyl, haloalkyl, hydroxyalkyl, alkoxy, halogen, hydroxy, cyano, cycloalkyl, heterocyclic group, -(CH 2 ) n1 C(O)R aa ,-(CH 2 ) n1 C(O)NR aa R bb ,-(CH 2 ) n1 S(O) m1 R aa 、or -(CH 2 ) n1 S(O) m1 NR aa R bb ; wherein the alkyl, alkoxy, cycloalkyl, or heterocyclic group is optionally further substituted by one or more substituents selected from halogen, hydroxy, unsubstituted alkyl, or unsubstituted alkoxy;

[0040] R aa and R bb are the same or different and are each independently selected from a hydrogen atom, alkyl, amino, or heteroaryl; wherein the alkyl and amino are optionally further substituted by one or more substituents selected from unsubstituted alkyl, substituted or unsubstituted heterocyclic group, unsubstituted heteroaryl; wherein "substituted" means substituted by alkyl or halogen;

[0041] x is 0, 1, 2 or 3;

[0042] y is 0, 1, 2 or 3;

[0043] m 1 is 0, 1 or 2;

[0044] m 2 is 0, 1 or 2; and

[0045] n 1 is 0, 1 or 2.

[0046] In certain embodiments of the present invention, in the compounds represented by the general formula (I), the definitions of certain groups are as follows (groups not defined are as shown above):

[0047] L 1 is selected from a bond, an alkylene group, -(CH 2 ) n1 C(O)(CH 2 ) m1 -, -(CH 2 ) n1 C(O)(CH 2 ) m1 NR aa (CH 2 ) m2 -, or -(CH 2 ) n1 S(O) m1 -;

[0048] L 2 is selected from a bond, an oxygen atom, or -NR 4 -;

[0049] R 4 is selected from a hydrogen atom, or an alkyl group;

[0050] L 3 is -NR aa -;

[0051] Ring A is a 6- to 14-membered fused heteroaryl group;

[0052] Ring B is selected from a 3- to 10-membered monocyclic heteroaryl group, a 6- to 14-membered bridged heteroaryl group, or a 6- to 14-membered fused heteroaryl group;

[0053] Ring C is a heteroaryl group;

[0054] R 1 is selected from a hydrogen atom, an alkyl group, a haloalkyl group, an amino group, a heterocyclic group, or a heteroaryl group; wherein the alkyl group, amino group, heterocyclic group, or heteroaryl group is optionally further substituted by one or more substituents selected from halogen, cyano, alkyl, or alkoxy;

[0055] R 2 is selected from a hydrogen atom, an alkyl group, an alkoxy group, a halogen, a cycloalkyl group, a heterocyclic group, or a heteroaryl group; wherein the heteroaryl group is optionally further substituted by one or more substituents selected from unsubstituted alkyl, unsubstituted alkoxy, or unsubstituted cycloalkyl;

[0056] R 3 is selected from a hydrogen atom, an alkyl group, a hydroxyalkyl group, a halogen, a cyano group, a cycloalkyl group, -(CH 2 ) n1 C(O)Raa 、 or -(CH 2 ) n1 C(O)NR aa R bb ; wherein the alkyl group is optionally further substituted with a group selected from hydroxyl groups;

[0057] R aa and R bb are the same or different and are each independently selected from a hydrogen atom, an alkyl group, or an amino group;

[0058] x is 0, 1, 2, or 3;

[0059] y is 0, 1, 2, or 3;

[0060] m 1 is 0, 1, or 2;

[0061] m 2 is 0, 1, or 2; and

[0062] n 1 is 0, 1, or 2.

[0063] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): L 1 is selected from a bond, an alkylene group, -(CH 2 ) n1 C(O)(CH 2 ) m1 -, -(CH 2 ) n1 C(O)(CH 2 ) m1 NR aa (CH 2 ) m2 -, or -(CH 2 ) n1 S(O) m1 -.

[0064] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): L 2 is selected from a bond, an oxygen atom, or -NR 4 -.

[0065] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): R 4 is selected from a hydrogen atom, or an alkyl group.

[0066] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): L 3 is -NR aa -.

[0067] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): Ring A is a 6- to 14-membered fused heteroaryl group.

[0068] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): Ring B is selected from a 3- to 10-membered monocyclic heteroaryl group, a 6- to 14-membered bridged heteroaryl group, or a 6- to 14-membered fused heteroaryl group.

[0069] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): Ring C is a heteroaryl group.

[0070] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): R 1 is selected from a hydrogen atom, an alkyl group, a haloalkyl group, an amino group, a heterocyclic group, or a heteroaryl group; wherein the alkyl group, amino group, heterocyclic group, or heteroaryl group is optionally further substituted by one or more substituents selected from halogen, cyano, alkyl, or alkoxy.

[0071] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): R 2 is selected from a hydrogen atom, an alkyl group, an alkoxy group, a halogen, a cycloalkyl group, a heterocyclic group, or a heteroaryl group; wherein the heteroaryl group is optionally further substituted by one or more substituents selected from an unsubstituted alkyl group, an unsubstituted alkoxy group, or an unsubstituted cycloalkyl group.

[0072] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): R 3 is selected from a hydrogen atom, an alkyl group, a hydroxyalkyl group, a halogen, a cyano group, a cycloalkyl group, -(CH 2 ) n1 C(O)R aa 、or -(CH 2 ) n1 C(O)NR aa R bb ; wherein the alkyl group is optionally further substituted by a hydroxyl group.

[0073] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): R aa and R bb are the same or different, and each independently selected from a hydrogen atom, an alkyl group, or an amino group.

[0074] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): x is 0, 1, 2, or 3.

[0075] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): y is 0, 1, 2, or 3.

[0076] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): m 1 is 0, 1, or 2.

[0077] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): m 2 is 0, 1, or 2.

[0078] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): n 1 is 0, 1, or 2.

[0079] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): when the L 1 is an alkylene group, the alkylene group is preferably a C 1 -C 4 alkylene group, such as -CH 2 -、-(CH 2 ) 2 -、-(CH 2 ) 3 - or -(CH 2 ) 4 -, more preferably -CH 2 -、or -(CH 2 ) 2 -.

[0080] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): when the L 1When the cycloalkyl group is a cycloalkyl group, the cycloalkyl group is preferably a C 3 -C 8 cycloalkyl group, more preferably a C 3 -C 6 cycloalkyl group, such as

[0081] In some technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): When the L 1 is a heterocyclic group, the heterocyclic group is preferably a 3- to 8-membered monocyclic heterocyclic group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 4", and more preferably a 4- to 6-membered monocyclic heterocyclic group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 3", such as

[0082] In some technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): When the L 1 is -(CH 2 ) n1 C(O)(CH 2 ) m1 -, the -(CH 2 ) n1 C(O)(CH 2 ) m1 - is preferably -C(O)-, -C(O)CH 2 -, or -CH 2 C(O)-.

[0083] In some technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): When the L 1 is -(CH 2 ) n1 C(O)(CH 2 ) m1 NR aa (CH 2 ) m2 -, the -(CH 2 ) n1 C(O)(CH 2 ) m1 NR aa (CH 2 ) m2 - is preferably -C(O)CH 2 NH-, -C(O)CH 2 N(CH 3 )-, -C(O)CH2 NHCH 2 -、 -C(O)CH 2 NH(CH 2 ) 2 -、 or -CH 2 C(O)N(CH 3 )-.

[0084] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): When the L 1 is -NR aa (CH 2 ) n1 -, the -NR aa (CH 2 ) n1 - is preferably -NH(CH 2 ) 2 -.

[0085] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): When the L 1 is -(CH 2 ) n1 S(O) m1 -, the -(CH 2 ) n1 S(O) m1 - is preferably -S(O) 2 -.

[0086] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): When the L 1 is -(CH 2 ) n1 S(O) m1 NR aa -, the -(CH 2 ) n1 S(O) m1 NR aa - is preferably -S(O) 2 NH-.

[0087] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): The left end of L 1 is connected to ring B, and the right end of L 1 is connected to R 1 .

[0088] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): When the L 2 is -CR aa R bb -, the -CR aa R bb - is preferably -CH 2 - or -CH(OH)-.

[0089] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): When the L 2 is -(CH 2 ) n1 C(O)-, the -(CH 2 ) n1 C(O)- is preferably -C(O)-.

[0090] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): When the L 2 is -NR 4 -, the -NR 4 - is preferably -NH- or -N(CH 3 )-.

[0091] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): When the L 2 is -(CH 2 ) n1 S(O) m1 -, the -(CH 2 ) n1 S(O) m1 - is preferably -S(O) 2 -.

[0092] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): The left end of L 2 is connected to ring A, and the right end of L 2 is connected to ring B.

[0093] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 4 is an alkyl group, the alkyl group is preferably C 1 -C 8alkyl group, more preferably C 1 -C 6 alkyl group, still more preferably C 1 -C 3 alkyl group, such as methyl, ethyl, propyl or isopropyl, still more preferably methyl.

[0094] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): When the L 3 is -NR aa -, the -NR aa - is preferably -NH-.

[0095] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): When the L 3 is -C(O)NR aa -, the -C(O)NR aa - is preferably -C(O)NH-.

[0096] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): The left end of L 3 is connected to ring C, and the right end of L 3 is connected to ring B.

[0097] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): When the ring A is a 6- to 14-membered fused heteroaryl group, the 6- to 14-membered fused heteroaryl group is preferably a 6- to 14-membered fused heteroaryl group in which "the heteroatoms are selected from one or more of N, O and S, and the number of heteroatoms is 1 to 4", more preferably a 5-fused-6-membered fused heteroaryl group or a 6-fused-6-membered fused heteroaryl group in which "the heteroatoms are selected from one or more of N, O and S, and the number of heteroatoms is 1 to 4". The 5-fused-6-membered fused heteroaryl group is preferably thienopyrimidinyl or pyrazolopyrimidinyl, benzopyrrolyl, pyrrolopyridinyl, imidazopyridinyl, triazolopyridinyl, imidazopyridazinyl, pyrrolopyrimidinyl, pyrazolopyrimidinyl, imidazopyrimidinyl, triazolopyrimidinyl, thienopyrimidinyl, thiazolopyrimidinyl, pyrrolopyrazinyl, pyrazolopyrazinyl, imidazopyrazinyl, triazolopyrazinyl, pyrrolotriazinyl, imidazotriazinyl or imidazopyrazinone group, more preferably Still more preferably The 6-connected 6-membered heteroaryl group is preferably an isoquinolinyl group, a naphthyridinyl group, a pyridopyrazinyl group, a pyridopyrimidinyl group, a quinazolinyl group, a pteridinyl group, a quinoxalinyl group, a dihydropyranopyrimidinyl group, a dihydrodioxacyclohexadienopyrimidinyl group, More preferably Even more preferably The left end of ring A is connected to L 3 and the right end of ring A is connected to L 2 to be connected.

[0098] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): when the ring B is a 3- to 10-membered monocyclic heteroaryl group, the 3- to 10-membered monocyclic heteroaryl group is preferably a 3- to 8-membered monocyclic heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 4", and more preferably a 4- to 6-membered monocyclic heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 3", for example

[0099] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): when the ring B is a 6- to 14-membered bridged heteroaryl group, the 6- to 14-membered bridged heteroaryl group is preferably a 6- to 14-membered bridged heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 4", and more preferably a 7- to 10-membered bridged heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 3", for example Also for example

[0100] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): when the ring B is a 6- to 14-membered fused heteroaryl group, the 6- to 14-membered fused heteroaryl group is preferably a 6- to 14-membered fused heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 4", and more preferably a 7- to 10-membered fused heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 3", for example

[0101] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): When the ring B is a 6-14-membered spiroheterocyclic group, the 6-14-membered spiroheterocyclic group is preferably a 6-14-membered spiroheterocyclic group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-4", more preferably a 7-10-membered spiroheterocyclic group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-3", for example

[0102] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): The upper end of the ring B is connected to L 1 and the lower end of the ring B is connected to L 2 and connected.

[0103] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): When the ring C is a heteroaryl group, the heteroaryl group is preferably a 6-14-membered heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-4", more preferably a 5-6-membered monocyclic heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-3", or an 8-10-membered fused heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-3". The 5-6-membered monocyclic heteroaryl group is preferably a pyrazolyl group, an imidazolyl group, a thiazolyl group, a triazolyl group, a pyridazinyl group, a pyrimidinyl group, or a pyrazinyl group, for example For another example The 8-10-membered fused heteroaryl group is preferably an indazolyl group or a pyrazolopyridyl group, for example

[0104] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 1 is an alkyl group, the alkyl group is preferably an alkyl group of C 1 -C 8 more preferably an alkyl group of C 1 -C 6 even more preferably an alkyl group of C 1 -C 3 such as methyl, ethyl, propyl, or isopropyl, and even more preferably methyl or ethyl.

[0105] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 1When it is a haloalkyl group, the haloalkyl group is preferably C 1 -C 8 haloalkyl group, more preferably C 1 -C 6 haloalkyl group, still more preferably C 1 -C 3 haloalkyl group, such as -CHF 2 or CF 3 .

[0106] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 1 is an alkoxy group, the alkoxy group is preferably C 1 -C 8 alkoxy group, more preferably C 1 -C 6 alkoxy group, still more preferably C 1 -C 3 alkoxy group, such as methoxy, ethoxy, propoxy or isopropoxy, still more preferably methoxy or ethoxy.

[0107] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 1 is a halogen, the halogen is preferably fluorine.

[0108] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 1 is a cycloalkyl group, the cycloalkyl group is preferably C 3 -C 8 cycloalkyl group, more preferably C 3 -C 6 cycloalkyl group, such as

[0109] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 1 is a heterocyclic group, the heterocyclic group is preferably a 3- to 8-membered monocyclic heterocyclic group in which "the heteroatoms are selected from one or more of N, O and S, and the number of heteroatoms is 1 to 4", more preferably a 4- to 6-membered monocyclic heterocyclic group in which "the heteroatoms are selected from one or more of N, O and S, and the number of heteroatoms is 1 to 3", such as

[0110] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 1 is an aryl group, the aryl group is preferably a 6- to 10-membered aryl group, more preferably a phenyl group.

[0111] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 1 is a heteroaryl group, the heteroaryl group is preferably a 5- to 10-membered heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-4", more preferably a 5- to 6-membered heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-3", such as

[0112] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 1 is an alkyl group, an amino group, a heterocyclic group, an aryl group or a heteroaryl group, and the alkyl group, amino group, heterocyclic group, aryl group or heteroaryl group is optionally further substituted by a halogen, the halogen is preferably fluorine.

[0113] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 1 is an amino group, a heterocyclic group, an aryl group or a heteroaryl group, and the amino group, heterocyclic group, aryl group or heteroaryl group is optionally further substituted by an alkyl group, the alkyl group is preferably a C 1 -C 8 alkyl group, more preferably a C 1 -C 6 alkyl group, further preferably a C 1 -C 3 alkyl group, such as methyl, ethyl, propyl or isopropyl, and further preferably methyl.

[0114] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 1 is an alkyl group, an amino group, a heterocyclic group, an aryl group or a heteroaryl group, and the alkyl group, amino group, heterocyclic group, aryl group or heteroaryl group is optionally further substituted by an alkoxy group, the alkoxy group is preferably a C 1 -C 8 alkoxy group, more preferably a C 1 -C 6 alkoxy group, further preferably a C 1 -C 3An alkoxy group, such as a methoxy group, an ethoxy group, a propoxy group or an isopropoxy group, more preferably a methoxy group.

[0115] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): when the R 2 is an alkyl group, the alkyl group is preferably C 1 -C 8 alkyl group, more preferably C 1 -C 6 alkyl group, further preferably C 1 -C 3 alkyl group, such as a methyl group, an ethyl group, a propyl group or an isopropyl group, further preferably a methyl group or an ethyl group.

[0116] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): when the R 2 is an alkoxy group, the alkoxy group is preferably C 1 -C 8 alkoxy group, more preferably C 1 -C 6 alkoxy group, further preferably C 1 -C 3 alkoxy group, such as a methoxy group, an ethoxy group, a propyl group or an isopropyl group, further preferably a methoxy group or an ethoxy group.

[0117] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): when the R 2 is a halogen, the halogen is preferably fluorine, chlorine or bromine.

[0118] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): when the R 2 is a cycloalkyl group, the cycloalkyl group is preferably C 3 -C 8 cycloalkyl group, more preferably C 3 -C 6 cycloalkyl group, such as

[0119] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): when the R 2When it is a heterocyclic group, the heterocyclic group is preferably a 3- to 8-membered monocyclic heterocyclic group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 4", more preferably a 4- to 6-membered monocyclic heterocyclic group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 3". For example

[0120] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 2 is an aryl group, the aryl group is preferably an aryl group having 6 to 10 members, more preferably a phenyl group.

[0121] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 2 is a heteroaryl group, the heteroaryl group is preferably a 5- to 10-membered heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 4", more preferably a 5- to 6-membered heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 3". For example

[0122] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 2 is -(CH 2 ) n1 C(O)R cc When it is, the -(CH 2 ) n1 C(O)R cc is preferably

[0123] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 2 is -(CH 2 ) n1 SR aa When it is, the -(CH 2 ) n1 SR aa is preferably

[0124] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 2 is -(CH 2 )n1 NR aa R bb When, the described -(CH 2 ) n1 NR aa R bb Preferably

[0125] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 2 is an alkyl group, and the alkyl group is optionally further substituted by an unsubstituted alkoxy group, the alkoxy group is preferably a C 1 -C 8 alkoxy group, more preferably a C 1 -C 6 alkoxy group, further preferably a C 1 -C 3 alkoxy group, such as methoxy, ethoxy, propoxy or isopropoxy, and further preferably methoxy.

[0126] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 2 is an alkyl group, and the alkyl group is optionally further substituted by a substituted or unsubstituted heterocyclic group, the heterocyclic group is preferably a 3-8 membered monocyclic heterocyclic group in which "the heteroatoms are selected from one or more of N, O and S, and the number of heteroatoms is 1-4", more preferably a 4-6 membered monocyclic heterocyclic group in which "the heteroatoms are selected from one or more of N, O and S, and the number of heteroatoms is 1-3", such as

[0127] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 2 is an alkyl group, and the alkyl group is optionally further substituted by a substituted or unsubstituted heterocyclic group, the heterocyclic group is preferably substituted by an alkyl group, and the alkyl group is preferably a C 1 -C 8 alkyl group, more preferably a C 1 -C 6 alkyl group, further preferably a C 1 -C 3 alkyl group, such as methyl, ethyl, propyl or isopropyl, and further preferably methyl.

[0128] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R2 is an alkoxy group. When the alkoxy group is optionally further substituted by an unsubstituted alkoxy group, the unsubstituted alkoxy group is preferably a C 1 -C 8 alkoxy group, more preferably a C 1 -C 6 alkoxy group, even more preferably a C 1 -C 3 alkoxy group, such as methoxy, ethoxy, propoxy or isopropoxy, even more preferably methoxy.

[0129] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 2 is an alkoxy group, and the alkoxy group is optionally further substituted by a substituted or unsubstituted heterocyclic group, the heterocyclic group is preferably a 3- to 8-membered monocyclic heterocyclic group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-4", more preferably a 4- to 6-membered monocyclic heterocyclic group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-3", such as

[0130] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 2 is an alkoxy group, and the alkoxy group is optionally further substituted by a substituted or unsubstituted heterocyclic group, the heterocyclic group is preferably substituted by an alkyl group, and the alkyl group is preferably a C 1 -C 8 alkyl group, more preferably a C 1 -C 6 alkyl group, even more preferably a C 1 -C 3 alkyl group, such as methyl, ethyl, propyl or isopropyl, even more preferably methyl.

[0131] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 2 is an alkoxy group, and the alkoxy group is optionally further substituted by an unsubstituted heteroaryl group, the heteroaryl group is preferably a 5- to 10-membered heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-4", more preferably a 5- to 6-membered heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-3", such as

[0132] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 2 is an amino group, and the amino group is optionally further substituted by an unsubstituted alkyl group, the alkyl group is preferably C 1 -C 8 alkyl group, more preferably C 1 -C 6 alkyl group, further preferably C 1 -C 3 alkyl group, such as methyl, ethyl, propyl or isopropyl, and further preferably methyl.

[0133] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 2 is a heterocyclic group, and the heterocyclic group is optionally further substituted by an unsubstituted alkyl group, the alkyl group is preferably C 1 -C 8 alkyl group, more preferably C 1 -C 6 alkyl group, further preferably C 1 -C 3 alkyl group, such as methyl, ethyl, propyl or isopropyl, and further preferably methyl.

[0134] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 2 is a heterocyclic group, and the heterocyclic group is optionally further substituted by an unsubstituted alkoxy group, the alkoxy group is preferably C 1 -C 8 alkoxy group, more preferably C 1 -C 6 alkoxy group, further preferably C 1 -C 3 alkoxy group, such as methoxy, ethoxy, propoxy or isopropoxy, and further preferably methoxy.

[0135] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 2 is a heterocyclic group, and the heterocyclic group is optionally further substituted by a substituted or unsubstituted amino group, the amino group is preferably substituted by an alkyl group, and the alkyl group is preferably C 1 -C 8 alkyl group, more preferably C 1 -C 6 alkyl group, further preferably C 1-C 3 alkyl groups such as methyl, ethyl, propyl or isopropyl, more preferably methyl.

[0136] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 2 is a heteroaryl group and the heteroaryl group is optionally further substituted by a substituted or unsubstituted alkyl group, the alkyl group is preferably C 1 -C 8 alkyl group, more preferably C 1 -C 6 alkyl group, further preferably C 1 -C 3 alkyl group, such as methyl, ethyl, propyl or isopropyl, more preferably methyl.

[0137] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 2 is a heteroaryl group and the heteroaryl group is optionally further substituted by a substituted or unsubstituted alkyl group, the alkyl group is preferably substituted by a halogen, and the halogen is preferably fluorine.

[0138] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 2 is a heteroaryl group and the heteroaryl group is optionally further substituted by an unsubstituted alkoxy group, the alkoxy group is preferably C 1 -C 8 alkoxy group, more preferably C 1 -C 6 alkoxy group, further preferably C 1 -C 3 alkoxy group, such as methoxy, ethoxy, propoxy or isopropoxy, more preferably methoxy.

[0139] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 2 is a heteroaryl group and the heteroaryl group is optionally further substituted by an unsubstituted cycloalkyl group, the cycloalkyl group is preferably C 3 -C 8 cycloalkyl group, more preferably C 3 -C 6 cycloalkyl group, such as

[0140] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R cc is a heterocyclic group, the heterocyclic group is preferably a 3- to 8-membered monocyclic heterocyclic group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-4", more preferably a 4- to 6-membered monocyclic heterocyclic group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-3", such as

[0141] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R cc is a heterocyclic group, and the heterocyclic group is optionally substituted by an unsubstituted alkyl group, the alkyl group is preferably a C 1 -C 8 alkyl group, more preferably a C 1 -C 6 alkyl group, further preferably a C 1 -C 3 alkyl group, such as methyl, ethyl, propyl or isopropyl, and further preferably methyl.

[0142] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 3 is an alkyl group, the alkyl group is preferably a C 1 -C 8 alkyl group, more preferably a C 1 -C 6 alkyl group, further preferably a C 1 -C 3 alkyl group, such as methyl, ethyl, propyl or isopropyl, and further preferably methyl or ethyl.

[0143] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 3 is a hydroxyalkyl group, the alkyl group is preferably a C 1 -C 8 hydroxyalkyl group, more preferably a C 1 -C 6 hydroxyalkyl group, further preferably a C 1 -C 3 hydroxyalkyl group, such as hydroxymethyl, hydroxyethyl, hydroxypropyl or hydroxyisopropyl, and further preferably hydroxymethyl.

[0144] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 3 is a haloalkyl group, the haloalkyl group is preferably a C 1 -C 8 haloalkyl group, more preferably a C 1 -C 6 haloalkyl group, further preferably a C 1 -C 3 haloalkyl group, such as -CHF 2 or CF 3 .

[0145] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 3 is an alkoxy group, the alkoxy group is preferably a C 1 -C 8 alkoxy group, more preferably a C 1 -C 6 alkoxy group, further preferably a C 1 -C 3 alkoxy group, such as methoxy, ethoxy, propoxy or isopropoxy, and further preferably methoxy.

[0146] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 3 is a halogen, the halogen is preferably fluorine.

[0147] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 3 is a cycloalkyl group, the cycloalkyl group is preferably a C 3 -C 8 cycloalkyl group, more preferably a C 3 -C 6 cycloalkyl group, such as

[0148] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 3 is a heterocyclic group, the heterocyclic group is preferably a 3-8 membered monocyclic heterocyclic group in which "the heteroatoms are selected from one or more of N, O and S, and the number of heteroatoms is 1-4", more preferably a 4-6 membered monocyclic heterocyclic group in which "the heteroatoms are selected from one or more of N, O and S, and the number of heteroatoms is 1-3", such as

[0149] In certain embodiments of the present invention, in the compounds represented by the general formula (I), the definitions of certain groups are as follows (the groups not defined are as shown above): When the R 3 is an alkyl group, the alkyl group is optionally further substituted by a halogen, and the halogen is preferably fluorine.

[0150] In certain embodiments of the present invention, in the compounds represented by the general formula (I), the definitions of certain groups are as follows (the groups not defined are as shown above): When the R 3 is an alkyl group, and the alkyl group is optionally further substituted by an unsubstituted alkoxy group, the alkoxy group is preferably a C 1 -C 8 alkoxy group, more preferably a C 1 -C 6 alkoxy group, further preferably a C 1 -C 3 alkoxy group, such as methoxy, ethoxy, propoxy or isopropoxy, and further preferably methoxy.

[0151] In certain embodiments of the present invention, in the compounds represented by the general formula (I), the definitions of certain groups are as follows (the groups not defined are as shown above): When the R 3 is an alkoxy group, and the alkoxy group is optionally further substituted by an unsubstituted alkyl group, the alkyl group is preferably a C 1 -C 8 alkyl group, more preferably a C 1 -C 6 alkyl group, further preferably a C 1 -C 3 alkyl group, such as methyl, ethyl, propyl or isopropyl, and further preferably methyl.

[0152] In certain embodiments of the present invention, in the compounds represented by the general formula (I), the definitions of certain groups are as follows (the groups not defined are as shown above): When the R 3 is a cycloalkyl group, the cycloalkyl group is preferably substituted by a hydroxyl group.

[0153] In certain embodiments of the present invention, in the compounds represented by the general formula (I), the definitions of certain groups are as follows (the groups not defined are as shown above): When the R 3 is a heterocyclic group, and the heterocyclic group is optionally further substituted by an unsubstituted alkyl group, the alkyl group is preferably a C 1 -C 8 alkyl group, more preferably a C 1 -C 6 alkyl group, further preferably a C 1 -C3 an alkyl group, such as methyl, ethyl, propyl or isopropyl, more preferably methyl.

[0154] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): when the R 3 is an alkyl group and the alkyl group is substituted by a halogen, the R 3 is -CHF 2 or CF 3 .

[0155] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): when the R 3 is an alkyl group and the alkyl group is substituted by a hydroxyl group, the R 3 is

[0156] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): when the R 3 is an alkyl group and the alkyl group is substituted by an unsubstituted alkoxy group, the R 3 is

[0157] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): when the R 3 is a cycloalkyl group and the cycloalkyl group is optionally further substituted by a hydroxyl group, the R 3 is

[0158] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): when the R 3 is a heterocyclic group and the heterocyclic group is optionally further substituted by an unsubstituted alkyl group, the R 3 is

[0159] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): when the R 3 is -(CH 2 ) n1 C(O)R aa is, the -(CH 2 ) n1 C(O)R aaPreferably

[0160] In certain embodiments of the present invention, in the compounds of formula (I), the definitions of certain groups are as follows (groups not defined are as shown above): When the R 3 is -(CH 2 ) n1 C(O)NR aa R bb then the -(CH 2 ) n1 C(O)NR aa R bb Preferably

[0161] In certain embodiments of the present invention, in the compounds of formula (I), the definitions of certain groups are as follows (groups not defined are as shown above): When the R 3 is -(CH 2 ) n1 S(O) m1 R aa then the -(CH 2 ) n1 S(O) m1 R aa Preferably

[0162] In certain embodiments of the present invention, in the compounds of formula (I), the definitions of certain groups are as follows (groups not defined are as shown above): When the R 3 is -(CH 2 ) n1 S(O) m1 NR aa R bb then the -(CH 2 ) n1 S(O) m1 NR aa R bb Preferably

[0163] In certain embodiments of the present invention, in the compounds of formula (I), the definitions of certain groups are as follows (groups not defined are as shown above): When the R aa and R bb are independently alkyl, the alkyl is preferably C 1 -C 8 alkyl, more preferably C 1 -C 6 alkyl, still more preferably C 1 -C 3An alkyl group, such as methyl, ethyl, propyl or isopropyl, more preferably methyl.

[0164] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R aa and R bb are independently heteroaryl groups, the heteroaryl group is preferably a 5- to 10-membered heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-4", more preferably a 5- to 6-membered heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-3", such as

[0165] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R aa and R bb are independently alkyl groups, and the alkyl group is optionally further substituted or unsubstituted by a heterocyclic group, the heterocyclic group is preferably a 3- to 8-membered monocyclic heterocyclic group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-4", more preferably a 4- to 6-membered monocyclic heterocyclic group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-3", such as

[0166] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R aa and R bb are independently alkyl groups, and the alkyl group is optionally further substituted or unsubstituted by a heterocyclic group, the heterocyclic group is preferably substituted by an alkyl group, and the alkyl group is preferably a C 1 -C 8 alkyl group, more preferably a C 1 -C 6 alkyl group, further preferably a C 1 -C 3 alkyl group, such as methyl, ethyl, propyl or isopropyl, more preferably methyl.

[0167] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R aa and R bbIndependently being alkyl, when the alkyl is further optionally unsubstituted heteroaryl, the heteroaryl is preferably a 5- to 10-membered heteroaryl in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 4", more preferably a 5- to 6-membered heteroaryl in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 3", such as

[0168] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): when the R aa and R bb independently are amino, when the amino is further optionally unsubstituted alkyl, the alkyl is preferably C 1 -C 8 alkyl, more preferably C 1 -C 6 alkyl, further preferably C 1 -C 3 alkyl, such as methyl, ethyl, propyl or isopropyl, further preferably methyl.

[0169] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): -L 1 - is preferably a bond, -CH 2 -, -(CH 2 ) 2 -, -C(O)-, -C(O)CH 2 -, -CH 2 C(O)-, -C(O)CH 2 NH-, -C(O)CH 2 N(CH 3 )-, -C(O)CH 2 NHCH 2 -, -C(O)CH 2 NH(CH 2 ) 2 -, -CH 2 C(O)N(CH 3 )-, -NH(CH 2 ) 2 -, -S(O) 2 -, or -S(O) 2 NH-, more preferably a bond, -CH 2 -, -(CH 2 ) 2 -, -C(O)-, -C(O)CH 2 -, -C(O)CH2 NH-, -C(O)CH 2 N(CH 3 )-, -C(O)CH 2 NH(CH 2 ) 2 -, -CH 2 C(O)N(CH 3 )-, or -S(O) 2 -; L 1 The left end of L is connected to ring B, and the right end of L 1 is connected to R 1 .

[0170] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): The L 2 is preferably a bond, an oxygen atom, -CH 2 -, -CH(OH)-, -C(O)-, -NH-, -N(CH 3 )-, or -S(O) 2 -; more preferably a bond, an oxygen atom, -NH-, or -N(CH 3 )-; The left end of L 2 is connected to ring A, and the right end of L 2 is connected to ring B

[0171] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): The L 3 is preferably a bond, -NH-, or -C(O)NH-; more preferably -NH-; The left end of L 3 is connected to ring C, and the right end of L 3 is connected to ring B

[0172] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above): Ring A is preferably the following groups

[0173]

[0174]

[0175] More preferably

[0176] The left end of ring A is connected to L 3 and the right end of ring A is connected to L 2 .

[0177] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): The ring B is preferably the following group,

[0178] More preferably The upper end of the ring B is connected to L 1 and the lower end of the ring B is connected to L 2 as well.

[0179] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): The ring C is preferably the following group,

[0180]

[0181] More preferably

[0182] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): The R 1 is preferably a hydrogen atom, methyl, ethyl, fluorine, methoxy, ethoxy, phenyl, cyano, -CHF 2 , -CH 2 CH 2 CN, -CH 2 CH 2 F, -NHCH 2 CH 2 CN,

[0183] More preferably a hydrogen atom, methyl, ethyl, fluorine, cyano, -CHF 2 , -CH 2 CH 2 CN, -CH 2 CH 2 F,

[0184] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): The R 2 is preferably a hydrogen atom, fluorine, chlorine, bromine, amino, hydroxyl, cyano, methyl, methoxy,

[0185] More preferably, a hydrogen atom, fluorine, chlorine, bromine, methyl, methoxy,

[0186] In certain embodiments of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): The R 3 is preferably a hydrogen atom, methyl, ethyl, fluorine, cyano, -CHF 2 , CF 3 , More preferably, a hydrogen atom, methyl, ethyl, fluorine, cyano,

[0187] In certain embodiments of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): The structure -L 1 -R 1 is preferably

[0188] More preferably

[0189]

[0190] In certain embodiments of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above):

[0191] L 1 and R 1 are defined as any one of the following sets of definitions:

[0192] (1) L 1 is an alkylene group, and R 1 is a cycloalkyl group, a heterocyclic group or a 5-membered heteroaryl group; wherein the cycloalkyl group or heterocyclic group is optionally further substituted by cyano; the 5-membered heteroaryl group is optionally further substituted by an alkyl group;

[0193] (2) L 1 is a cycloalkyl group or a heterocyclic group, and R 1 is cyano or an alkyl group; the alkyl group is optionally further substituted by cyano;

[0194] (3) L 1 is -(CH 2 ) n1 C(O)(CH 2 ) m1 -, and R 1is a heterocyclic group or a 5-membered heteroaryl group; the heterocyclic group or 5-membered heteroaryl group is optionally further substituted by an alkyl group;

[0195] (4)L 1 is -C(O)(CH 2 ) m1 NH(CH 2 ) m2 -, R 1 is a hydrogen atom, an alkoxy group, a cycloalkyl group, an aryl group or a heteroaryl group; the aryl group is optionally further substituted by an alkoxy group;

[0196] (5)L 1 is -(CH 2 ) n1 S(O) m1 -, R 1 is a 5-membered heteroaryl group; the 5-membered heteroaryl group is optionally further substituted by an alkyl group;

[0197] (6)L 1 is -(CH 2 ) n1 S(O) m1 NH-, R 1 is an alkyl group; the alkyl group is optionally further substituted by a cyano group.

[0198] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above):

[0199] L 1 and R 1 are defined as any one of the following groups of definitions:

[0200] (1)L 1 is an alkylene group, R 1 is a cycloalkyl group, a heterocyclic group, or a 5-membered heteroaryl group; wherein the cycloalkyl group or heterocyclic group is optionally further substituted by a cyano group; the 5-membered heteroaryl group is optionally further substituted by an alkyl group;

[0201] (2)L 1 is a cycloalkyl group, or a heterocyclic group, R 1 is a cyano group, or an alkyl group; the alkyl group is optionally further substituted by a cyano group;

[0202] (3)L 1 is -(CH 2 ) n1 C(O)(CH 2 ) m1 -, R 1 is a heterocyclic group, or a 5-membered heteroaryl group; the heterocyclic group, or 5-membered heteroaryl group is optionally further substituted by an alkyl group;

[0203] (4)L 1 is -C(O)(CH 2 ) m1 NH(CH 2 ) m2 -, R 1 is a hydrogen atom, an alkoxy group, a cycloalkyl group, an aryl group, or a heteroaryl group; the aryl group is optionally further substituted by an alkoxy group;

[0204] (5)L 1 is -(CH 2 ) n1 S(O) m1 -, R 1 is a 5 - membered heteroaryl group; the 5 - membered heteroaryl group is optionally further substituted by an alkyl group;

[0205] (6)L 1 is -(CH 2 ) n1 S(O) m1 NH -, R 1 is an alkyl group; the alkyl group is optionally further substituted by a cyano group;

[0206] L 2 is -NR 4 -;

[0207] R 4 is selected from a hydrogen atom, or an alkyl group;

[0208] L 3 is -NH -;

[0209] Ring A is a 6 - to 14 - membered fused heteroaryl group;

[0210] Ring B is selected from a 3 - to 10 - membered monocyclic heteroaryl group, or a 6 - to 14 - membered bridged heteroaryl group;

[0211] Ring C is a heteroaryl group;

[0212] R 2 is selected from a hydrogen atom, or an alkyl group;

[0213] R 3 is selected from a hydrogen atom, an alkyl group, or a hydroxyalkyl group.

[0214] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the groups not defined are as shown above):

[0215] L 1 and R 1 are defined as any one of the following groups of definitions:

[0216] (1)L 1 is an alkylene group, R1 is a 5 - membered heteroaryl; wherein the 5 - membered heteroaryl is optionally further substituted by an alkyl group;

[0217] (2)L 1 is -(CH 2 ) n1 C(O)(CH 2 ) m1 -, R 1 is a heterocyclic group or a 5 - membered heteroaryl; the heterocyclic group or 5 - membered heteroaryl is optionally further substituted by an alkyl group;

[0218] (3)L 1 is -C(O)(CH 2 ) m1 NH(CH 2 ) m2 -, R 1 is a hydrogen atom;

[0219] (4)L 1 is -(CH 2 ) n1 S(O) m1 -, R 1 is a 5 - membered heteroaryl; the 5 - membered heteroaryl is optionally further substituted by an alkyl group;

[0220] L 2 is -NR 4 -;

[0221] R 4 is selected from a hydrogen atom, or an alkyl group;

[0222] L 3 is -NH-;

[0223] Ring A is a 6 - to 14 - membered fused heteroaryl;

[0224] Ring B is a 6 - to 14 - membered bridged heterocyclic group;

[0225] Ring C is a heteroaryl;

[0226] R 2 is selected from a hydrogen atom, or an alkyl group;

[0227] R 3 is selected from a hydrogen atom, or an alkyl group.

[0228] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the groups not defined are as shown above): L 1 is an alkylene group, R 1 is a cycloalkyl group, a heterocyclic group or a 5 - membered heteroaryl; wherein the cycloalkyl group or heterocyclic group is optionally further substituted by a cyano group; the 5 - membered heteroaryl is optionally further substituted by an alkyl group.

[0229] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): L 1 is a cycloalkyl group or a heterocyclic group, R 1 is a cyano group or an alkyl group; the alkyl group is optionally further substituted by a cyano group.

[0230] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): L 1 is -(CH 2 ) n1 C(O)(CH 2 ) m1 -, R 1 is a heterocyclic group or a 5-membered heteroaryl group; the heterocyclic group or 5-membered heteroaryl group is optionally further substituted by an alkyl group.

[0231] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): L 1 is -C(O)(CH 2 ) m1 NH(CH 2 ) m2 -, R 1 is a hydrogen atom, an alkoxy group, a cycloalkyl group, an aryl group or a heteroaryl group; the aryl group is optionally further substituted by an alkoxy group.

[0232] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): L 1 is -(CH 2 ) n1 S(O) m1 -, R 1 is a 5-membered heteroaryl group; the 5-membered heteroaryl group is optionally further substituted by an alkyl group.

[0233] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): L 1 is -(CH 2 ) n1 S(O) m1 NH-, R 1 is an alkyl group; the alkyl group is optionally further substituted by a cyano group.

[0234] In certain technical solutions of the present invention, the compound represented by formula (I) can be any of the following structures,

[0235]

[0236]

[0237] In certain technical solutions of the present invention, in the compounds represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above):

[0238] Ring B is selected from

[0239] In certain technical solutions of the present invention, in the compounds represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above):

[0240] Ring B is selected from

[0241] L 1 is alkylene or -NH(CH 2 ) n1 -;

[0242] L 2 is selected from a bond, or -NH-;

[0243] L 3 is NH;

[0244] Ring A is a 6- to 14-membered fused heteroaryl;

[0245] Ring C is heteroaryl;

[0246] R 1 is cyano;

[0247] R 2 is a hydrogen atom;

[0248] R 3 is selected from a hydrogen atom, or alkyl;

[0249] n 1 is 0, 1 or 2.

[0250] In certain technical solutions of the present invention, in the compounds represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above):

[0251] Ring B is

[0252] L 1 is alkylene;

[0253] L 2 is a bond;

[0254] L 3 is NH;

[0255] Ring A is a 6- to 14-membered fused heteroaryl group;

[0256] Ring C is a heteroaryl group;

[0257] R 1 is a cyano group;

[0258] R 2 is a hydrogen atom;

[0259] R 3 is a hydrogen atom or an alkyl group.

[0260] In certain technical solutions of the present invention, the compound represented by formula (I) may be any of the following structures,

[0261] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the groups not defined are as shown above):

[0262] L 2 is selected from a bond, -CHR aa -, -(CH 2 ) n1 C(O)-, or -(CH 2 ) n1 S(O) 2 -; R aa is selected from a hydrogen atom or a hydroxyl group;

[0263] n 1 is 0, 1 or 2.

[0264] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the groups not defined are as shown above):

[0265] L 2 is selected from a bond, -CHR aa -, -(CH 2 ) n1 C(O)- or -(CH 2 ) n1 S(O) 2 -; R aa is selected from a hydrogen atom or a hydroxyl group;

[0266] n 1 is 0, 1 or 2;

[0267] L 1 is an alkylene group;

[0268] L 3 is NH;

[0269] Ring A is a 6-14 membered fused heteroaryl group;

[0270] Ring B is a 6-14 membered bridged heterocyclic group;

[0271] Ring C is a heteroaryl group;

[0272] R 1 is a cyano group;

[0273] R 2 is selected from a hydrogen atom, an alkyl group, an alkoxy group, or a heterocyclic group;

[0274] R 3 is selected from a hydrogen atom or an alkyl group.

[0275] In certain technical solutions of the present invention, the compound represented by formula (I) may be any of the following structures,

[0276]

[0277] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above):

[0278] Ring A is a 6-14 membered fused heteroaryl group, and Ring A is not wherein, the left end of Ring A is connected to L 3 and the right end of Ring A is connected to L 2 and is connected.

[0279] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the undefined groups are as shown above):

[0280] Ring A is a 6-14 membered fused heteroaryl group, and Ring A is not wherein, the left end of Ring A is connected to L 3 and the right end of Ring A is connected to L 2 and is connected;

[0281] L 1 is selected from an alkylene group, -(CH 2 ) n1 C(O)(CH 2 ) m1 -, -(CH 2 ) n1 C(O)(CH 2 ) m1 NR aa (CH 2 ) m2 -, or -(CH 2 ) n1 S(O)m1 -;

[0282] L 2 selected from a bond, an oxygen atom, or -NR 4 -;

[0283] R 4 selected from a hydrogen atom, or an alkyl group;

[0284] L 3 is -NH-;

[0285] Ring B is selected from a 3- to 10-membered monocyclic heteroaryl group, a 6- to 14-membered bridged heteroaryl group, or a 6- to 14-membered fused heteroaryl group;

[0286] Ring C is a heteroaryl group;

[0287] R 1 selected from a hydrogen atom, an alkyl group, an alkoxy group, a cyano group, a cycloalkyl group, a heterocyclic group, an aryl group, or a heteroaryl group; the heterocyclic group or heteroaryl group is optionally further substituted by a cyano group or an alkyl group; the aryl group is optionally further substituted by an alkoxy group;

[0288] R 2 selected from a hydrogen atom, an alkyl group, an alkoxy group, a halogen, or a heterocyclic group; the alkyl group is optionally further substituted by an unsubstituted alkoxy group, an alkyl-substituted or unsubstituted heterocyclic group; the heterocyclic group is optionally further substituted by an alkyl group;

[0289] R 3 selected from a hydrogen atom, an alkyl group, or a hydroxyalkyl group;

[0290] R aa selected from a hydrogen atom, or an alkyl group.

[0291] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the groups not defined are as shown above):

[0292] Ring A is a 6- to 14-membered fused heteroaryl group, and Ring A is not wherein, the left end of Ring A is connected to L 3 and the right end of Ring A is connected to L 2 and connected;

[0293] L 1 selected from an alkylene group, -(CH 2 ) n1 C(O)(CH 2 ) m1 -, -(CH 2 ) n1 C(O)(CH 2 ) m1 NR aa (CH2 ) m2 -, or -(CH 2 ) n1 S(O) m1 -;

[0294] L 2 is selected from an oxygen atom, or -NR 4 -;

[0295] R 4 is selected from a hydrogen atom, or an alkyl group;

[0296] L 3 is -NH-;

[0297] Ring B is selected from a 3- to 10-membered monocyclic heterocyclic group, a 6- to 14-membered bridged heterocyclic group, or a 6- to 14-membered fused heterocyclic group;

[0298] Ring C is a heteroaryl group;

[0299] R 1 is selected from a hydrogen atom, an alkyl group, an alkoxy group, a cyano group, a heterocyclic group, or a heteroaryl group; the heterocyclic group or heteroaryl group is optionally further substituted by a cyano group or an alkyl group;

[0300] R 2 is selected from a hydrogen atom, an alkyl group, an alkoxy group, a halogen, or a heterocyclic group; the alkyl group is optionally further substituted by an unsubstituted alkoxy group, an alkyl-substituted or unsubstituted heterocyclic group; the heterocyclic group is optionally further substituted by an alkyl group;

[0301] R 3 is selected from a hydrogen atom, an alkyl group, or a hydroxyalkyl group;

[0302] R aa is selected from a hydrogen atom, or an alkyl group.

[0303] In certain technical solutions of the present invention, in the compounds represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): When the ring A is a 6-14 membered fused heteroaryl group, the 6-14 membered fused heteroaryl group is preferably a 6-14 membered fused heteroaryl group in which "the heteroatoms are selected from one or more of N, O and S, and the number of heteroatoms is 1-4", more preferably a 5-fused-6 membered fused heteroaryl group in which "the heteroatoms are selected from one or more of N, O and S, and the number of heteroatoms is 1-4", or a 6-fused-6 membered fused heteroaryl group in which "the heteroatoms are selected from one or more of N, O and S, and the number of heteroatoms is 1-4". The 5-fused-6 membered fused heteroaryl group is preferably thienopyrimidinyl or pyrazolopyrimidinyl, benzopyrrolyl, pyrrolopyridinyl, imidazopyridinyl, triazolopyridinyl, imidazopyridazinyl, pyrrolopyrimidinyl, pyrazolopyrimidinyl, imidazopyrimidinyl, triazolopyrimidinyl, thienopyrimidinyl, thiazolopyrimidinyl, pyrrolopyrazinyl, pyrazolopyrazinyl, imidazopyrazinyl, triazolopyrazinyl, pyrrolotriazinyl, imidazotriazinyl or imidazopyrazinone group, more preferably

[0304] The 6-fused-6 membered fused heteroaryl group is preferably isoquinolinyl, naphthyridinyl, pyridopyrazinyl, pyridopyrimidinyl, quinazolinyl, pteridinyl, quinoxalinyl, dihydropyranopyrimidinyl, dihydrodioxacyclohexadienopyrimidinyl, more preferably

[0305] Among them, the left end of the ring A is connected to L 3 and the right end of the ring A is connected to L 2 and connected.

[0306] In certain technical solutions of the present invention, in the compounds represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): The ring A is preferably pyrrolopyrazinyl, pyrazolopyrazinyl, imidazopyrazinyl, triazolopyrazinyl, pyridopyrazinyl, pteridinyl or quinoxalinyl, more preferably

[0307] In certain technical solutions of the present invention, in the compounds represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): The ring A is preferably pyrazolopyrimidinyl or pyrazolopyrazinyl, more preferably

[0308] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): Ring A is preferably imidazopyridyl, imidazopyridazinyl, imidazopyrimidinyl, imidazopyrazinyl or imidazotriazinyl, more preferably

[0309] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): Ring A is preferably thiazolopyrimidinyl, more preferably

[0310] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of certain groups are as follows (the undefined groups are as shown above): Ring A is preferably triazolopyridyl, triazolopyrimidinyl or triazolopyrazinyl, more preferably

[0311] In certain technical solutions of the present invention, the compound represented by formula (I) can be any of the following structures,

[0312]

[0313]

[0314]

[0315]

[0316]

[0317] In certain technical solutions of the present invention, the compound represented by formula (I) is preferably the compound represented by formula (I-1),

[0318]

[0319] wherein, ring D is heteroalkenyl, aryl, or heteroaryl;

[0320] X 1 、X 2 and X 3 are independently CH or N;

[0321] L 1 is selected from alkylene, -(CH 2 ) n1 C(O)(CH 2 ) m1 -, -(CH 2 ) n1C(O)(CH 2 ) m1 NR aa (CH 2 ) m2 -, or -(CH 2 ) n1 S(O) m1 -;

[0322] R 1 is selected from halogen, cyano, alkyl, alkoxy, cycloalkyl, heterocyclic group, or heteroaryl; the alkyl is optionally further substituted by halogen or alkoxy; the heterocyclic group is optionally further substituted by cyano; the heteroaryl is optionally further substituted by alkyl;

[0323] When L 1 is -(CH 2 ) n1 C(O)(CH 2 ) m1 -, R 1 is alkyl, heterocyclic group, or heteroaryl; the alkyl is optionally further substituted by halogen; the heterocyclic group or heteroaryl is optionally further substituted by alkyl;

[0324] L 2 , L 3 , R 2 , R 3 , ring B, ring C, x and y are as defined above.

[0325] In certain technical solutions of the present invention, in the compound represented by the general formula (I-1), the definitions of certain groups are as follows (the undefined groups are as shown above):

[0326] Ring D is heterocyclic alkenyl, aryl, or heteroaryl;

[0327] X 1 , X 2 and X 3 are independently CH or N;

[0328] L 1 is selected from alkylene, -(CH 2 ) n1 C(O)(CH 2 ) m1 -, -(CH 2 ) n1 C(O)(CH 2 ) m1 NR aa (CH 2 ) m2 -, or -(CH 2 ) n1 S(O)m1 -;

[0329] R 1 is selected from halogen, cyano, alkyl, alkoxy, cycloalkyl, heterocyclic group, or heteroaryl; the alkyl is optionally further substituted by halogen or alkoxy; the heterocyclic group is optionally further substituted by cyano; the heteroaryl is optionally further substituted by alkyl;

[0330] When L 1 is -(CH 2 ) n1 C(O)(CH 2 ) m1 -, R 1 is alkyl, heterocyclic group, or heteroaryl; the alkyl is optionally further substituted by halogen; the heterocyclic group or heteroaryl is optionally further substituted by alkyl;

[0331] L 2 is selected from an oxygen atom, or -NR 4 -;

[0332] R 4 is selected from a hydrogen atom, or alkyl;

[0333] L 3 is -NH-;

[0334] Ring B is selected from a 3- to 10-membered monocyclic heterocyclic group, a 6- to 14-membered fused heterocyclic group, or a 6- to 14-membered bridged heterocyclic group;

[0335] Ring C is heteroaryl;

[0336] R 2 is selected from a hydrogen atom, alkyl, alkoxy, halogen, cycloalkyl, heterocyclic group, aryl, heteroaryl, -(CH 2 ) n1 OR cc 、or -(CH 2 ) n1 NR aa R bb ; the alkyl is optionally further substituted by an alkyl-substituted or unsubstituted heterocyclic group; the alkoxy is optionally further substituted by an unsubstituted alkoxy, an alkyl-substituted or unsubstituted heterocyclic group, or an unsubstituted heteroaryl; the heterocyclic group is optionally further substituted by an unsubstituted alkyl, an unsubstituted alkoxy, or an alkyl-substituted amino group; the heteroaryl is optionally further substituted by a halogen-substituted or unsubstituted alkyl, an unsubstituted alkoxy, or an unsubstituted cycloalkyl;

[0337] R aa and R bbSame or different and each independently selected from a hydrogen atom or an alkyl group; the alkyl group is optionally further substituted with a heterocyclic group which is optionally substituted with an alkyl group or unsubstituted, or an unsubstituted heteroaryl group;

[0338] R cc is a heterocyclic group; the heterocyclic group is optionally further substituted with an unsubstituted alkyl group;

[0339] R 3 is selected from a hydrogen atom, an alkyl group, or a hydroxyalkyl group.

[0340] In certain technical solutions of the present invention, in the compound represented by the general formula (I-1), the definitions of certain groups are as follows (the groups not defined are as shown above):

[0341] Ring D is a heteroalkenyl group, an aryl group, or a heteroaryl group;

[0342] X 1 、X 2 and X 3 are independently CH or N;

[0343] L 1 is selected from an alkylene group, -(CH 2 ) n1 C(O)(CH 2 ) m1 -, -(CH 2 ) n1 C(O)(CH 2 ) m1 NR aa (CH 2 ) m2 -, or -(CH 2 ) n1 S(O) m1 -;

[0344] R 1 is selected from a halogen atom, a cyano group, an alkyl group, a heterocyclic group, or a heteroaryl group; the alkyl group is optionally further substituted with a halogen atom or an alkoxy group; the heterocyclic group is optionally further substituted with a cyano group; the heteroaryl group is optionally further substituted with an alkyl group;

[0345] When L 1 is -(CH 2 ) n1 C(O)(CH 2 ) m1 -, R 1 is an alkyl group, a heterocyclic group, or a heteroaryl group; the alkyl group is optionally further substituted with a halogen atom; the heterocyclic group or heteroaryl group is optionally further substituted with an alkyl group;

[0346] L 2 is selected from an oxygen atom, or -NR4 -;

[0347] R 4 is selected from a hydrogen atom, or an alkyl group;

[0348] L 3 is -NH-;

[0349] Ring B is selected from a 3- to 10-membered monocyclic heteroalkyl group, a 6- to 14-membered fused heteroalkyl group, or a 6- to 14-membered bridged heteroalkyl group;

[0350] Ring C is a heteroaryl group;

[0351] R 2 is selected from a hydrogen atom, an alkyl group, an alkoxy group, a halogen, a cycloalkyl group, a heterocyclic group, an aryl group, or a heteroaryl group; the said heteroaryl group is optionally further substituted by an unsubstituted alkyl group, an unsubstituted alkoxy group, or an unsubstituted cycloalkyl group;

[0352] R aa is selected from a hydrogen atom, or an alkyl group;

[0353] R 3 is selected from a hydrogen atom, an alkyl group, or a hydroxyalkyl group.

[0354] In certain technical solutions of the present invention, in the compound represented by the general formula (I-1), the definitions of certain groups are as follows (the undefined groups are as shown above): Ring D is a heteroalkenyl group, an aryl group, or a heteroaryl group.

[0355] In certain technical solutions of the present invention, in the compound represented by the general formula (I-1), the definitions of certain groups are as follows (the undefined groups are as shown above): X 1 , X 2 and X 3 are independently CH or N.

[0356] In certain technical solutions of the present invention, in the compound represented by the general formula (I-1), the definitions of certain groups are as follows (the undefined groups are as shown above): L 1 is selected from an alkylene group, -(CH 2 ) n1 C(O)(CH 2 ) m1 -, -(CH 2 ) n1 C(O)(CH 2 ) m1 NR aa (CH 2 ) m2 -, or -(CH 2 ) n1 S(O) m1 -.

[0357] In certain embodiments of the present invention, in the compounds of formula (I-1), the definitions of certain groups are as follows (groups not defined are as shown above): R 1 is selected from halogen, cyano, alkyl, heterocyclic group, or heteroaryl; the alkyl is optionally further substituted by halogen or alkoxy; the heterocyclic group is optionally further substituted by cyano; the heteroaryl is optionally further substituted by alkyl.

[0358] In certain embodiments of the present invention, in the compounds of formula (I-1), the definitions of certain groups are as follows (groups not defined are as shown above): When L 1 is -(CH 2 ) n1 C(O)(CH 2 ) m1 -, R 1 is alkyl, heterocyclic group, or heteroaryl; the alkyl is optionally further substituted by halogen; the heterocyclic group or heteroaryl is optionally further substituted by alkyl.

[0359] In certain embodiments of the present invention, in the compounds of formula (I-1), the definitions of certain groups are as follows (groups not defined are as shown above): L 2 is selected from an oxygen atom, or -NR 4 -.

[0360] In certain embodiments of the present invention, in the compounds of formula (I-1), the definitions of certain groups are as follows (groups not defined are as shown above): R 4 is selected from a hydrogen atom, or alkyl.

[0361] In certain embodiments of the present invention, in the compounds of formula (I-1), the definitions of certain groups are as follows (groups not defined are as shown above): L 3 is -NH-.

[0362] In certain embodiments of the present invention, in the compounds of formula (I-1), the definitions of certain groups are as follows (groups not defined are as shown above): Ring B is selected from a 3- to 10-membered monocyclic heterocyclic group, a 6- to 14-membered fused heterocyclic group, or a 6- to 14-membered bridged heterocyclic group.

[0363] In certain embodiments of the present invention, in the compounds of formula (I-1), the definitions of certain groups are as follows (groups not defined are as shown above): Ring C is heteroaryl.

[0364] In certain embodiments of the present invention, in the compounds of formula (I-1), the definitions of certain groups are as follows (groups not defined are as shown above): R 2Selected from a hydrogen atom, an alkyl group, an alkoxy group, a halogen, a cycloalkyl group, a heterocyclic group, an aryl group, or a heteroaryl group; the heteroaryl group is optionally further substituted by an unsubstituted alkyl group, an unsubstituted alkoxy group, or an unsubstituted cycloalkyl group.

[0365] In certain embodiments of the present invention, in the compound represented by the general formula (I-1), the definitions of certain groups are as follows (the undefined groups are as shown above): R aa Selected from a hydrogen atom or an alkyl group.

[0366] In certain embodiments of the present invention, in the compound represented by the general formula (I-1), the definitions of certain groups are as follows (the undefined groups are as shown above): R 3 Selected from a hydrogen atom, an alkyl group, or a hydroxyalkyl group.

[0367] In certain embodiments of the present invention, in the compound represented by the general formula (I-1), the definitions of certain groups are as follows (the undefined groups are as shown above): When ring D is a heteroalkenyl group, the heteroalkenyl group is preferably a 3-8 membered heteroalkenyl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-3", more preferably a 4-6 membered heteroalkenyl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-3", for example

[0368] In certain embodiments of the present invention, in the compound represented by the general formula (I-1), the definitions of certain groups are as follows (the undefined groups are as shown above): When ring D is an aryl group, the aryl group is preferably a 6-10 membered aryl group, more preferably a phenyl group.

[0369] In certain embodiments of the present invention, in the compound represented by the general formula (I-1), the definitions of certain groups are as follows (the undefined groups are as shown above): When ring D is a heteroaryl group, the heteroaryl group is preferably a 5-10 membered heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-4", more preferably a 5-6 membered heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-3", for example

[0370] More preferably

[0371] In certain embodiments of the present invention, the compound represented by the formula (I) is preferably the compound represented by the formula (I-2),

[0372]

[0373] wherein, L1 , L 2 , L 3 , R 1 , R 2 , R 3 , the definitions of ring B, ring C, and y are the same as described above;

[0374] x is 0, 1, or 2.

[0375] In certain technical solutions of the present invention, in the compound represented by the general formula (I-2), the definitions of certain groups are as follows (the groups not defined are as shown above):

[0376] L 1 is an alkylene group, -(CH 2 ) n1 C(O)(CH 2 ) m1 -, -(CH 2 ) n1 C(O)(CH 2 ) m1 NR aa (CH 2 ) m2 -, or -(CH 2 ) n1 S(O) m1 -;

[0377] R aa is selected from a hydrogen atom or an alkyl group;

[0378] L 2 is -NH-;

[0379] L 3 is -NH-;

[0380] Ring B is selected from a 3- to 10-membered monocyclic heterocyclic group, a 6- to 14-membered bridged heterocyclic group, or a 6- to 14-membered fused heterocyclic group;

[0381] Ring C is a heteroaryl group;

[0382] R 1 is an alkyl group, a cyano group, a heterocyclic group, or a heteroaryl group; the heterocyclic group is optionally further substituted by a cyano group;

[0383] R 2 is selected from a hydrogen atom or an alkyl group;

[0384] R 3 is selected from a hydrogen atom, an alkyl group, or a hydroxyalkyl group;

[0385] x is 0, 1, or 2.

[0386] In certain technical solutions of the present invention, in the compounds represented by the general formula (I-2), the definitions of certain groups are as follows (the undefined groups are as shown above):

[0387] L 1 is an alkylene group, -(CH 2 ) n1 C(O)(CH 2 ) m1 -, -(CH 2 ) n1 C(O)(CH 2 ) m1 NR aa (CH 2 ) m2 -, -(CH 2 ) n1 S(O) m1 -;

[0388] R aa is selected from a hydrogen atom, or an alkyl group;

[0389] L 2 is -NH-;

[0390] L 3 is -NH-;

[0391] Ring B is selected from a 6- to 14-membered bridged heterocyclic group, or a 6- to 14-membered fused heterocyclic group;

[0392] Ring C is a heteroaryl group;

[0393] R 1 is an alkyl group, a cyano group, or a heterocyclic group;

[0394] R 2 is selected from a hydrogen atom, or an alkyl group;

[0395] R 3 is selected from a hydrogen atom, an alkyl group, or a hydroxyalkyl group;

[0396] x is 0, 1 or 2.

[0397] In certain technical solutions of the present invention, in the compounds represented by the general formula (I-2), the definitions of certain groups are as follows (the undefined groups are as shown above):

[0398] L 1 is an alkylene group of C 1 -C 4 -(CH 2 ) n1 C(O)(CH 2 ) m1 -, -(CH 2 ) n1C(O)(CH 2 ) m1 NR aa (CH 2 ) m2 -、-(CH 2 ) n1 S(O) m1 -;

[0399] R aa is selected from a hydrogen atom, or an alkyl group of C 1 -C 3 ;

[0400] L 2 is -NH-;

[0401] L 3 is -NH-;

[0402] Ring B is selected from a 7- to 10-membered bridged heterocyclic group in which "heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 3", or a 7- to 10-membered fused heterocyclic group in which "heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 3";

[0403] Ring C is a 5- to 6-membered monocyclic heteroaryl group in which "heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 3";

[0404] R 1 is an alkyl group of C 1 -C 4 , a cyano group, or a 4- to 6-membered monocyclic heterocyclic group in which "heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 3";

[0405] R 2 is selected from a hydrogen atom, or an alkyl group of C 1 -C 3 ;

[0406] R 3 is selected from a hydrogen atom, an alkyl group of C 1 -C 3 , or a hydroxyalkyl group of C 1 -C 3 ;

[0407] x is 0, 1, or 2.

[0408] In certain technical solutions of the present invention, in the compound represented by the general formula (I-2), the definitions of certain groups are as follows (the groups not defined are as shown above): When L 1 is an alkylene group, the alkylene group is preferably an alkylene group of C 1 -C 4 , for example, -CH 2 -、-(CH2 ) 2 -, -(CH 2 ) 3 - or -(CH 2 ) 4 -, more preferably -CH 2 -, or -(CH 2 ) 2 -.

[0409] In certain technical solutions of the present invention, in the compound represented by the general formula (I-2), the definitions of certain groups are as follows (the undefined groups are as shown above): When the L 1 is -(CH 2 ) n1 C(O)(CH 2 ) m1 -, the -(CH 2 ) n1 C(O)(CH 2 ) m1 - is preferably -C(O)-, -C(O)CH 2 -, or -CH 2 C(O)-.

[0410] In certain technical solutions of the present invention, in the compound represented by the general formula (I-2), the definitions of certain groups are as follows (the undefined groups are as shown above): When the L 1 is -(CH 2 ) n1 C(O)(CH 2 ) m1 NR aa (CH 2 ) m2 -, the -(CH 2 ) n1 C(O)(CH 2 ) m1 NR aa (CH 2 ) m2 - is preferably -C(O)CH 2 NH-, -C(O)CH 2 N(CH 3 )-, or -CH 2 C(O)N(CH 3 )-.

[0411] In certain technical solutions of the present invention, in the compound represented by the general formula (I-2), the definitions of certain groups are as follows (the undefined groups are as shown above): When the L 1 is -(CH 2 ) n1S(O) m1 - When, the said -(CH 2 ) n1 S(O) m1 - Preferably - S(O) 2 -.

[0412] In certain technical solutions of the present invention, in the compound represented by the general formula (I-2), the definitions of some groups are as follows (the undefined groups are as shown above): When R aa is an alkyl group, the said alkyl group is preferably an alkyl group of C 1 - C 8 alkyl group, more preferably an alkyl group of C 1 - C 6 alkyl group, further preferably an alkyl group of C 1 - C 3 alkyl group, such as methyl, ethyl, propyl or isopropyl, and further preferably methyl.

[0413] In certain technical solutions of the present invention, in the compound represented by the general formula (I-2), the definitions of some groups are as follows (the undefined groups are as shown above): When the ring B is a 3- to 10-membered monocyclic heterocyclic group, the said 3- to 10-membered monocyclic heterocyclic group is preferably a 3- to 8-membered monocyclic heterocyclic group in which "the heteroatom is selected from one or more of N, O and S, and the number of heteroatoms is 1 to 4", more preferably a 4- to 6-membered monocyclic heterocyclic group in which "the heteroatom is selected from one or more of N, O and S, and the number of heteroatoms is 1 to 3", such as

[0414] In certain technical solutions of the present invention, in the compound represented by the general formula (I-2), the definitions of some groups are as follows (the undefined groups are as shown above): When the ring B is a 6- to 14-membered bridged heterocyclic group, the said 6- to 14-membered bridged heterocyclic group is preferably a 6- to 14-membered bridged heterocyclic group in which "the heteroatom is selected from one or more of N, O and S, and the number of heteroatoms is 1 to 4", more preferably a 7- to 10-membered bridged heterocyclic group in which "the heteroatom is selected from one or more of N, O and S, and the number of heteroatoms is 1 to 3", such as

[0415] In certain technical solutions of the present invention, in the compound represented by the general formula (I-2), the definitions of some groups are as follows (the undefined groups are as shown above): When the ring B is a 6- to 14-membered fused heterocyclic group, the said 6- to 14-membered fused heterocyclic group is preferably a 6- to 14-membered fused heterocyclic group in which "the heteroatom is selected from one or more of N, O and S, and the number of heteroatoms is 1 to 4", more preferably a 7- to 10-membered fused heterocyclic group in which "the heteroatom is selected from one or more of N, O and S, and the number of heteroatoms is 1 to 3", such as

[0416] In certain technical solutions of the present invention, in the compound represented by the general formula (I-2), the definitions of certain groups are as follows (the undefined groups are as shown above): When the ring C is a heteroaryl group, the heteroaryl group is preferably a 6- to 14-membered heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 4", more preferably a 5- to 6-membered monocyclic heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 3", or an 8- to 10-membered fused heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 3". The 5- to 6-membered monocyclic heteroaryl group is preferably

[0417] In certain technical solutions of the present invention, in the compound represented by the general formula (I-2), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 1 is an alkyl group, the alkyl group is preferably a C 1 -C 8 alkyl group, more preferably a C 1 -C 6 alkyl group, further preferably a C 1 -C 3 alkyl group, such as methyl, ethyl, propyl or isopropyl, and further preferably methyl.

[0418] In certain technical solutions of the present invention, in the compound represented by the general formula (I-2), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 1 is a heterocyclic group, the heterocyclic group is preferably a 3- to 8-membered monocyclic heterocyclic group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 4", more preferably a 4- to 6-membered monocyclic heterocyclic group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 3", such as

[0419] In certain technical solutions of the present invention, in the compound represented by the general formula (I-2), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 1 is a heteroaryl group, the heteroaryl group is preferably a 5- to 10-membered heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 4", more preferably a 5- to 6-membered heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 3", such as

[0420] In certain technical solutions of the present invention, in the compound represented by the general formula (I-2), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 2 is an alkyl group, the alkyl group is preferably a C1 -C 8 alkyl group, more preferably C 1 -C 6 alkyl group, still more preferably C 1 -C 3 alkyl group, such as methyl, ethyl, propyl or isopropyl, still more preferably methyl.

[0421] In certain technical solutions of the present invention, in the compound represented by the general formula (I-2), the definitions of some groups are as follows (the undefined groups are as shown above): when the R 3 is an alkyl group, the alkyl group is preferably C 1 -C 8 alkyl group, more preferably C 1 -C 6 alkyl group, still more preferably C 1 -C 3 alkyl group, such as methyl, ethyl, propyl or isopropyl, still more preferably methyl.

[0422] In certain technical solutions of the present invention, in the compound represented by the general formula (I-2), the definitions of some groups are as follows (the undefined groups are as shown above): when the R 3 is a hydroxyalkyl group, the alkyl group is preferably C 1 -C 8 hydroxyalkyl group, more preferably C 1 -C 6 hydroxyalkyl group, still more preferably C 1 -C 3 hydroxyalkyl group, such as hydroxymethyl, hydroxyethyl, hydroxypropyl or hydroxyisopropyl, still more preferably hydroxymethyl.

[0423] In certain technical solutions of the present invention, the compound represented by the formula (I) is preferably the compound represented by the formula (I-3),

[0424]

[0425] wherein, L 1 , L 2 , L 3 , R 1 , R 2 , R 3 , ring B, ring C, and the definition of y are the same as described above;

[0426] x is 0, 1 or 2.

[0427] In certain technical solutions of the present invention, in the compound represented by the general formula (I-3), the definitions of some groups are as follows (the undefined groups are as shown above):

[0428] L1 is an alkylene group, -(CH 2 ) n1 C(O)(CH 2 ) m1 -, -(CH 2 ) n1 C(O)(CH 2 ) m1 NR aa (CH 2 ) m2 -, or -(CH 2 ) n1 S(O) m1 -;

[0429] L 2 is an oxygen atom, or -NR 4 -;

[0430] R 4 is selected from a hydrogen atom, or an alkyl group;

[0431] L 3 is -NH-;

[0432] Ring B is selected from a 3- to 10-membered monocyclic heterocyclic group, a 6- to 14-membered bridged heterocyclic group, or a 6- to 14-membered fused heterocyclic group;

[0433] Ring C is a heteroaryl group;

[0434] R 1 is a hydrogen atom, an alkyl group, an alkoxy group, a cyano group, a cycloalkyl group, a heterocyclic group, an aryl group, or a heteroaryl group; the heterocyclic group or heteroaryl group is optionally further substituted by an unsubstituted alkyl group or a cyano group; the aryl group is optionally further substituted by an unsubstituted alkoxy group;

[0435] R 2 is selected from a hydrogen atom, an alkyl group, a heterocyclic group, or -(CH 2 ) n1 SR aa ; the alkyl group is optionally further substituted by an unsubstituted alkoxy group or an alkyl-substituted or unsubstituted heterocyclic group; the heterocyclic group is optionally further substituted by an alkyl group;

[0436] R 3 is selected from a hydrogen atom, an alkyl group, or a hydroxyalkyl group;

[0437] R aa is selected from a hydrogen atom, or an alkyl group;

[0438] x is 0, 1, or 2.

[0439] In certain technical solutions of the present invention, in the compound represented by the general formula (I-3), the definitions of certain groups are as follows (the undefined groups are as shown above):

[0440] L 1 is an alkylene group, -(CH 2 ) n1 C(O)(CH 2 ) m1 -, -(CH 2 ) n1 C(O)(CH 2 ) m1 NR aa (CH 2 ) m2 -, or -(CH 2 ) n1 S(O) m1 -;

[0441] L 2 is an oxygen atom, or -NR 4 -;

[0442] R 4 is selected from a hydrogen atom, or an alkyl group;

[0443] L 3 is -NH-;

[0444] Ring B is selected from a 3- to 10-membered monocyclic heteroaryl group, a 6- to 14-membered bridged heteroaryl group, or a 6- to 14-membered fused heteroaryl group;

[0445] Ring C is a heteroaryl group;

[0446] R 1 is a hydrogen atom, an alkyl group, a cyano group, a heterocyclic group, or a heteroaryl group; the said heterocyclic group, or heteroaryl group is optionally further substituted by an unsubstituted alkyl group, or a cyano group;

[0447] R 2 is selected from a hydrogen atom, or an alkyl group;

[0448] R 3 is selected from a hydrogen atom, an alkyl group, or a hydroxyalkyl group;

[0449] R aa is selected from a hydrogen atom, or an alkyl group;

[0450] x is 0, 1 or 2.

[0451] In certain technical solutions of the present invention, in the compound represented by the general formula (I-3), the definitions of some groups are as follows (the groups not defined are as shown above):

[0452] L 1 is an alkylene group of C 1 -C 4 of -(CH 2 ) n1 C(O)(CH2 ) m1 -, -(CH 2 ) n1 C(O)(CH 2 ) m1 NR aa (CH 2 ) m2 -, or -(CH 2 ) n1 S(O) m1 -;

[0453] L 2 is an oxygen atom, or -NR 4 -;

[0454] R 4 is selected from a hydrogen atom, or an alkyl group of C 1 -C 3 ;

[0455] L 3 is -NH-;

[0456] Ring B is selected from a 4- to 6-membered monocyclic heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 3", a 7- to 10-membered bridged heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 3", or a 7- to 10-membered fused heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 3";

[0457] Ring C is a 5- to 6-membered monocyclic heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 3";

[0458] R 1 is a hydrogen atom, an alkyl group of C 1 -C 3 ; a cyano group; a 4- to 6-membered monocyclic heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 3"; or a 5- to 6-membered heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 3"; the monocyclic heteroaryl group or heteroaryl group is optionally further substituted by an alkyl group of C 1 -C 3 ; or a cyano group;

[0459] R 2 is selected from a hydrogen atom, or an alkyl group of C 1 -C 3 ;

[0460] R 3 is selected from a hydrogen atom, an alkyl group of C 1 -C 3 ; or an alkyl group of C 1 -C3 hydroxyalkyl;

[0461] R aa selected from a hydrogen atom or C 1 -C 3 alkyl;

[0462] x is 0, 1 or 2.

[0463] Preferred:

[0464] L 1 is alkylene, -(CH 2 ) n1 C(O)(CH 2 ) m1 -, or -(CH 2 ) n1 C(O)(CH 2 ) m1 NR aa (CH 2 ) m2 -;

[0465] R 1 is alkyl, cyano, heterocyclic group or heteroaryl; the heterocyclic group is optionally further substituted by alkyl;

[0466] L 2 is an oxygen atom or -NR 4 -;

[0467] R 4 is selected from a hydrogen atom or alkyl;

[0468] L 3 is -NH-;

[0469] Ring B is a 6- to 14-membered bridged heterocyclic group;

[0470] Ring C is heteroaryl;

[0471] R 2 is selected from a hydrogen atom or alkyl;

[0472] R 3 is selected from a hydrogen atom or alkyl;

[0473] R aa is selected from a hydrogen atom or alkyl.

[0474] In certain technical solutions of the present invention, in the compound represented by the general formula (I-3), the definitions of some groups are as follows (the undefined groups are as shown above): When the L 1 is alkylene, the alkylene is preferably C 1 -C 4 alkylene, for example -CH2 -, -(CH 2 ) 2 -, -(CH 2 ) 3 - or -(CH 2 ) 4 -, more preferably -CH 2 -, or -(CH 2 ) 2 -.

[0475] In certain technical solutions of the present invention, in the compound represented by the general formula (I-3), the definitions of certain groups are as follows (the undefined groups are as shown above): When the L 1 is -(CH 2 ) n1 C(O)(CH 2 ) m1 -, the -(CH 2 ) n1 C(O)(CH 2 ) m1 - is preferably -C(O)-, -C(O)CH 2 -, or -CH 2 C(O)-.

[0476] In certain technical solutions of the present invention, in the compound represented by the general formula (I-3), the definitions of certain groups are as follows (the undefined groups are as shown above): When the L 1 is -(CH 2 ) n1 C(O)(CH 2 ) m1 NR aa (CH 2 ) m2 -, the -(CH 2 ) n1 C(O)(CH 2 ) m1 NR aa (CH 2 ) m2 - is preferably -C(O)CH 2 NH-, -C(O)CH 2 N(CH 3 )-, -C(O)CH 2 NHCH 2 -, -C(O)CH 2 NH(CH 2 ) 2 -, or -CH 2 C(O)N(CH 3 )-.

[0477] In certain technical solutions of the present invention, in the compounds represented by the general formula (I-3), the definitions of certain groups are as follows (the undefined groups are as shown above): When the L 1 is -(CH 2 ) n1 S(O) m1 -, the -(CH 2 ) n1 S(O) m1 - is preferably -S(O) 2 -.

[0478] In certain technical solutions of the present invention, in the compounds represented by the general formula (I-3), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 4 is an alkyl group, the alkyl group is preferably an alkyl group of C 1 -C 8 , more preferably an alkyl group of C 1 -C 6 , further preferably an alkyl group of C 1 -C 3 , such as methyl, ethyl, propyl or isopropyl, and further preferably methyl.

[0479] In certain technical solutions of the present invention, in the compounds represented by the general formula (I-3), the definitions of certain groups are as follows (the undefined groups are as shown above): When the ring B is a 3- to 10-membered monocyclic heterocyclic group, the 3- to 10-membered monocyclic heterocyclic group is preferably a 3- to 8-membered monocyclic heterocyclic group in which "the heteroatom is selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 4", more preferably a 4- to 6-membered monocyclic heterocyclic group in which "the heteroatom is selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 3", such as

[0480] In certain technical solutions of the present invention, in the compounds represented by the general formula (I-3), the definitions of certain groups are as follows (the undefined groups are as shown above): When the ring B is a 6- to 14-membered bridged heterocyclic group, the 6- to 14-membered bridged heterocyclic group is preferably a 6- to 14-membered bridged heterocyclic group in which "the heteroatom is selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 4", more preferably a 7- to 10-membered bridged heterocyclic group in which "the heteroatom is selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 3", such as

[0481] In certain technical solutions of the present invention, in the compound represented by the general formula (I-3), the definitions of certain groups are as follows (the undefined groups are as shown above): when the ring B is a 6-14 membered fused heterocyclic group, the 6-14 membered fused heterocyclic group is preferably a 6-14 membered fused heterocyclic group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-4", more preferably a 7-10 membered fused heterocyclic group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-3", for example

[0482] In certain technical solutions of the present invention, in the compound represented by the general formula (I-3), the definitions of certain groups are as follows (the undefined groups are as shown above): when the ring C is a heteroaryl group, the heteroaryl group is preferably a 6-14 membered heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-4", more preferably a 5-6 membered monocyclic heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-3", for example

[0483] In certain technical solutions of the present invention, in the compound represented by the general formula (I-3), the definitions of certain groups are as follows (the undefined groups are as shown above): when the R 1 is an alkyl group, the alkyl group is preferably an alkyl group of C 1 -C 8 more preferably an alkyl group of C 1 -C 6 even more preferably an alkyl group of C 1 -C 3 such as methyl, ethyl, propyl or isopropyl, and even more preferably methyl or ethyl.

[0484] In certain technical solutions of the present invention, in the compound represented by the general formula (I-3), the definitions of certain groups are as follows (the undefined groups are as shown above): when the R 1 is an alkoxy group, the alkoxy group is preferably an alkoxy group of C 1 -C 8 more preferably an alkoxy group of C 1 -C 6 even more preferably an alkoxy group of C 1 -C 3 such as methoxy, ethoxy, propoxy or isopropoxy, and even more preferably methoxy.

[0485] In certain technical solutions of the present invention, in the compound represented by the general formula (I-3), the definitions of certain groups are as follows (the undefined groups are as shown above): when the R 1 is a cycloalkyl group, the cycloalkyl group is preferably a C 3 -C8 cycloalkyl group, more preferably C 3 -C 6 cycloalkyl group, such as

[0486] In certain technical solutions of the present invention, in the compound represented by the general formula (I-3), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 1 is a heterocyclic group, the heterocyclic group is preferably a 3- to 8-membered monocyclic heterocyclic group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-4", more preferably a 4- to 6-membered monocyclic heterocyclic group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-3", such as

[0487] In certain technical solutions of the present invention, in the compound represented by the general formula (I-3), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 1 is an aryl group, the aryl group is preferably a 6- to 10-membered aryl group, more preferably a phenyl group.

[0488] In certain technical solutions of the present invention, in the compound represented by the general formula (I-3), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 1 is a heteroaryl group, the heteroaryl group is preferably a 5- to 10-membered heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-4", more preferably a 5- to 6-membered heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-3", such as

[0489] In certain technical solutions of the present invention, in the compound represented by the general formula (I-3), the definitions of some groups are as follows (the undefined groups are as shown above): When the heterocyclic group or heteroaryl group is optionally further substituted by an alkyl group, the alkyl group is preferably C 1 -C 8 alkyl group, more preferably C 1 -C 6 alkyl group, further preferably C 1 -C 3 alkyl group, such as methyl, ethyl, propyl or isopropyl, further preferably methyl.

[0490] In certain technical solutions of the present invention, in the compound represented by the general formula (I-3), the definitions of some groups are as follows (the undefined groups are as shown above): When the aryl group is optionally further substituted by an alkoxy group, the alkoxy group is preferably C 1 -C 8alkoxy group, more preferably C 1 -C 6 alkoxy group, still more preferably C 1 -C 3 alkoxy group, such as methoxy, ethoxy, propoxy or isopropoxy, still more preferably methoxy.

[0491] In certain technical solutions of the present invention, in the compound represented by the general formula (I-3), the definitions of some groups are as follows (the undefined groups are as shown above): when the R 2 is an alkyl group, the alkyl group is preferably C 1 -C 8 alkyl group, more preferably C 1 -C 6 alkyl group, still more preferably C 1 -C 3 alkyl group, such as methyl, ethyl, propyl or isopropyl, still more preferably methyl or ethyl.

[0492] In certain technical solutions of the present invention, in the compound represented by the general formula (I-3), the definitions of some groups are as follows (the undefined groups are as shown above): when the R 2 is a heterocyclic group, the heterocyclic group is preferably a 3- to 8-membered monocyclic heterocyclic group in which "the heteroatoms are selected from one or more of N, O and S, and the number of heteroatoms is 1-4", more preferably a 4- to 6-membered monocyclic heterocyclic group in which "the heteroatoms are selected from one or more of N, O and S, and the number of heteroatoms is 1-3", such as

[0493] In certain technical solutions of the present invention, in the compound represented by the general formula (I-3), the definitions of some groups are as follows (the undefined groups are as shown above): when the R 2 is -(CH 2 ) n1 SR aa when, the -(CH 2 ) n1 SR aa is preferably

[0494] In certain technical solutions of the present invention, in the compound represented by the general formula (I-3), the definitions of some groups are as follows (the undefined groups are as shown above): when the R 2 is an alkyl group, and the alkyl group is optionally further substituted by an unsubstituted alkoxy group, the alkoxy group is preferably C 1 -C 8 alkoxy group, more preferably C 1 -C 6 alkoxy group, still more preferably C 1-C 3 alkoxy groups such as methoxy, ethoxy, propoxy or isopropoxy, and more preferably methoxy.

[0495] In certain technical solutions of the present invention, in the compound represented by the general formula (I-3), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 2 is an alkyl group and the alkyl group is optionally further substituted by an unsubstituted or substituted heterocyclic group, the heterocyclic group is preferably a 3- to 8-membered monocyclic heterocyclic group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-4", and more preferably a 4- to 6-membered monocyclic heterocyclic group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-3", for example

[0496] In certain technical solutions of the present invention, in the compound represented by the general formula (I-3), the definitions of some groups are as follows (the undefined groups are as shown above): When the heterocyclic group is optionally further substituted by an alkyl group, the alkyl group is preferably C 1 -C 8 alkyl group, more preferably C 1 -C 6 alkyl group, and further preferably C 1 -C 3 alkyl group, such as methyl, ethyl, propyl or isopropyl, and further preferably methyl.

[0497] In certain technical solutions of the present invention, in the compound represented by the general formula (I-3), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 3 is an alkyl group, the alkyl group is preferably C 1 -C 8 alkyl group, more preferably C 1 -C 6 alkyl group, and further preferably C 1 -C 3 alkyl group, such as methyl, ethyl, propyl or isopropyl, and further preferably methyl or ethyl.

[0498] In certain technical solutions of the present invention, in the compound represented by the general formula (I-3), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 3 is a hydroxyalkyl group, the alkyl group is preferably C 1 -C 8 hydroxyalkyl group, more preferably C 1 -C 6 hydroxyalkyl group, and further preferably C 1 -C 3The hydroxyalkyl group, such as hydroxymethyl, hydroxyethyl, hydroxypropyl or hydroxyisopropyl, more preferably hydroxymethyl.

[0499] In certain technical solutions of the present invention, in the compound represented by the general formula (I-3), the definitions of some groups are as follows (the undefined groups are as shown above): when the R aa is an alkyl group, the alkyl group is preferably C 1 -C 8 alkyl group, more preferably C 1 -C 6 alkyl group, further preferably C 1 -C 3 alkyl group, such as methyl, ethyl, propyl or isopropyl, further preferably methyl.

[0500] In certain technical solutions of the present invention, the compound represented by the general formula (I) can be the compound represented by the following formula (I-4):

[0501]

[0502] Wherein, L 1 is selected from alkylene, -(CH 2 ) n1 C(O)(CH 2 ) m1 -, -(CH 2 ) n1 C(O)(CH 2 ) m1 NR aa (CH 2 ) m2 -, or -(CH 2 ) n1 S(O) m1 -;

[0503] R 1 is selected from halogen, cyano, alkyl, alkoxy, heterocyclic group, or heteroaryl; the alkyl group is optionally further substituted by halogen or alkoxy; the heterocyclic group is optionally further substituted by cyano;

[0504] When L 1 is -(CH 2 ) n1 C(O)(CH 2 ) m1 -, R 1 is alkyl, heterocyclic group, or heteroaryl; the alkyl group is optionally further substituted by halogen; the heterocyclic group or heteroaryl is optionally further substituted by alkyl;

[0505] L 2 、L 3 、R2 、R 3 、The definitions of ring B, ring C, x and y are as described above.

[0506] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of certain groups are as follows (the groups not defined are as shown above):

[0507] L 1 is selected from alkylene, -(CH 2 ) n1 C(O)(CH 2 ) m1 -, -(CH 2 ) n1 C(O)(CH 2 ) m1 NR aa (CH 2 ) m2 -, or -(CH 2 ) n1 S(O) m1 -;

[0508] R 1 is selected from halogen, cyano, alkyl, alkoxy, heterocyclic group, or heteroaryl; the alkyl is optionally further substituted by halogen or alkoxy; the heterocyclic group is optionally further substituted by cyano;

[0509] When L 1 is -(CH 2 ) n1 C(O)(CH 2 ) m1 -, R 1 is alkyl, heterocyclic group, or heteroaryl; the alkyl is optionally further substituted by halogen; the heterocyclic group or heteroaryl is optionally further substituted by alkyl;

[0510] L 2 is -NR 4 -;

[0511] R 4 is selected from a hydrogen atom, or alkyl;

[0512] L 3 is -NH-;

[0513] Ring B is selected from 3- to 10-membered monocyclic heterocyclic groups, 6- to 14-membered bridged heterocyclic groups, or 6- to 14-membered fused heterocyclic groups;

[0514] Ring C is heteroaryl;

[0515] R 2Selected from a hydrogen atom, an alkyl group, an alkoxy group, a halogen, a cycloalkyl group, a heterocyclic group, an aryl group, a heteroaryl group, -(CH 2 ) n1 OR cc 、or -(CH 2 ) n1 NR aa R bb ; the alkyl group is optionally further substituted by an alkyl group or an unsubstituted heterocyclic group; the alkoxy group is optionally further substituted by an unsubstituted alkoxy group, an alkyl group or an unsubstituted heterocyclic group, or an unsubstituted heteroaryl group; the heterocyclic group is optionally further substituted by an unsubstituted alkyl group, an unsubstituted alkoxy group, or an alkyl-substituted amino group; the heteroaryl group is optionally further substituted by a halogen-substituted or unsubstituted alkyl group, an unsubstituted alkoxy group, or an unsubstituted cycloalkyl group;

[0516] R aa and R bb are the same or different and are each independently selected from a hydrogen atom or an alkyl group; the alkyl group is optionally further substituted by an alkyl group or an unsubstituted heterocyclic group, or an unsubstituted heteroaryl group;

[0517] R cc is a heterocyclic group; the heterocyclic group is optionally further substituted by an unsubstituted alkyl group;

[0518] R 3 is selected from a hydrogen atom, an alkyl group, or a hydroxyalkyl group.

[0519] In some technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of some groups are as follows (the undefined groups are as shown above):

[0520] L 1 is selected from an alkylene group, -(CH 2 ) n1 C(O)(CH 2 ) m1 -, -(CH 2 ) n1 C(O)(CH 2 ) m1 NR aa (CH 2 ) m2 -, or -(CH 2 ) n1 S(O) m1 -;

[0521] R 1Selected from halogen, cyano, alkyl, heterocyclic group, or heteroaryl; the alkyl is optionally further substituted by halogen or alkoxy; the heterocyclic group is optionally further substituted by cyano; the heteroaryl is optionally further substituted by alkyl;

[0522] When L 1 is -(CH 2 ) n1 C(O)(CH 2 ) m1 -, R 1 is alkyl, heterocyclic group, or heteroaryl; the alkyl is optionally further substituted by halogen; the heterocyclic group or heteroaryl is optionally further substituted by alkyl;

[0523] L 2 is -NR 4 -;

[0524] R 4 is selected from a hydrogen atom, or alkyl;

[0525] L 3 is -NH-;

[0526] Ring B is selected from a 3- to 10-membered monocyclic heterocyclic group, a 6- to 14-membered bridged heterocyclic group, or a 6- to 14-membered fused heterocyclic group;

[0527] Ring C is heteroaryl;

[0528] R 2 is selected from a hydrogen atom, alkyl, alkoxy, halogen, cycloalkyl, heterocyclic group, aryl, or heteroaryl; the heteroaryl is optionally further substituted by unsubstituted alkyl, unsubstituted alkoxy, or unsubstituted cycloalkyl;

[0529] R 3 is selected from a hydrogen atom, alkyl, or hydroxyalkyl.

[0530] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of certain groups are as follows (the groups not defined are as shown above):

[0531] L 1 is selected from the alkylene group of C 1 -C 4 of -(CH 2 ) n1 C(O)(CH 2 ) m1 -, -(CH 2 ) n1 C(O)(CH 2 ) m1 NR aa (CH 2 ) m2-, or -(CH 2 ) n1 S(O) m1 -;

[0532] R 1 is selected from halogen, cyano, C 1 -C 3 alkyl, a 4- to 6-membered monocyclic heterocyclic group in which "the heteroatom is selected from one or more of N, O, and S and the number of heteroatoms is 1 to 3", or a 5- to 6-membered monocyclic heteroaryl group in which "the heteroatom is selected from one or more of N, O, and S and the number of heteroatoms is 1 to 3"; the C 1 -C 3 alkyl is optionally further substituted by halogen or C 1 -C 3 alkoxy; the heterocyclic group is optionally further substituted by cyano; the heteroaryl group is optionally further substituted by C 1 -C 3 alkyl;

[0533] When L 1 is -(CH 2 ) n1 C(O)(CH 2 ) m1 -, R 1 is C 1 -C 3 alkyl, a 4- to 6-membered monocyclic heterocyclic group in which "the heteroatom is selected from one or more of N, O, and S and the number of heteroatoms is 1 to 3", or a 5- to 6-membered monocyclic heteroaryl group in which "the heteroatom is selected from one or more of N, O, and S and the number of heteroatoms is 1 to 3"; the C 1 -C 3 alkyl is optionally further substituted by halogen; the heterocyclic group or heteroaryl group is optionally further substituted by C 1 -C 3 alkyl;

[0534] L 2 is -NR 4 -;

[0535] R 4 is selected from a hydrogen atom, or C 1 -C 3 alkyl;

[0536] L 3 is -NH-;

[0537] Ring B is selected from a 4- to 6-membered monocyclic heteroaryl group in which "the heteroatom is one or more selected from N, O, and S, and the number of heteroatoms is 1 to 3", a 7- to 10-membered bridged heteroaryl group in which "the heteroatom is one or more selected from N, O, and S, and the number of heteroatoms is 1 to 3", or a 7- to 10-membered fused heteroaryl group in which "the heteroatom is one or more selected from N, O, and S, and the number of heteroatoms is 1 to 3";

[0538] Ring C is a 5- to 6-membered monocyclic heteroaryl group in which "the heteroatom is one or more selected from N, O, and S, and the number of heteroatoms is 1 to 3";

[0539] R 2 is selected from a hydrogen atom, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, halogen, cycloalkyl, a 4- to 6-membered monocyclic heteroaryl group in which "the heteroatom is one or more selected from N, O, and S, and the number of heteroatoms is 1 to 3", a 6- to 10-membered aryl group, or a 5- to 6-membered heteroaryl group in which "the heteroatom is one or more selected from N, O, and S, and the number of heteroatoms is 1 to 3"; the heteroaryl group is optionally further substituted with an alkyl group selected from unsubstituted C 1 -C 3 alkyl, an alkoxy group selected from unsubstituted C 1 -C 3 alkoxy, or a 4- to 6-membered monocyclic heteroaryl group in which "the heteroatom is one or more selected from N, O, and S, and the number of heteroatoms is 1 to 3" and is unsubstituted;

[0540] R 3 is selected from a hydrogen atom, C 1 -C 3 alkyl, or C 1 -C 3 hydroxyalkyl.

[0541] L 1 is an alkylene group, or -(CH 2 ) n1 S(O) m1 -;

[0542] R 1 is a cyano group, or a heterocyclic group; the heterocyclic group is optionally further substituted with a cyano group;

[0543] L 2 is -NH-;

[0544] L 3 is -NH-;

[0545] R 2 is selected from a hydrogen atom, halogen, or alkoxy;

[0546] R 3Selected from a hydrogen atom or an alkyl group.

[0547] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of certain groups are as follows (the undefined groups are as shown above): When the L 1 is an alkylene group, the alkylene group is preferably C 1 -C 4 alkylene group, such as -CH 2 -, -(CH 2 ) 2 -, -(CH 2 ) 3 - or -(CH 2 ) 4 -, more preferably -CH 2 -, or -(CH 2 ) 2 -.

[0548] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of certain groups are as follows (the undefined groups are as shown above): When the L 1 is -(CH 2 ) n1 C(O)(CH 2 ) m1 -, the -(CH 2 ) n1 C(O)(CH 2 ) m1 - is preferably -C(O)-, -C(O)CH 2 -, or -CH 2 C(O)-.

[0549] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of certain groups are as follows (the undefined groups are as shown above): When the L 1 is -(CH 2 ) n1 C(O)(CH 2 ) m1 NR aa (CH 2 ) m2 -, the -(CH 2 ) n1 C(O)(CH 2 ) m1 NR aa (CH 2 ) m2 - is preferably -C(O)CH 2 NH-, or -C(O)CH 2 N(CH3 )-.

[0550] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of certain groups are as follows (the undefined groups are as shown above): When the L 1 is -(CH 2 ) n1 S(O) m1 -, the -(CH 2 ) n1 S(O) m1 - is preferably -S(O) 2 -.

[0551] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 4 is an alkyl group, the alkyl group is preferably a C 1 -C 8 alkyl group, more preferably a C 1 -C 6 alkyl group, further preferably a C 1 -C 3 alkyl group, such as methyl, ethyl, propyl or isopropyl, and further preferably methyl.

[0552] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of certain groups are as follows (the undefined groups are as shown above): When the ring B is a 3- to 10-membered monocyclic heterocyclic group, the 3- to 10-membered monocyclic heterocyclic group is preferably a 3- to 8-membered monocyclic heterocyclic group in which "the heteroatom is selected from one or more of N, O and S, and the number of heteroatoms is 1 to 4", and more preferably a 4- to 6-membered monocyclic heterocyclic group in which "the heteroatom is selected from one or more of N, O and S, and the number of heteroatoms is 1 to 3", such as

[0553] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of certain groups are as follows (the undefined groups are as shown above): When the ring B is a 6- to 14-membered bridged heterocyclic group, the 6- to 14-membered bridged heterocyclic group is preferably a 6- to 14-membered bridged heterocyclic group in which "the heteroatom is selected from one or more of N, O and S, and the number of heteroatoms is 1 to 4", and more preferably a 7- to 10-membered bridged heterocyclic group in which "the heteroatom is selected from one or more of N, O and S, and the number of heteroatoms is 1 to 3", such as

[0554] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of certain groups are as follows (the undefined groups are as shown above): When the ring B is a 6-14 membered fused heterocyclic group, the 6-14 membered fused heterocyclic group is preferably a 6-14 membered fused heterocyclic group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-4", more preferably a 7-10 membered fused heterocyclic group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-3", for example

[0555] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of certain groups are as follows (the undefined groups are as shown above): When the ring C is a heteroaryl group, the heteroaryl group is preferably a 6-14 membered heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-4", more preferably a 5-6 membered monocyclic heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-3", for example

[0556] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 1 is a halogen, the halogen is preferably fluorine.

[0557] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 1 is an alkyl group, the alkyl group is preferably an alkyl group of C 1 -C 8 more preferably an alkyl group of C 1 -C 6 even more preferably an alkyl group of C 1 -C 3 such as methyl, ethyl, propyl or isopropyl, even more preferably methyl or ethyl.

[0558] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 1 is an alkoxy group, the alkoxy group is preferably an alkoxy group of C 1 -C 8 more preferably an alkoxy group of C 1 -C 6 even more preferably an alkoxy group of C 1 -C 3 such as methoxy, ethoxy, propoxy or isopropoxy, even more preferably methoxy or ethoxy.

[0559] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 1 is a heterocyclic group, the heterocyclic group is preferably a 3- to 8-membered monocyclic heterocyclic group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-4", more preferably a 4- to 6-membered monocyclic heterocyclic group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-3". For example

[0560] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 1 is a heteroaryl group, the heteroaryl group is preferably a 5- to 10-membered heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-4", more preferably a 5- to 6-membered heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-3". For example

[0561] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 2 is an alkyl group, the alkyl group is preferably a C 1 -C 8 alkyl group, more preferably a C 1 -C 6 alkyl group, further preferably a C 1 -C 3 alkyl group, such as methyl, ethyl, propyl or isopropyl, and further preferably methyl or ethyl.

[0562] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 2 is an alkoxy group, the alkoxy group is preferably a C 1 -C 8 alkoxy group, more preferably a C 1 -C 6 alkoxy group, further preferably a C 1 -C 3 alkoxy group, such as methoxy, ethoxy, propoxy or isopropoxy, and further preferably methoxy or ethoxy.

[0563] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 2When X is a halogen, the halogen is preferably fluorine, chlorine or bromine.

[0564] In certain embodiments of the present invention, in the compound represented by the general formula (I-4), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 2 is a heterocyclic group, the heterocyclic group is preferably a 3- to 8-membered monocyclic heterocyclic group in which "the heteroatoms are selected from one or more of N, O and S, and the number of heteroatoms is 1 to 4", more preferably a 4- to 6-membered monocyclic heterocyclic group in which "the heteroatoms are selected from one or more of N, O and S, and the number of heteroatoms is 1 to 3", for example

[0565] In certain embodiments of the present invention, in the compound represented by the general formula (I-4), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 2 is an aryl group, the aryl group is preferably a 6- to 10-membered aryl group, more preferably a phenyl group.

[0566] In certain embodiments of the present invention, in the compound represented by the general formula (I-4), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 2 is a heteroaryl group, the heteroaryl group is preferably a 5- to 10-membered heteroaryl group in which "the heteroatoms are selected from one or more of N, O and S, and the number of heteroatoms is 1 to 4", more preferably a 5- to 6-membered heteroaryl group in which "the heteroatoms are selected from one or more of N, O and S, and the number of heteroatoms is 1 to 3", for example

[0567] In certain embodiments of the present invention, in the compound represented by the general formula (I-4), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 2 is -(CH 2 ) n1 NR aa R bb , the -(CH 2 ) n1 NR aa R bb is preferably

[0568] In certain embodiments of the present invention, in the compound represented by the general formula (I-4), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 2When R is an alkyl group, and when the alkyl group is optionally further substituted by an unsubstituted or substituted heterocyclic group, the heterocyclic group is preferably a 3- to 8-membered monocyclic heterocyclic group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 4", more preferably a 4- to 6-membered monocyclic heterocyclic group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 3". For example

[0569] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 2 is an alkoxy group, and when the alkoxy group is optionally further substituted by an unsubstituted alkoxy group, the unsubstituted alkoxy group is preferably a C 1 -C 8 alkoxy group, more preferably a C 1 -C 6 alkoxy group, further preferably a C 1 -C 3 alkoxy group, such as methoxy, ethoxy, propoxy or isopropoxy, and further preferably methoxy.

[0570] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 2 is an alkoxy group, and when the alkoxy group is optionally further substituted by an alkyl group or an unsubstituted heterocyclic group, the heterocyclic group is preferably a 3- to 8-membered monocyclic heterocyclic group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 4", more preferably a 4- to 6-membered monocyclic heterocyclic group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1 to 3". For example

[0571] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of some groups are as follows (the undefined groups are as shown above): When the R 2 is an alkoxy group, and when the alkoxy group is optionally further substituted by an alkyl group or an unsubstituted heterocyclic group, the alkyl group is preferably a C 1 -C 8 alkyl group, more preferably a C 1 -C 6 alkyl group, further preferably a C 1 -C 3 alkyl group, such as methyl, ethyl, propyl or isopropyl, and further preferably methyl.

[0572] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 2 is an alkoxy group, and the alkoxy group is optionally further substituted by an unsubstituted heteroaryl group, the heteroaryl group is preferably a 5- to 10-membered heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-4", more preferably a 5- to 6-membered heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-3", for example

[0573] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 2 is a heterocyclic group, and the heterocyclic group is optionally further substituted by an unsubstituted alkyl group, the alkyl group is preferably a C 1 -C 8 alkyl group, more preferably a C 1 -C 6 alkyl group, further preferably a C 1 -C 3 alkyl group, such as methyl, ethyl, propyl or isopropyl, and further preferably methyl.

[0574] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 2 is a heterocyclic group, and the heterocyclic group is optionally further substituted by an unsubstituted alkoxy group, the alkoxy group is preferably a C 1 -C 8 alkoxy group, more preferably a C 1 -C 6 alkoxy group, further preferably a C 1 -C 3 alkoxy group, such as methoxy, ethoxy, propoxy or isopropoxy, and further preferably methoxy.

[0575] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 2 is a heterocyclic group, and the heterocyclic group is optionally further substituted by an alkyl-substituted amino group, the alkyl group is preferably a C 1 -C 8 alkyl group, more preferably a C 1 -C 6 alkyl group, further preferably a C 1 -C 3alkyl groups such as methyl, ethyl, propyl or isopropyl, more preferably methyl.

[0576] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of some groups are as follows (the undefined groups are as shown above): when the R 2 is a heteroaryl group, and the heteroaryl group is optionally further substituted by a halogen or an unsubstituted alkyl group, the alkyl group is preferably C 1 -C 8 alkyl group, more preferably C 1 -C 6 alkyl group, further preferably C 1 -C 3 alkyl group, such as methyl, ethyl, propyl or isopropyl, more preferably methyl.

[0577] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of some groups are as follows (the undefined groups are as shown above): when the R 2 is a heteroaryl group, and the heteroaryl group is optionally further substituted by a halogen or an unsubstituted alkyl group, the halogen is preferably fluorine.

[0578] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of some groups are as follows (the undefined groups are as shown above): when the R 2 is a heteroaryl group, and the heteroaryl group is optionally further substituted by an unsubstituted alkoxy group, the alkoxy group is preferably C 1 -C 8 alkoxy group, more preferably C 1 -C 6 alkoxy group, further preferably C 1 -C 3 alkoxy group, such as methoxy, ethoxy, propoxy or isopropoxy, more preferably methoxy.

[0579] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of some groups are as follows (the undefined groups are as shown above): when the R 2 is a heteroaryl group, and the heteroaryl group is optionally further substituted by an unsubstituted cycloalkyl group, the cycloalkyl group is preferably C 3 -C 8 cycloalkyl group, more preferably C 3 -C 6 cycloalkyl group, such as

[0580] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R aa and R bb are independently alkyl groups, the alkyl group is preferably a C 1 -C 8 alkyl group, more preferably a C 1 -C 6 alkyl group, further preferably a C 1 -C 3 alkyl group, such as methyl, ethyl, propyl or isopropyl, and further preferably methyl.

[0581] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R aa and R bb are independently alkyl groups, and the alkyl group is optionally further substituted by an alkyl group or an unsubstituted heterocyclic group, the heterocyclic group is preferably a 3- to 8-membered monocyclic heterocyclic group in which "the heteroatoms are selected from one or more of N, O and S, and the number of heteroatoms is 1-4", more preferably a 4- to 6-membered monocyclic heterocyclic group in which "the heteroatoms are selected from one or more of N, O and S, and the number of heteroatoms is 1-3", such as

[0582] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R aa and R bb are independently alkyl groups, and the alkyl group is optionally further substituted by an alkyl group or an unsubstituted heterocyclic group, the alkyl group is preferably a C 1 -C 8 alkyl group, more preferably a C 1 -C 6 alkyl group, further preferably a C 1 -C 3 alkyl group, such as methyl, ethyl, propyl or isopropyl, and further preferably methyl.

[0583] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R aa and R bb are independently alkyl groups, and the alkyl group is optionally further substituted by an unsubstituted heteroaryl group, the heteroaryl group is preferably a 5- to 10-membered heteroaryl group in which "the heteroatoms are selected from one or more of N, O and S, and the number of heteroatoms is 1-4", more preferably a 5- to 6-membered heteroaryl group in which "the heteroatoms are selected from one or more of N, O and S, and the number of heteroatoms is 1-3", such as

[0584] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 3 is an alkyl group, the alkyl group is preferably C 1 -C 8 alkyl group, more preferably C 1 -C 6 alkyl group, further preferably C 1 -C 3 alkyl group, such as methyl, ethyl, propyl or isopropyl, and further preferably methyl or ethyl.

[0585] In certain technical solutions of the present invention, in the compound represented by the general formula (I-4), the definitions of certain groups are as follows (the undefined groups are as shown above): When the R 3 is a hydroxyalkyl group, the alkyl group is preferably C 1 -C 8 hydroxyalkyl group, more preferably C 1 -C 6 hydroxyalkyl group, further preferably C 1 -C 3 hydroxyalkyl group, such as hydroxymethyl, hydroxyethyl, hydroxypropyl or hydroxyisopropyl, and further preferably hydroxymethyl.

[0586] In certain technical solutions of the present invention, the compound represented by the formula (I) can be any of the following structures,

[0587]

[0588]

[0589]

[0590] In certain technical solutions of the present invention, the compound represented by the general formula (I) can be the compound represented by the following formula (I-5):

[0591]

[0592] Among them,

[0593] R 2a is a hydrogen atom, a cyano group, an alkyl group or an alkoxy group;

[0594] R 2b is a hydrogen atom or a cyano group;

[0595] R 2c is a hydrogen atom or a halogen;

[0596] R 2d is a hydrogen atom or a hydroxyl group;

[0597] n is 1 or 2;

[0598] L 1 、L 2 、L 3 、R 1 、R 3 The definitions of ring C and y are the same as described above.

[0599] In some technical solutions of the present invention, the compound represented by formula (I-5) is preferably the compound represented by formula (I-5-1),

[0600]

[0601] wherein, n, R 2a 、R 2b 、R 2c and R 2d are defined the same as described above.

[0602] In some technical solutions of the present invention, the compound represented by formula (I) can be any of the following structures,

[0603] In some technical solutions of the present invention, in the compound represented by the general formula (I), the definitions of some groups are as follows (the groups not defined are as shown above):

[0604] L 3 is selected from a bond, or -C(O)NR aa -;

[0605] R aa is selected from a hydrogen atom, or an alkyl group.

[0606] In some technical solutions of the present invention, the compound represented by formula (I) is preferably the compound represented by formula (I-6),

[0607]

[0608] wherein, L 2 is selected from -NH-;

[0609] L 3 is selected from a bond, or -C(O)NH-;

[0610] Ring A is selected from 6-14 membered fused heteroaryl groups;

[0611] Ring C is selected from heteroaryl groups;

[0612] y is 0, 1, 2 or 3;

[0613] n is 1 or 2.

[0614] In certain technical solutions of the present invention, the compound represented by formula (I) may have the following structure

[0615]

[0616] In certain technical solutions of the present invention, the compound represented by the general formula (I) may be the compound represented by the following formula (I-7):

[0617]

[0618] wherein, ring C is a heteroaryl, and ring C is not

[0619] L 1 、L 2 、L 3 、R 1 、R 2 、R 3 、ring A, x and y are defined as described above.

[0620] In certain technical solutions of the present invention, in the compound represented by the general formula (I-7), the definitions of some groups are as follows (the groups not defined are as shown above):

[0621] Ring C is a heteroaryl, and ring C is not

[0622] L 1 is selected from alkylene, -(CH 2 ) n1 C(O)(CH 2 ) m1 -, -(CH 2 ) n1 C(O)(CH 2 ) m1 NR aa (CH 2 ) m2 -, or -(CH 2 ) n1 S(O) m1 -;

[0623] L 2 is selected from an oxygen atom, or -NR 4 -;

[0624] R 4 is selected from a hydrogen atom, or an alkyl group;

[0625] L 3 is a hydrogen atom;

[0626] Ring A is a 6- to 14-membered fused heteroaryl group;

[0627] R 1 is a hydrogen atom, a halogen, an alkyl group, a cyano group, or a heterocyclic group; the heterocyclic group is optionally further substituted by a cyano group;

[0628] R 2 is a hydrogen atom;

[0629] R 3 is selected from a hydrogen atom, an alkyl group, a hydroxyalkyl group, a cycloalkyl group, -(CH 2 ) n1 C(O)NR aa R bb 、or -(CH 2 ) n1 S(O) m1 NR aa R bb ;

[0630] R aa and R bb are independently selected from a hydrogen atom or an alkyl group.

[0631] In certain technical solutions of the present invention, in the compound represented by the general formula (I-7), the definitions of some groups are as follows (the undefined groups are as shown above):

[0632] Ring C is a heteroaryl group, and Ring C is not

[0633] L 1 is selected from an alkylene group, -(CH 2 ) n1 C(O)(CH 2 ) m1 -, -(CH 2 ) n1 C(O)(CH 2 ) m1 NR aa (CH 2 ) m2 -;

[0634] L 2 is selected from an oxygen atom or -NR 4 -;

[0635] R 4 is selected from a hydrogen atom or an alkyl group;

[0636] L 3 is a hydrogen atom;

[0637] Ring A is a 6- to 14-membered fused heteroaryl group;

[0638] R 1 is a hydrogen atom, halogen, alkyl, cyano, or heterocyclic group;

[0639] R 2 is a hydrogen atom;

[0640] R 3 is selected from a hydrogen atom, alkyl, hydroxyalkyl, -(CH 2 ) n1 C(O)NR aa R bb ;

[0641] R aa and R bb are independently selected from a hydrogen atom or alkyl.

[0642] In certain technical solutions of the present invention, in the compound represented by the general formula (I-7), the definitions of some groups are as follows (the undefined groups are as shown above): when the ring C is a heteroaryl group, the heteroaryl group is preferably a 6-14 membered heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-4", and more preferably a 5-6 membered monocyclic heteroaryl group in which "the heteroatoms are selected from one or more of N, O, and S, and the number of heteroatoms is 1-3". The 5-6 membered monocyclic heteroaryl group is preferably

[0643] In certain technical solutions of the present invention, the compound represented by the formula (I) can be any of the following structures,

[0644]

[0645] In certain technical solutions of the present invention, the compound represented by the general formula (I) can be the compound represented by the following formula (I-8):

[0646]

[0647] wherein, R 3a and R 3b are independently a hydrogen atom, halogen, hydroxy, cyano, alkyl, hydroxyalkyl, alkoxy, cycloalkyl, heterocyclic group or -(CH 2 ) n1 C(O)NR aa R bb ; the alkyl, cycloalkyl or heterocyclic group is optionally further substituted with a group selected from halogen, hydroxy, unsubstituted alkyl;

[0648] R aa and R bb are the same or different and are each independently selected from a hydrogen atom or alkyl;

[0649] When R 3a is methyl, R 3b is not a hydrogen atom;

[0650] R 1 , L 1 , L 2 and L 3 are as defined above;

[0651] n is 1 or 2.

[0652] In certain technical solutions of the present invention, in the compound represented by the general formula (I-8), the definitions of some groups are as follows (the undefined groups are as shown above):

[0653] R 3a and R 3b independently are a hydrogen atom, a halogen, a hydroxyl group, a cyano group, an alkyl group, a hydroxyalkyl group, an alkoxy group, a cycloalkyl group, a heterocyclic group or -(CH 2 ) n1 C(O)NR aa R bb ; the alkyl group, cycloalkyl group or heterocyclic group is optionally further substituted by a halogen, a hydroxyl group, an unsubstituted alkyl group;

[0654] R aa and R bb are the same or different and each independently is a hydrogen atom or an alkyl group;

[0655] When R 3a is methyl, R 3b is not a hydrogen atom;

[0656] L 1 is selected from an alkylene group or -(CH 2 ) n1 S(O) m1 -;

[0657] L 2 is -NR 4 -;

[0658] L 3 is -NH-;

[0659] R 1 is selected from a cyano group or a heterocyclic group; the heterocyclic group is optionally further substituted by a cyano group;

[0660] n is 1 or 2.

[0661] In certain technical solutions of the present invention, in the compound represented by the general formula (I-8), the definitions of some groups are as follows (the undefined groups are as shown above):

[0662] R 3a and R 3b are independently a hydrogen atom, a halogen, an alkyl group, a hydroxyalkyl group, or a cycloalkyl group;

[0663] When R 3a is a methyl group, R 3b is not a hydrogen atom;

[0664] L 1 is selected from alkylene groups;

[0665] L 2 is -NH-;

[0666] L 3 is -NH-;

[0667] R 1 is a cyano group;

[0668] n is 1 or 2.

[0669] In certain technical solutions of the present invention, the compound represented by formula (I) may be any of the following structures,

[0670]

[0671] In certain technical solutions of the present invention, in the compound represented by the general formula (I), the compound represented by the general formula (I) may be a compound represented by the following formula (I-9), and the definitions of certain groups are as follows (the undefined groups are as shown above):

[0672]

[0673] wherein, ring B is selected from 3- to 10-membered monocyclic heterocyclic groups, or 6- to 14-membered fused heterocyclic groups;

[0674] R 1 , R 3 , L 1 , L 2 , L 3 and the definition of y are the same as those described above.

[0675] In certain technical solutions of the present invention, in the compound represented by the general formula (I-8), the definitions of certain groups are as follows (the undefined groups are as shown above):

[0676] Ring B is selected from 3- to 10-membered monocyclic heterocyclic groups, or 6- to 14-membered fused heterocyclic groups;

[0677] L 1 is selected from alkylene groups, or -(CH 2 ) n1 S(O) m1 -;

[0678] L 2 is -NH-;

[0679] L 3 is -NH-;

[0680] R 1 is selected from a cyano group, or a heterocyclic group; the heterocyclic group is optionally further substituted by a cyano group;

[0681] R 3 is selected from a hydrogen atom, or an alkyl group;

[0682] y is 0, 1 or 2.

[0683] In certain technical solutions of the present invention, the compound represented by formula (I) may be any of the following structures,

[0684] In certain technical solutions of the present invention, among the compounds represented by the general formula (I), the compound represented by the general formula (I) may be the compound represented by the following formula (I - 10), and the definitions of some groups are as follows (the undefined groups are as shown above):

[0685]

[0686] wherein, L 2 is selected from an oxygen atom, or -NR 4 -;

[0687] R 4 is an alkyl group;

[0688] R 1 、R 3 、L 1 、L 3 and the definition of y are the same as those described above.

[0689] In certain technical solutions of the present invention, among the compounds represented by the general formula (I - 10), the definitions of some groups are as follows (the undefined groups are as shown above):

[0690] L 2 is selected from an oxygen atom, or -NR 4 -;

[0691] R 4 is an alkyl group;

[0692] L 1 is selected from an alkylene group, or -(CH 2 ) n1 S(O) m1 -;

[0693] L 3is -NH-;

[0694] R 1 is selected from a cyano group, or a heterocyclic group; the heterocyclic group is optionally further substituted by a cyano group;

[0695] R 3 is selected from a hydrogen atom, or an alkyl group;

[0696] y is 0, 1 or 2.

[0697] In certain technical solutions of the present invention, the compound represented by formula (I) may be any of the following structures,

[0698]

[0699] In certain technical solutions of the present invention, the compound represented by formula (I) may be any of the following structures,

[0700]

[0701]

[0702]

[0703]

[0704]

[0705]

[0706]

[0707]

[0708]

[0709]

[0710]

[0711]

[0712]

[0713] The object of the present invention is to provide a compound represented by general formula (I), its stereoisomers or its pharmaceutically acceptable salts, wherein the structure of the compound represented by general formula (I) is as follows:

[0714]

[0715] Wherein:

[0716] L 1 Selected from a bond, an alkylene, an alkenylene, an alkynyl, a cycloalkyl, a heterocyclic group, -(CH 2 ) n1 C(O)(CH 2 ) m1 -, -(CH 2 ) n1 C(O)(CH 2 ) m1 NR aa (CH 2 ) m2 -, -NR aa (CH 2 ) n1 -, -(CH 2 ) n1 S(O) m1 - or -(CH 2 ) n1 S(O) m1 NR aa -;

[0717] L 2 Selected from a bond, an oxygen atom, a sulfur atom, -CR aa R bb -, -(CH 2 ) n1 C(O)-, -NR 4 - or -(CH 2 ) n1 S(O) m1 -;

[0718] L 3 Selected from a bond, -NR aa - or -C(O)NR aa -;

[0719] Ring A is selected from 6- to 14-membered heteroaryl groups, wherein the 6- to 14-membered heteroaryl groups are selected from 6- to 14-membered fused heteroaryl groups; preferably 5-fused 5-membered heteroaryl groups, 5-fused 6-membered heteroaryl groups or 6-fused 6-membered heteroaryl groups;

[0720] Ring B is selected from 3- to 10-membered monocyclic heteroalkyl groups, 6- to 14-membered bridged heteroalkyl groups or 6- to 14-membered fused heteroalkyl groups;

[0721] Ring C is selected from heteroaryl groups;

[0722] R 1 Selected from a hydrogen atom, a deuterium atom, an oxo group, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, an alkoxy group, a halogenated alkoxy group, a hydroxyalkyl group, a halogen, an amino group, a nitro group, a hydroxy group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclic group, an oxoheterocyclic group, a thioheterocyclic group, an aryl group, a heteroaryl group, -(CH 2 )n1 R aa 、 -(CH 2 ) n1 OR aa 、 -NR aa C(O)(CH 2 ) n1 OR aa 、 -NR aa C(=S)(CH 2 ) n1 OR bb 、 -(CH 2 ) n1 SR aa 、 -(CH 2 ) n1 C(O)R aa 、 -(CH 2 ) n1 C(O)OR aa 、 -(CH 2 ) n1 S(O) m1 R aa 、 -(CH 2 ) n1 NR aa R bb 、 -(CH 2 ) n1 C(O)NR aa R bb 、 -(CH 2 ) n1 NR aa C(O)R bb or -(CH 2 ) n1 NR aa S(O) m1 R bb , wherein the alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, amino, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl and heteroaryl are optionally further selected from a hydrogen atom, a deuterium atom, an alkyl, a haloalkyl, a halogen, an amino, an oxo group, a nitro group, a cyano group, a hydroxy group, an alkenyl, an alkynyl, an alkoxy, a haloalkoxy, a hydroxyalkyl, a cycloalkyl, a heterocyclic group, an aryl, a heteroaryl, -(CH 2 ) n1 -, -(CH 2 ) n1 R cc 、 -(CH 2 ) n1 OR cc 、 -(CH 2 ) n1 SR cc 、 -(CH2 ) n1 C(O)R cc 、-(CH 2 ) n1 C(O)OR cc 、-(CH 2 ) n1 S(O) m1 R cc 、-(CH 2 ) n1 NR cc R dd 、-(CH 2 ) n1 C(O)NR cc R dd 、-(CH 2 ) n1 NR cc C(O)R dd or -(CH 2 ) n1 NR cc S(O) m1 R dd is substituted by one or more substituents;

[0723] R 2 is selected from the group consisting of a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a hydroxyalkyl group, a heterocyclic group, an oxoheterocyclic group, a thioheterocyclic group, an aryl group, a heteroaryl group, -(CH 2 ) n1 R aa 、-(CH 2 ) n1 O(CH 2 ) m1 R aa 、-(CH 2 ) n1 OR aa 、-(CH 2 ) n1 NR aa (CH 2 ) m1 R aa 、-NR aa C(O)(CH 2 ) n1 OR aa 、-NR aa C(=S)(CH 2 ) n1 OR bb 、-(CH 2 ) n1 SRaa ,-(CH 2 ) n1 C(O)R aa ,-(CH 2 ) n1 C(O)OR aa ,-(CH 2 ) n1 S(O) m1 R aa ,-(CH 2 ) n1 S(O) m1 NR aa R bb ,-(CH 2 ) n1 P(O) m2 R aa R bb ,-(CH 2 ) n1 NR aa R bb ,-(CH 2 ) n1 S-,-(CH 2 ) n1 C(O)NR aa R bb ,-(CH 2 ) n1 NR aa C(O)R bb or-(CH 2 ) n1 NR aa S(O) m1 R bb ,wherein the alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, amino, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl and heteroaryl are optionally further selected from a hydrogen atom, a deuterium atom, a substituted or unsubstituted alkyl, a halogen, a hydroxyl group, a substituted or unsubstituted amino, an oxo group, a nitro group, a cyano group, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, a substituted or unsubstituted alkoxy, a substituted or unsubstituted hydroxyalkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aryl and a substituted or unsubstituted heteroaryl,-(CH 2 ) n1 -,-(CH 2 ) n1 R cc ,-(CH 2 ) n1 OR cc ,-(CH 2 ) n1 SR cc ,-(CH2 ) n1 C(O)R cc 、-(CH 2 ) n1 C(O)OR cc 、-(CH 2 ) n1 S(O) m1 R cc 、-(CH 2 ) n1 S(O) m1 NR cc R dd 、-(CH 2 ) n1 NR cc R dd 、-(CH 2 ) n1 C(O)NR cc R dd 、-(CH 2 ) n1 C(O)NR cc S(O) m1 R dd 、-(CH 2 ) n1 NR cc S(O) m1 R dd or -(CH 2 ) n1 NR cc S(O) m1 R dd is substituted by one or more substituents;

[0724] R 3 is selected from the group consisting of a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a hydroxyalkyl group, a heterocyclic group, an oxoheterocyclic group, a thioheterocyclic group, an aryl group, a heteroaryl group, -(CH 2 ) n1 R aa 、-(CH 2 ) n1 OR aa 、-NR aa C(O)(CH 2 ) n1 OR aa 、-NR aa C(=S)(CH 2 ) n1 OR bb 、-(CH 2 ) n1 SRaa ,-(CH 2 ) n1 C(O)R aa ,-(CH 2 ) n1 C(O)OR aa ,-(CH 2 ) n1 S(O) m1 R aa ,-(CH 2 ) n1 S(O) m1 NR aa R bb ,-(CH 2 ) n1 P(O) m2 R aa R bb ,-(CH 2 ) n1 NR aa R bb ,-(CH 2 ) n1 C(O)NR aa R bb ,-(CH 2 ) n1 NR aa C(O)R bb or -(CH 2 ) n1 NR aa S(O) m1 R bb , wherein the alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, amino, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl and heteroaryl are optionally further selected from a hydrogen atom, a deuterium atom, a substituted or unsubstituted alkyl, a halogen, a hydroxyl group, a substituted or unsubstituted amino, an oxo group, a nitro group, a cyano group, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, a substituted or unsubstituted alkoxy, a substituted or unsubstituted hydroxyalkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl,-(CH 2 ) n1 ,-(CH 2 ) n1 R cc ,-(CH 2 ) n1 OR cc ,-(CH 2 ) n1 SR cc ,-(CH 2 ) n1 C(O)Rcc 、 -(CH 2 ) n1 C(O)OR cc 、 -(CH 2 ) n1 S(O) m1 R cc 、 -(CH 2 ) n1 S(O) m1 NR cc R dd 、 -(CH 2 ) n1 NR cc R dd 、 -(CH 2 ) n1 C(O)NR cc R dd 、 -(CH 2 ) n1 C(O)NR cc S(O) m1 R dd 、 -(CH 2 ) n1 NR cc S(O) m1 R dd or -(CH 2 ) n1 NR cc S(O) m1 R dd is substituted by one or more substituents selected from the group consisting of;

[0725] R 4 is selected from the group consisting of a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a haloalkyl group, an alkoxy group, a hydroxyalkyl group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxy group, a cyano group, an alkenyl group, and an alkynyl group;

[0726] R aa 、 R bb 、 R cc and R ddSame or different and each independently selected from a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a haloalkyl group, an alkoxy group, a hydroxyalkyl group, a haloalkoxy group, a halogen, a cyano group, a nitro group, a hydroxy group, an amino group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclic group, an aryl group and a heteroaryl group, wherein the alkyl group, deuterated alkyl group, haloalkyl group, alkoxy group, hydroxyalkyl group, haloalkoxy group, alkenyl group, alkynyl group, cycloalkyl group, heterocyclic group, aryl group and heteroaryl group are optionally further substituted by one or more substituents selected from a hydrogen atom, a deuterium atom, a substituted or unsubstituted alkyl group, a halogen, a hydroxy group, a substituted or unsubstituted amino group, an oxo group, a nitro group, a cyano group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aryl group and a substituted or unsubstituted heteroaryl group;

[0727] x is an integer of 0, 1, 2 or 3;

[0728] y is an integer of 0, 1, 2, 3, 4 or 5;

[0729] m 1 is an integer of 0, 1 or 2;

[0730] m 2 is an integer of 0, 1 or 2; and

[0731] n 1 is an integer of 0, 1, 2, 3, 4 or 5.

[0732] The present invention also relates to a preferred embodiment, the general formula (I), its stereoisomers or its pharmaceutically acceptable salts, characterized in that,

[0733] wherein:

[0734] L 1 is selected from a bond, an alkylene group, an alkenylene group, an alkynyl group, a cycloalkyl group, a heterocyclic group, -NR aa (CH 2 ) n1 -, -(CH 2 ) n1 S(O) m1 - or -(CH 2 ) n1 S(O) m1 NR aa -;

[0735] L 2 is selected from a bond, an oxygen atom, a sulfur atom, -CR aa R bb -, -(CH 2 ) n1 C(O)-, -NR 4 - or -(CH2 ) n1 S(O) m1 -;

[0736] L 3 is selected from a bond, -NR aa - or -C(O)NR aa -;

[0737] Ring A is selected from 6- to 14-membered heteroaryl groups, wherein the 6- to 14-membered heteroaryl groups are selected from 6- to 14-membered fused heteroaryl groups; preferably 5-fused 5-membered heteroaryl groups, 5-fused 6-membered heteroaryl groups or 6-fused 6-membered heteroaryl groups;

[0738] Ring B is selected from 6- to 14-membered bridged heterocyclic groups or 6- to 14-membered fused heterocyclic groups;

[0739] Ring C is selected from heteroaryl groups;

[0740] R 1 is selected from a hydrogen atom, a deuterium atom, an oxo group, an alkyl group, a deuterated alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a halogen, an amino group, a nitro group, a hydroxy group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclic group, an oxo heterocyclic group, a thio heterocyclic group, an aryl group, a heteroaryl group, -(CH 2 ) n1 R aa 、-(CH 2 ) n1 OR aa 、-NR aa C(O)(CH 2 ) n1 OR aa 、-NR aa C(=S)(CH 2 ) n1 OR bb 、-(CH 2 ) n1 SR aa 、-(CH 2 ) n1 C(O)R aa 、-(CH 2 ) n1 C(O)OR aa 、-(CH 2 ) n1 S(O) m1 R aa 、-(CH 2 ) n1 NR aa R bb 、-(CH 2 ) n1 C(O)NR aa R bb 、-(CH2 ) n1 NR aa C(O)R bb or -(CH 2 ) n1 NR aa S(O) m1 R bb , wherein the alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, amino, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl and heteroaryl are optionally further substituted by one or more substituents selected from a hydrogen atom, deuterium atom, alkyl, haloalkyl, halogen, amino, oxo group, nitro group, cyano group, hydroxy group, alkenyl, alkynyl, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclic group, aryl, heteroaryl, -(CH 2 ) n1 -, -(CH 2 ) n1 R cc , -(CH 2 ) n1 OR cc , -(CH 2 ) n1 SR cc , -(CH 2 ) n1 C(O)R cc , -(CH 2 ) n1 C(O)OR cc , -(CH 2 ) n1 S(O) m1 R cc , -(CH 2 ) n1 NR cc R dd , -(CH 2 ) n1 C(O)NR cc R dd , -(CH 2 ) n1 NR cc C(O)R dd or -(CH 2 ) n1 NR cc S(O) m1 R dd substituted by one or more of the substituents;

[0741] R 2 is a hydrogen atom, deuterium atom, alkyl, deuterated alkyl, oxo group, haloalkyl, alkoxy, hydroxyalkyl, haloalkoxy, halogen, amino, nitro group, hydroxy group, cyano group, alkenyl or alkynyl;

[0742] R 3 Selected from a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a hydroxyalkyl group, a heterocyclic group, an oxoheterocyclic group, a thioheterocyclic group, an aryl group, a heteroaryl group, -(CH 2 ) n1 R aa 、-(CH 2 ) n1 OR aa 、-NR aa C(O)(CH 2 ) n1 OR aa 、-NR aa C(=S)(CH 2 ) n1 OR bb 、-(CH 2 ) n1 SR aa 、-(CH 2 ) n1 C(O)R aa 、-(CH 2 ) n1 C(O)OR aa 、-(CH 2 ) n1 S(O) m1 R aa 、-(CH 2 ) n1 S(O) m1 NR aa R bb 、-(CH 2 ) n1 P(O) m2 R aa R bb 、-(CH 2 ) n1 NR aa R bb 、-(CH 2 ) n1 C(O)NR aa R bb 、-(CH 2 ) n1 NR aa C(O)R bb or -(CH 2 ) n1 NR aa S(O) m1 R bb, wherein the alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, amino, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl and heteroaryl are optionally further substituted by one or more substituents selected from a hydrogen atom, a deuterium atom, a substituted or unsubstituted alkyl group, a halogen, a hydroxy group, a substituted or unsubstituted amino group, an oxo group, a nitro group, a cyano group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH 2 ) n1 -, -(CH 2 ) n1 R cc , -(CH 2 ) n1 OR cc , -(CH 2 ) n1 SR cc , -(CH 2 ) n1 C(O)R cc , -(CH 2 ) n1 C(O)OR cc , -(CH 2 ) n1 S(O) m1 R cc , -(CH 2 ) n1 S(O) m1 NR cc R dd , -(CH 2 ) n1 NR cc R dd , -(CH 2 ) n1 C(O)NR cc R dd , -(CH 2 ) n1 C(O)NR cc S(O) m1 R dd , -(CH 2 ) n1 NR cc S(O) m1 R dd or -(CH 2 ) n1 NR cc S(O) m1 R dd ;

[0743] R 4 A hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a haloalkyl group, an alkoxy group, a hydroxyalkyl group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxy group, a cyano group, an alkenyl group, an alkynyl group;

[0744] R aa 、R bb 、R cc and R dd are the same or different and each independently selected from a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a haloalkyl group, an alkoxy group, a hydroxyalkyl group, a haloalkoxy group, a halogen, a cyano group, a nitro group, a hydroxy group, an amino group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclic group, an aryl group and a heteroaryl group, wherein the alkyl group, deuterated alkyl group, haloalkyl group, alkoxy group, hydroxyalkyl group, haloalkoxy group, alkenyl group, alkynyl group, cycloalkyl group, heterocyclic group, aryl group and heteroaryl group are optionally further substituted by one or more substituents selected from a hydrogen atom, a deuterium atom, a substituted or unsubstituted alkyl group, a halogen, a hydroxy group, a substituted or unsubstituted amino group, an oxo group, a nitro group, a cyano group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aryl group and a substituted or unsubstituted heteroaryl group;

[0745] x is an integer of 0, 1, 2 or 3;

[0746] y is an integer of 0, 1, 2, 3, 4 or 5;

[0747] m 1 is an integer of 0, 1 or 2;

[0748] m 2 is an integer of 0, 1 or 2; and

[0749] n 1 is an integer of 0, 1, 2, 3, 4 or 5.

[0750] The present invention also relates to a preferred embodiment, the compound of formula (I), its stereoisomers or its pharmaceutically acceptable salts, which are the compounds of formula (II) and formula (IIA), their stereoisomers or their pharmaceutically acceptable salts:

[0751]

[0752] Wherein:

[0753] W is selected from a nitrogen atom or an alkylene group; and

[0754] n is an integer of 0, 1, 2 or 3;

[0755] L 1 、L 2, L 3 , ring A, ring C, R 1 ~R 3 , x and y are as described in general formula (I).

[0756] The present invention also relates to a preferred embodiment, the compound represented by general formula (I), its stereoisomers or its pharmaceutically acceptable salts, which are the compounds represented by general formula (IIIA), its stereoisomers or its pharmaceutically acceptable salts:

[0757]

[0758] Wherein:

[0759] R 5 is selected from a hydrogen atom, a halogen, a cyano group, an alkyl group, an alkoxy group, a hydroxyalkyl group, a haloalkyl group, -(CH 2 ) n1 OR aa , -(CH 2 ) n1 C(O)NR aa R bb , a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkyl group, alkoxy group, hydroxyalkyl group, haloalkyl group, cycloalkyl group, heterocyclic group, aryl group and heteroaryl group are optionally further selected from a hydrogen atom, a deuterium atom, a substituted or unsubstituted alkyl group, a halogen, a hydroxy group, a substituted or unsubstituted amino group, an oxo group, a nitro group, a cyano group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aryl group and a substituted or unsubstituted heteroaryl group, -(CH 2 ) n1 -, -(CH 2 ) n1 R cc , -(CH 2 ) n1 OR cc , -(CH 2 ) n1 SR cc , -(CH 2 ) n1 C(O)R cc , -(CH 2 ) n1 C(O)OR cc , -(CH 2 ) n1 S(O) m1 R cc , -(CH 2 ) n1 S(O) m1 NR ccR dd ,-(CH 2 ) n1 NR cc R dd ,-(CH 2 ) n1 C(O)NR cc R dd ,-(CH 2 ) n1 C(O)NR cc S(O) m1 R dd ,-(CH 2 ) n1 NR cc S(O) m1 R dd or -(CH 2 ) n1 NR cc S(O) m1 R dd is substituted by one or more substituents selected from the group consisting of;

[0760] R 6 is selected from the group consisting of a hydrogen atom, a halogen, a cyano group, an alkyl group, an alkoxy group, a hydroxyalkyl group, a haloalkyl group, a cycloalkyl group, a heterocyclic group, or -(CH 2 ) n1 C(O)NR aa R bb ;

[0761] L 1 、L 2 、L 3 、ring A, ring B, R 1 、R 2 and x are as defined in general formula (I).

[0762] The present invention also relates to a preferred embodiment, the compound represented by general formula (I), its stereoisomers or its pharmaceutically acceptable salts, which are the compound represented by general formula (III), its stereoisomers or its pharmaceutically acceptable salts:

[0763]

[0764] Wherein:

[0765] R 10 and R 11 are the same or different and are each independently selected from the group consisting of a hydrogen atom, a halogen, a cyano group, an alkyl group, an alkoxy group, a hydroxyalkyl group, a haloalkyl group, -(CH 2 ) n1 OR aa 、-(CH 2 ) n1 C(O)NRaa R bb -, -(CH 2 ) n1 S(O) m1 NR aa R bb -, cycloalkyl, heterocyclic group, aryl or heteroaryl, wherein the alkyl, alkoxy, hydroxyalkyl, haloalkyl, cycloalkyl, heterocyclic group, aryl and heteroaryl are optionally further selected from a hydrogen atom, a deuterium atom, a substituted or unsubstituted alkyl, halogen, hydroxy, a substituted or unsubstituted amino, oxo, nitro, cyano, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, a substituted or unsubstituted alkoxy, a substituted or unsubstituted hydroxyalkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aryl and a substituted or unsubstituted heteroaryl, -(CH 2 ) n1 -, -(CH 2 ) n1 R cc -, -(CH 2 ) n1 OR cc -, -(CH 2 ) n1 SR cc -, -(CH 2 ) n1 C(O)R cc -, -(CH 2 ) n1 C(O)OR cc -, -(CH 2 ) n1 S(O) m1 R cc -, -(CH 2 ) n1 S(O) m1 NR cc R dd -, -(CH 2 ) n1 NR cc R dd -, -(CH 2 ) n1 C(O)NR cc R dd -, -(CH 2 ) n1 C(O)NR cc S(O) m1 R dd -, -(CH 2 ) n1 NR cc S(O) m1 R dd or -(CH2 ) n1 NR cc S(O) m1 R dd is substituted by one or more substituents selected from the following:

[0766] L 1 、L 2 、L 3 、ring A, ring B, R 1 、R 2 and x are as defined in general formula (I).

[0767] The present invention also relates to a preferred embodiment, a compound of general formula (I), its stereoisomers or its pharmaceutically acceptable salts, which is a compound of general formula (IV), its stereoisomers or its pharmaceutically acceptable salts:

[0768]

[0769] Wherein:

[0770] Ring D is selected from a heterocyclic group, an aryl group or a heteroaryl group; preferably a 5-6 membered heterocyclic group, a 6-10 membered aryl group or a 5-6 membered heteroaryl group;

[0771] E 1 、E 2 and E 3 are the same or different and each independently selected from a nitrogen atom or -CR aa -;

[0772] R 4 is selected from a hydrogen atom, a halogen, a cyano group, an alkyl group, an alkenyl group, an alkynyl group or an alkoxy group;

[0773] R 7 is selected from a hydrogen atom, a halogen, a cyano group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an oxo group or a thio group; and

[0774] z is an integer of 0, 1, 2 or 3;

[0775] L 1 、L 3 、ring C, R 1 、R 3 、R aa 、y and n are as defined in general formula (I).

[0776] The present invention also relates to a preferred embodiment, a compound of general formula (I), its stereoisomers or its pharmaceutically acceptable salts, which is a compound of general formula (V), its stereoisomers or its pharmaceutically acceptable salts:

[0777]

[0778] Wherein:

[0779] Ring G is selected from a heterocyclic group, an aryl group or a heteroaryl group; preferably a 5- to 6-membered heterocyclic group, a 6- to 10-membered aryl group or a 5- to 6-membered heteroaryl group;

[0780] R 8 is selected from a hydrogen atom, a halogen, a cyano group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an oxo group or a thio group; and

[0781] p is an integer of 0, 1, 2 or 3;

[0782] R 5 and R 6 are as defined herein;

[0783] L 1 、E 1 、E 2 、E 3 、R 4 and n are as described in general formula (IV).

[0784] The present invention also relates to a preferred embodiment, the compound represented by general formula (I), its stereoisomers or its pharmaceutically acceptable salts, which are the compound represented by general formula (VI), its stereoisomers or its pharmaceutically acceptable salts:

[0785]

[0786] Wherein:

[0787] Ring K is selected from a heterocyclic group, an aryl group or a heteroaryl group; preferably a 5- to 6-membered heterocyclic group, a 6- to 10-membered aryl group, a 5- to 6-membered heteroaryl group;

[0788] R 9 is selected from a hydrogen atom, a halogen, a cyano group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an oxo group or a thio group; and

[0789] q is an integer of 0, 1, 2 or 3;

[0790] R 5 and R 6 are as defined herein;

[0791] E 1 、E 2 、E 3 and R 4 are as described in general formula (IV).

[0792] The present invention also relates to a preferred embodiment, the compound represented by general formula (I), its stereoisomers or its pharmaceutically acceptable salts, which are the compound represented by general formula (VII), its stereoisomers or its pharmaceutically acceptable salts:

[0793]

[0794] Wherein:

[0795] n is an integer of 0, 1 or 2;

[0796] L 2 , ring A, R 2 , R 5 , R 6 and x are as described in general formula (IIIA).

[0797] The present invention also relates to a preferred embodiment, the compound represented by general formula (III), its stereoisomers or its pharmaceutically acceptable salts, which are the compound represented by general formula (VIII), its stereoisomers or its pharmaceutically acceptable salts:

[0798]

[0799] Wherein:

[0800] M 1 is selected from a nitrogen atom or -CR aa -;

[0801] R 12 is selected from a hydrogen atom, a cyano group, a halogen, an alkyl group or an alkoxy group; and

[0802] z is an integer of 0, 1 or 2;

[0803] L 1 , L 2 , ring C, R 1 , R 3 , R 7 , R aa and y are as described in general formula (IV).

[0804] The present invention also relates to a preferred embodiment, the compound represented by general formula (I), its stereoisomers or its pharmaceutically acceptable salts, which are the compound represented by general formula (IX), its stereoisomers or its pharmaceutically acceptable salts:

[0805]

[0806] Wherein:

[0807] ring C, R 3 , R 12 , R 7 , y and z are as described in general formula (VII).

[0808] The present invention also relates to a preferred embodiment, the compound represented by general formula (I), its stereoisomers or its pharmaceutically acceptable salts, which are the compound represented by general formula (X), its stereoisomers or its pharmaceutically acceptable salts:

[0809]

[0810] Wherein:

[0811] R 5 ~R 6 as described in general formula (IIIA);

[0812] R 12 、R 7 and z are as described in general formula (VII).

[0813] The present invention also relates to a preferred embodiment, the compound represented by general formula (I), its stereoisomers or its pharmaceutically acceptable salts, which are the compound represented by general formula (XI), its stereoisomers or its pharmaceutically acceptable salts:

[0814]

[0815] Wherein:

[0816] L 1 、L 2 、ring B, ring C, R 3 and R 12 are as described in general formula (I)

[0817] R 7 、y and z are as described in general formula (IX).

[0818] The present invention also relates to a preferred embodiment, the compound represented by general formula (I), its stereoisomers or its pharmaceutically acceptable salts, which are the compound represented by general formula (XII), its stereoisomers or its pharmaceutically acceptable salts:

[0819]

[0820] Wherein:

[0821] L 1 is selected from a bond, alkylene, alkenylene, alkynyl, cycloalkyl, heterocyclic group, -(CH 2 ) n1 C(O)(CH 2 ) m1 -, -(CH 2 ) n1 C(O)(CH 2 ) m1 NR aa (CH 2 ) m2 -, -(CH 2 ) n1 S(O) m1 - or -(CH 2) n1 S(O) m1 NR aa -;

[0822] Ring B is selected from a 3- to 10-membered monocyclic heteroaryl group, a 6- to 14-membered spiroheterocyclic ring, a 6- to 14-membered bridged heteroaryl group, or a 6- to 14-membered fused heteroaryl group;

[0823] Ring T is selected from an aryl group or a heteroaryl group;

[0824] R 1 is selected from a hydrogen atom, a deuterium atom, an oxo group, an alkyl group, a deuterated alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a halogen, an amino group, a nitro group, a hydroxy group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclic group, an oxoheterocyclic group, a thioheterocyclic group, an aryl group, a heteroaryl group, -(CH 2 ) n1 R aa 、-(CH 2 ) n1 OR aa 、-NR aa C(O)(CH 2 ) n1 OR aa 、-NR aa C(=S)(CH 2 ) n1 OR bb 、-(CH 2 ) n1 SR aa 、-(CH 2 ) n1 C(O)R aa 、-(CH 2 ) n1 C(O)OR aa 、-(CH 2 ) n1 S(O) m1 R aa 、-(CH 2 ) n1 NR aa R bb 、-(CH 2 ) n1 C(O)NR aa R bb 、-(CH 2 ) n1 NR aa C(O)R bb or -(CH 2 ) n1 NR aa S(O) m1 R bb, wherein the alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, amino, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl and heteroaryl are optionally further selected from a hydrogen atom, a deuterium atom, an alkyl, a haloalkyl, a halogen, an amino, an oxo group, a nitro group, a cyano group, a hydroxy group, an alkenyl, an alkynyl, an alkoxy, a haloalkoxy, a hydroxyalkyl, a cycloalkyl, a heterocyclic group, an aryl, a heteroaryl, -(CH 2 ) n1 -, -(CH 2 ) n1 R cc , -(CH 2 ) n1 OR cc , -(CH 2 ) n1 SR cc , -(CH 2 ) n1 C(O)R cc , -(CH 2 ) n1 C(O)OR cc , -(CH 2 ) n1 S(O) m1 R cc , -(CH 2 ) n1 NR cc R dd , -(CH 2 ) n1 C(O)NR cc R dd , -(CH 2 ) n1 NR cc C(O)R dd or -(CH 2 ) n1 NR cc S(O) m1 R dd and substituted by one or more substituents selected therefrom;

[0825] R 3 is selected from a hydrogen atom, a deuterium atom, an alkyl, a deuterated alkyl, a haloalkyl, an alkoxy, a haloalkoxy, a halogen, an amino, a nitro group, a hydroxy group, a cyano group, an alkenyl, an alkynyl, a cycloalkyl, a hydroxyalkyl, a heterocyclic group, an oxo heterocyclic group, a thio heterocyclic group, an aryl, a heteroaryl, -(CH 2 ) n1 R aa , -(CH 2 ) n1 OR aa , -NR aa C(O)(CH 2) n1 OR aa 、 -NR aa C(=S)(CH 2 ) n1 OR bb 、 -(CH 2 ) n1 SR aa 、 -(CH 2 ) n1 C(O)R aa 、 -(CH 2 ) n1 C(O)OR aa 、 -(CH 2 ) n1 S(O) m1 R aa 、 -(CH 2 ) n1 S(O) m1 NR aa R bb 、 -(CH 2 ) n1 P(O) m2 R aa R bb 、 -(CH 2 ) n1 NR aa R bb 、 -(CH 2 ) n1 C(O)NR aa R bb 、 -(CH 2 ) n1 NR aa C(O)R bb or -(CH 2 ) n1 NR aa S(O) m1 R bb wherein the alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, amino, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl and heteroaryl are optionally further selected from a hydrogen atom, a deuterium atom, a substituted or unsubstituted alkyl, a halogen, a hydroxy group, a substituted or unsubstituted amino, an oxo group, a nitro group, a cyano group, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, a substituted or unsubstituted alkoxy, a substituted or unsubstituted hydroxyalkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aryl and a substituted or unsubstituted heteroaryl, -(CH 2 ) n1 -, -(CH 2 ) n1 R cc, -(CH 2 ) n1 OR cc , -(CH 2 ) n1 SR cc , -(CH 2 ) n1 C(O)R cc , -(CH 2 ) n1 C(O)OR cc , -(CH 2 ) n1 S(O) m1 R cc , -(CH 2 ) n1 S(O) m1 NR cc R dd , -(CH 2 ) n1 NR cc R dd , -(CH 2 ) n1 C(O)NR cc R dd , -(CH 2 ) n1 C(O)NR cc S(O) m1 R dd , -(CH 2 ) n1 NR cc S(O) m1 R dd or -(CH 2 ) n1 NR cc S(O) m1 R dd is substituted by one or more substituents selected from the group consisting of;

[0826] R 4 a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a haloalkyl group, an alkoxy group, a hydroxyalkyl group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxy group, a cyano group, an alkenyl group, an alkynyl group;

[0827] R 13 is selected from a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxy group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a hydroxyalkyl group, a heterocyclic group, an oxoheterocyclic group, a thioheterocyclic group, an aryl group, a heteroaryl group, -(CH 2 ) n1 R aa , -(CH 2 )n1 O(CH 2 ) m1 R aa 、-(CH 2 ) n1 OR aa 、-(CH 2 ) n1 NR aa (CH 2 ) m1 R aa 、-NR aa C(O)(CH 2 ) n1 OR aa 、-NR aa C(=S)(CH 2 ) n1 OR bb 、-(CH 2 ) n1 SR aa 、-(CH 2 ) n1 C(O)R aa 、-(CH 2 ) n1 C(O)OR aa 、-(CH 2 ) n1 S(O) m1 R aa 、-(CH 2 ) n1 S(O) m1 NR aa R bb 、-(CH 2 ) n1 P(O) m2 R aa R bb 、-(CH 2 ) n1 NR aa R bb 、-(CH 2 ) n1 S-、-(CH 2 ) n1 C(O)NR aa R bb 、-(CH 2 ) n1 NR aa C(O)R bb 或-(CH 2 ) n1 NR aa S(O) m1 R bb, wherein the alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, amino, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl and heteroaryl are optionally further selected from a hydrogen atom, a deuterium atom, a substituted or unsubstituted alkyl, halogen, hydroxy, a substituted or unsubstituted amino, oxo, nitro, cyano, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, a substituted or unsubstituted alkoxy, a substituted or unsubstituted hydroxyalkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -(CH 2 ) n1 -, -(CH 2 ) n1 R cc , -(CH 2 ) n1 OR cc , -(CH 2 ) n1 SR cc , -(CH 2 ) n1 C(O)R cc , -(CH 2 ) n1 C(O)OR cc , -(CH 2 ) n1 S(O) m1 R cc , -(CH 2 ) n1 S(O) m1 NR cc R dd , -(CH 2 ) n1 NR cc R dd , -(CH 2 ) n1 C(O)NR cc R dd , -(CH 2 ) n1 C(O)NR cc S(O) m1 R dd , -(CH 2 ) n1 NR cc S(O) m1 R dd or -(CH 2 ) n1 NR cc S(O) m1 R dd and is substituted by one or more substituents selected therefrom;

[0828] R aa 、R bb 、R cc and R dd are the same or different and each independently selected from a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a haloalkyl group, an alkoxy group, a hydroxyalkyl group, a haloalkoxy group, a halogen, a cyano group, a nitro group, a hydroxy group, an amino group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclic group, an aryl group and a heteroaryl group, wherein the alkyl group, deuterated alkyl group, haloalkyl group, alkoxy group, hydroxyalkyl group, haloalkoxy group, alkenyl group, alkynyl group, cycloalkyl group, heterocyclic group, aryl group and heteroaryl group are optionally further substituted by one or more substituents selected from a hydrogen atom, a deuterium atom, a substituted or unsubstituted alkyl group, a halogen, a hydroxy group, a substituted or unsubstituted amino group, an oxo group, a nitro group, a cyano group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aryl group and a substituted or unsubstituted heteroaryl group;

[0829] y is an integer of 0, 1, 2, 3, 4 or 5;

[0830] q is an integer of 0, 1, 2, 3, 4 or 5;

[0831] m 1 is an integer of 0, 1 or 2;

[0832] m 2 is an integer of 0, 1 or 2; and

[0833] n 1 is an integer of 0, 1, 2, 3, 4 or 5.

[0834] The present invention also relates to a preferred embodiment, the compound represented by the general formula (I), its stereoisomers or its pharmaceutically acceptable salts, which are the compound represented by the general formula (XIII), its stereoisomers or its pharmaceutically acceptable salts:

[0835]

[0836] Wherein:

[0837] R 5 is selected from a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxy group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a hydroxyalkyl group, a heterocyclic group, an oxoheterocyclic group, a thioheterocyclic group, an aryl group or a heteroaryl group;

[0838] R 6selected from a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a hydroxyalkyl group, a heterocyclic group, an oxoheterocyclic group, a thioheterocyclic group, an aryl group or a heteroaryl group;

[0839] n is an integer of 0, 1 or 2;

[0840] L 1 , ring T, R 1 , R 3 , R 4 , R 13 and q are as described in general formula (XII).

[0841] The present invention also relates to a preferred embodiment, the compound represented by general formula (I), its stereoisomers or its pharmaceutically acceptable salts, which are the compound represented by general formula (XIV), its stereoisomers or its pharmaceutically acceptable salts:

[0842]

[0843] Wherein:

[0844] L 1 , R 1 , R 4 ~R 6 , R 13 , q and n are as described in general formula (XIII).

[0845] The present invention also relates to a preferred embodiment, the compound represented by general formula (I), its stereoisomers or its pharmaceutically acceptable salts, which are the compound represented by general formula (XV), its stereoisomers or its pharmaceutically acceptable salts:

[0846]

[0847] Wherein:

[0848] L 1 selected from a bond, an alkylene group, an alkenylene group, an alkynylene group, a cycloalkyl group, a heterocyclic group, -(CH 2 ) n1 C(O)(CH 2 ) m1 -, -(CH 2 ) n1 C(O)(CH 2 ) m1 NR aa (CH 2 ) m2 -, -(CH 2 ) n1 S(O) m1 - or -(CH 2) n1 S(O) m1 NR aa -;

[0849] J 1 , J 2 and J 3 are the same or different, each independently selected from nitrogen atoms, sulfur atoms, oxygen atoms, NR aa or CR 14 ;

[0850] R 1 is selected from the group consisting of a hydrogen atom, a deuterium atom, an oxo group, an alkyl group, a deuterated alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclic group, an oxoheterocyclic group, a thioheterocyclic group, an aryl group, a heteroaryl group, -(CH 2 ) n1 R aa 、-(CH 2 ) n1 OR aa 、-NR aa C(O)(CH 2 ) n1 OR aa 、-NR aa C(=S)(CH 2 ) n1 OR bb 、-(CH 2 ) n1 SR aa 、-(CH 2 ) n1 C(O)R aa 、-(CH 2 ) n1 C(O)OR aa 、-(CH 2 ) n1 S(O) m1 R aa 、-(CH 2 ) n1 NR aa R bb 、-(CH 2 ) n1 C(O)NR aa R bb 、-(CH 2 ) n1 NR aa C(O)R bb or -(CH 2 ) n1 NR aa S(O) m1 Rbb , wherein the alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, amino, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl and heteroaryl are optionally further selected from a hydrogen atom, a deuterium atom, an alkyl, a haloalkyl, a halogen, an amino, an oxo group, a nitro group, a cyano group, a hydroxy group, an alkenyl, an alkynyl, an alkoxy, a haloalkoxy, a hydroxyalkyl, a cycloalkyl, a heterocyclic group, an aryl, a heteroaryl, -(CH 2 ) n1 -, -(CH 2 ) n1 R cc , -(CH 2 ) n1 OR cc , -(CH 2 ) n1 SR cc , -(CH 2 ) n1 C(O)R cc , -(CH 2 ) n1 C(O)OR cc , -(CH 2 ) n1 S(O) m1 R cc , -(CH 2 ) n1 NR cc R dd , -(CH 2 ) n1 C(O)NR cc R dd , -(CH 2 ) n1 NR cc C(O)R dd or -(CH 2 ) n1 NR cc S(O) m1 R dd and is substituted by one or more substituents selected from;

[0851] R 4 a hydrogen atom, a deuterium atom, an alkyl, a deuterated alkyl, a haloalkyl, an alkoxy, a hydroxyalkyl, a haloalkoxy, a halogen, an amino, a nitro group, a hydroxy group, a cyano group, an alkenyl, an alkynyl;

[0852] R 5 is selected from a hydrogen atom, a deuterium atom, an alkyl, a deuterated alkyl, a haloalkyl, an alkoxy, a haloalkoxy, a halogen, an amino, a nitro group, a hydroxy group, a cyano group, an alkenyl, an alkynyl, a cycloalkyl, a hydroxyalkyl, a heterocyclic group, an oxo heterocyclic group, a thio heterocyclic group, an aryl or a heteroaryl;

[0853] R 6 is selected from a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a hydroxyalkyl group, a heterocyclic group, an oxoheterocyclic group, a thioheterocyclic group, an aryl group or a heteroaryl group;

[0854] R 14 is selected from a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a hydroxyalkyl group, a heterocyclic group, an oxoheterocyclic group, a thioheterocyclic group, an aryl group, a heteroaryl group, -(CH 2 ) n1 R aa 、-(CH 2 ) n1 O(CH 2 ) m1 R aa 、-(CH 2 ) n1 OR aa 、-(CH 2 ) n1 NR aa (CH 2 ) m1 R aa 、-NR aa C(O)(CH 2 ) n1 OR aa 、-NR aa C(=S)(CH 2 ) n1 OR bb 、-(CH 2 ) n1 SR aa 、-(CH 2 ) n1 C(O)R aa 、-(CH 2 ) n1 C(O)OR aa 、-(CH 2 ) n1 S(O) m1 R aa 、-(CH 2 ) n1 S(O) m1 NR aa R bb 、-(CH 2 ) n1 P(O) m2 R aa R bb 、-(CH2 ) n1 NR aa R bb 、-(CH 2 ) n1 S-、-(CH 2 ) n1 C(O)NR aa R bb 、-(CH 2 ) n1 NR aa C(O)R bb or -(CH 2 ) n1 NR aa S(O) m1 R bb wherein the alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, amino, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl and heteroaryl are optionally further selected from hydrogen atoms, deuterium atoms, substituted or unsubstituted alkyl, halogen, hydroxyl, substituted or unsubstituted amino, oxo, nitro, cyano, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl, -(CH 2 ) n1 -、-(CH 2 ) n1 R cc 、-(CH 2 ) n1 OR cc 、-(CH 2 ) n1 SR cc 、-(CH 2 ) n1 C(O)R cc 、-(CH 2 ) n1 C(O)OR cc 、-(CH 2 ) n1 S(O) m1 R cc 、-(CH 2 ) n1 S(O) m1 NR cc R dd 、-(CH 2 ) n1 NR cc R dd 、-(CH 2 ) n1 C(O)NRcc R dd 、-(CH 2 ) n1 C(O)NR cc S(O) m1 R dd 、-(CH 2 ) n1 NR cc S(O) m1 R dd or -(CH 2 ) n1 NR cc S(O) m1 R dd is substituted by one or more substituents;

[0855] R aa , R bb , R cc and R dd are the same or different and are each independently selected from the group consisting of hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, hydroxyalkyl, haloalkoxy, halogen, cyano, nitro, hydroxy, amino, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkyl, deuterated alkyl, haloalkyl, alkoxy, hydroxyalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally further substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, substituted or unsubstituted alkyl, halogen, hydroxy, substituted or unsubstituted amino, oxo, nitro, cyano, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;

[0856] n is an integer of 0, 1 or 2;

[0857] m 1 is an integer of 0, 1 or 2;

[0858] m 2 is an integer of 0, 1 or 2; and

[0859] n 1 is an integer of 0, 1, 2, 3, 4 or 5.

[0860] The present invention also relates to a preferred embodiment, wherein the compound represented by the general formula (I), its stereoisomer or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (XVI), its stereoisomer or a pharmaceutically acceptable salt thereof:

[0861]

[0862] Wherein:

[0863] R 15 is selected from a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a hydroxyalkyl group, a heterocyclic group, an oxoheterocyclic group, a thioheterocyclic group, an aryl group, a heteroaryl group, -(CH 2 ) n1 R aa 、-(CH 2 ) n1 O(CH 2 ) m1 R aa 、-(CH 2 ) n1 OR aa 、-(CH 2 ) n1 NR aa (CH 2 ) m1 R aa 、-NR aa C(O)(CH 2 ) n1 OR aa 、-NR aa C(=S)(CH 2 ) n1 OR bb 、-(CH 2 ) n1 SR aa 、-(CH 2 ) n1 C(O)R aa 、-(CH 2 ) n1 C(O)OR aa 、-(CH 2 ) n1 S(O) m1 R aa 、-(CH 2 ) n1 S(O) m1 NR aa R bb 、-(CH 2 ) n1 P(O) m2 R aa R bb 、-(CH 2 ) n1 NR aa R bb 、-(CH 2 ) n1 S-、-(CH2 ) n1 C(O)NR aa R bb 、-(CH 2 ) n1 NR aa C(O)R bb or -(CH 2 ) n1 NR aa S(O) m1 R bb wherein the alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, amino, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl and heteroaryl are optionally further selected from hydrogen atoms, deuterium atoms, substituted or unsubstituted alkyl, halogen, hydroxyl, substituted or unsubstituted amino, oxo, nitro, cyano, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl, -(CH 2 ) n1 -、-(CH 2 ) n1 R cc 、-(CH 2 ) n1 OR cc 、-(CH 2 ) n1 SR cc 、-(CH 2 ) n1 C(O)R cc 、-(CH 2 ) n1 C(O)OR cc 、-(CH 2 ) n1 S(O) m1 R cc 、-(CH 2 ) n1 S(O) m1 NR cc R dd 、-(CH 2 ) n1 NR cc R dd 、-(CH 2 ) n1 C(O)NR cc R dd 、-(CH 2 ) n1 C(O)NR cc S(O) m1 Rdd ,-(CH 2 ) n1 NR cc S(O) m1 R dd or -(CH 2 ) n1 NR cc S(O) m1 R dd is substituted by one or more substituents selected from the group consisting of;

[0864] L 1 , R 1 , R 5 ~R 6 , R aa ~R dd and n are as defined in general formula (XIV).

[0865] The present invention also relates to a preferred embodiment, the compound of general formula (I), its stereoisomers or its pharmaceutically acceptable salts, which are the compound of general formula (XVII), its stereoisomers or its pharmaceutically acceptable salts:

[0866]

[0867] Wherein:

[0868] R 16 is selected from the group consisting of a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a hydroxyalkyl group, a heterocyclic group, an oxo heterocyclic group, a thio heterocyclic group, an aryl group, a heteroaryl group,-(CH 2 ) n1 R aa ,-(CH 2 ) n1 O(CH 2 ) m1 R aa ,-(CH 2 ) n1 OR aa ,-(CH 2 ) n1 NR aa (CH 2 ) m1 R aa ,-NR aa C(O)(CH 2 ) n1 OR aa ,-NR aa C(=S)(CH 2 ) n1 OR bb, -(CH 2 ) n1 SR aa , -(CH 2 ) n1 C(O)R aa , -(CH 2 ) n1 C(O)OR aa , -(CH 2 ) n1 S(O) m1 R aa , -(CH 2 ) n1 S(O) m1 NR aa R bb , -(CH 2 ) n1 P(O) m2 R aa R bb , -(CH 2 ) n1 NR aa R bb , -(CH 2 ) n1 S-, -(CH 2 ) n1 C(O)NR aa R bb , -(CH 2 ) n1 NR aa C(O)R bb or -(CH 2 ) n1 NR aa S(O) m1 R bb , wherein the alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, amino, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl and heteroaryl are optionally further selected from a hydrogen atom, a deuterium atom, a substituted or unsubstituted alkyl, a halogen, a hydroxyl group, a substituted or unsubstituted amino, an oxo group, a nitro group, a cyano group, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, a substituted or unsubstituted alkoxy, a substituted or unsubstituted hydroxyalkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aryl and a substituted or unsubstituted heteroaryl, -(CH 2 ) n1 , -(CH 2 ) n1 R cc , -(CH 2 ) n1 OR cc , -(CH 2 )n1 SR cc 、-(CH 2 ) n1 C(O)R cc 、-(CH 2 ) n1 C(O)OR cc 、-(CH 2 ) n1 S(O) m1 R cc 、-(CH 2 ) n1 S(O) m1 NR cc R dd 、-(CH 2 ) n1 NR cc R dd 、-(CH 2 ) n1 C(O)NR cc R dd 、-(CH 2 ) n1 C(O)NR cc S(O) m1 R dd 、-(CH 2 ) n1 NR cc S(O) m1 R dd or -(CH 2 ) n1 NR cc S(O) m1 R dd is substituted by one or more substituents;

[0869] r is an integer of 0, 1 or 2; and

[0870] L 1 , R 1 , R 4 ~R 6 , R aa ~R dd , n, n1, m1 and m2 are as described in the general formula (XV).

[0871] The present invention also relates to a preferred embodiment, wherein any of the general formulas, stereoisomers thereof or pharmaceutically acceptable salts thereof are characterized in that:

[0872] Ring A is selected from the following groups:

[0873]

[0874]

[0875] Ring B is selected from the following groups:

[0876]

[0877] Ring C is selected from the following groups:

[0878]

[0879] The present invention also relates to a preferred embodiment, each general formula, its stereoisomers or its pharmaceutically acceptable salts as described in any one of the preceding claims, characterized in that,

[0880] L 1 is C 3-8 cycloalkyl, C 3-8 heterocycloalkyl, -(CH 2 ) n1 -, -(CH 2 ) n1 C(O)(CH 2 ) m1 -, -(CH 2 ) n1 C(O)(CH 2 ) m1 NR aa (CH 2 ) m2 -, -NR aa (CH 2 ) n1 -, -(CH 2 ) n1 S(O) m1 - or -(CH 2 ) n1 S(O) m1 NR aa -;

[0881] L 2 is selected from a bond, an oxygen atom, -CR aa R bb -, -(CH 2 ) n1 C(O)-, -NR 4 -, or -(CH 2 ) n1 S(O) m1 -;

[0882] L 3 is selected from a bond, -NR aa - or -C(O)NR aa -;

[0883] R 1Selected from cyano, -(CH 2 ) n1 R aa 、-(CH 2 ) n1 C(O)R aa 、C 3-8 cycloalkyl, 3- to 10-membered heterocyclic group, C 6-10 aryl or 5- to 10-membered heteroaryl, wherein said C 3-8 cycloalkyl, 3- to 10-membered heterocyclic group, C 6-10 aryl and 5- to 10-membered heteroaryl are optionally further substituted by one or more substituents selected from a hydrogen atom, cyano, C 1-6 alkyl, C 1-6 alkoxy;

[0884] R 2 is a hydrogen atom, halogen, cyano, hydroxy, oxo, C 1-6 alkyl, C 1-6 alkoxy, C 3-8 cycloalkyl, 3- to 10-membered heterocyclic group, C 6-12 aryl, 5- to 10-membered heteroaryl, -(CH 2 ) n1 R aa 、-O(CH 2 ) n1 R aa 、-S(CH 2 ) n1 R aa or -NR aa (CH 2 ) n1 R bb ,wherein said C 3-8 cycloalkyl, 3- to 10-membered heterocyclic group, C 6-10 aryl and 5- to 10-membered heteroaryl are optionally further substituted by one or more substituents selected from a hydrogen atom, cyano, C 1-6 alkyl, C 1-6 alkoxy, C 3-8 cycloalkyl or -NR cc R dd ;

[0885] R 3 is selected from a hydrogen atom, cyano, halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 3-8 cycloalkyl, 3- to 10-membered heterocyclic group, -(CH 2 ) n1 OR aa 、-C(O)NR aa R bbor -(CH 2 ) n1 S(O) m1 R aa , wherein the cycloalkyl group and the heterocyclic group are optionally further substituted by one or more substituents selected from a hydrogen atom, a C 1-6 alkyl group or a hydroxyl group;

[0886] R 4 is selected from a hydrogen atom or a methyl group;

[0887] R aa , R bb , R cc and R dd are the same or different and are each independently selected from a hydrogen atom, a C 1-6 alkyl group, a C 1-6 haloalkyl group, a cyano group, a hydroxyl group, an amino group, a C 3-8 cycloalkyl group, a 3- to 10-membered heterocyclic group, a C 6-10 aryl group or a 5- to 10-membered heteroaryl group; wherein the C 1-6 alkyl group, the C 1-6 haloalkyl group, the amino group, the C 3-8 cycloalkyl group, the 3- to 10-membered heterocyclic group, the C 6-10 aryl group and the 5- to 10-membered heteroaryl group are optionally further substituted by a hydrogen atom, a cyano group, a hydroxyl group, an amino group, an aminoalkyl group, a C 1-6 alkyl group, a C 1-6 alkoxy group, a C 3-8 cycloalkyl group, a 3- to 10-membered heterocyclic group, a C 6-10 aryl group or a 5- to 10-membered heteroaryl group.

[0888] The object of the present invention is to provide a compound represented by the general formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, wherein the structure of the compound represented by the general formula (I) is as follows:

[0889]

[0890] Wherein:

[0891] L 1 is selected from a bond, an alkylene group, an alkenylene group, an alkynyl group, a cycloalkyl group, a heterocyclic group, -NR aa (CH 2 ) n1 -, -(CH 2 ) n1 S(O) m1 - or -(CH 2 ) n1 S(O) m1 NR aa -;

[0892] L2 Selected from a bond, an oxygen atom, a sulfur atom, -CR aa R bb -, -(CH 2 ) n1 C(O)-, -NR 4 -, or -(CH 2 ) n1 S(O) m1 -;

[0893] L 3 Selected from a bond, -NR aa -, or -C(O)NR aa -;

[0894] Ring A is selected from 6- to 14-membered heteroaryl groups, wherein the 6- to 14-membered heteroaryl groups are selected from 6- to 14-membered fused heteroaryl groups; preferably 5-fused-5-membered heteroaryl groups, 5-fused-6-membered heteroaryl groups or 6-fused-6-membered heteroaryl groups;

[0895] Ring B is selected from 6- to 14-membered bridged heterocyclic groups or 6- to 14-membered fused heterocyclic groups;

[0896] Ring C is selected from heteroaryl groups;

[0897] R 1 Selected from a hydrogen atom, a deuterium atom, an oxo group, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, an alkoxy group, a halogenated alkoxy group, a hydroxyalkyl group, a halogen, an amino group, a nitro group, a hydroxy group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclic group, an oxo heterocyclic group, a thio heterocyclic group, an aryl group, a heteroaryl group, -(CH 2 ) n1 R aa , -(CH 2 ) n1 OR aa , -NR aa C(O)(CH 2 ) n1 OR aa , -NR aa C(=S)(CH 2 ) n1 OR bb , -(CH 2 ) n1 SR aa , -(CH 2 ) n1 C(O)R aa , -(CH 2 ) n1 C(O)OR aa , -(CH 2 ) n1 S(O) m1 R aa , -(CH2 ) n1 NR aa R bb 、-(CH 2 ) n1 C(O)NR aa R bb 、-(CH 2 ) n1 NR aa C(O)R bb or -(CH 2 ) n1 NR aa S(O) m1 R bb wherein the alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, amino, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl and heteroaryl groups are optionally further selected from hydrogen atoms, deuterium atoms, alkyl, haloalkyl, halogen, amino, oxo, nitro, cyano, hydroxyl, alkenyl, alkynyl, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclic, aryl, heteroaryl, -(CH 2 ) n1 -、-(CH 2 ) n1 R cc 、-(CH 2 ) n1 OR cc 、-(CH 2 ) n1 SR cc 、-(CH 2 ) n1 C(O)R cc 、-(CH 2 ) n1 C(O)OR cc 、-(CH 2 ) n1 S(O) m1 R cc 、-(CH 2 ) n1 NR cc R dd 、-(CH 2 ) n1 C(O)NR cc R dd 、-(CH 2 ) n1 NR cc C(O)R dd or -(CH 2 ) n1 NR cc S(O) m1 R ddsubstituted by one or more substituents therein;

[0898] R 2 a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, an oxo group, a haloalkyl group, an alkoxy group, a hydroxyalkyl group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxy group, a cyano group, an alkenyl group or an alkynyl group;

[0899] R 3 selected from a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxy group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a hydroxyalkyl group, a heterocyclic group, an oxoheterocyclic group, a thioheterocyclic group, an aryl group, a heteroaryl group, -(CH 2 ) n1 R aa 、-(CH 2 ) n1 OR aa 、-NR aa C(O)(CH 2 ) n1 OR aa 、-NR aa C(=S)(CH 2 ) n1 OR bb 、-(CH 2 ) n1 SR aa 、-(CH 2 ) n1 C(O)R aa 、-(CH 2 ) n1 C(O)OR aa 、-(CH 2 ) n1 S(O) m1 R aa 、-(CH 2 ) n1 S(O) m1 NR aa R bb 、-(CH 2 ) n1 P(O) m2 R aa R bb 、-(CH 2 ) n1 NR aa R bb 、-(CH 2 ) n1 C(O)NR aa R bb 、-(CH 2 ) n1 NR aaC(O)R bb or -(CH 2 ) n1 NR aa S(O) m1 R bb , wherein the alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, amino, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl and heteroaryl are optionally further selected from a hydrogen atom, a deuterium atom, a substituted or unsubstituted alkyl, a halogen, a hydroxy group, a substituted or unsubstituted amino group, an oxo group, a nitro group, a cyano group, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, a substituted or unsubstituted alkoxy, a substituted or unsubstituted hydroxyalkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aryl and a substituted or unsubstituted heteroaryl, -(CH 2 ) n1 -, -(CH 2 ) n1 R cc , -(CH 2 ) n1 OR cc , -(CH 2 ) n1 SR cc , -(CH 2 ) n1 C(O)R cc , -(CH 2 ) n1 C(O)OR cc , -(CH 2 ) n1 S(O) m1 R cc , -(CH 2 ) n1 S(O) m1 NR cc R dd , -(CH 2 ) n1 NR cc R dd , -(CH 2 ) n1 C(O)NR cc R dd , -(CH 2 ) n1 C(O)NR cc S(O) m1 R dd , -(CH 2 ) n1 NR cc S(O) m1 R dd or -(CH 2) n1 NR cc S(O) m1 R dd is substituted by one or more substituents selected from the group consisting of;

[0900] R 4 is a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a haloalkyl group, an alkoxy group, a hydroxyalkyl group, a haloalkoxy group, a halogen atom, an amino group, a nitro group, a hydroxy group, a cyano group, an alkenyl group, or an alkynyl group;

[0901] R aa 、R bb 、R cc and R dd are the same or different and each independently selected from a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a haloalkyl group, an alkoxy group, a hydroxyalkyl group, a haloalkoxy group, a halogen atom, a cyano group, a nitro group, a hydroxy group, an amino group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group, wherein the alkyl group, deuterated alkyl group, haloalkyl group, alkoxy group, hydroxyalkyl group, haloalkoxy group, alkenyl group, alkynyl group, cycloalkyl group, heterocyclic group, aryl group, and heteroaryl group are optionally further substituted by one or more substituents selected from the group consisting of a hydrogen atom, a deuterium atom, a substituted or unsubstituted alkyl group, a halogen atom, a hydroxy group, a substituted or unsubstituted amino group, an oxo group, a nitro group, a cyano group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heteroaryl group;

[0902] x is an integer of 0, 1, 2, or 3;

[0903] y is an integer of 0, 1, 2, 3, 4, or 5;

[0904] m 1 is an integer of 0, 1, or 2;

[0905] m 2 is an integer of 0, 1, or 2; and

[0906] n 1 is an integer of 0, 1, 2, 3, 4, or 5.

[0907] The present invention also relates to a preferred embodiment, the compound represented by the general formula (I), its stereoisomers, or its pharmaceutically acceptable salts, which are the compounds represented by the general formula (II) and the general formula (IIA), their stereoisomers, or their pharmaceutically acceptable salts:

[0908]

[0909] Wherein:

[0910] W is selected from a nitrogen atom or an alkylene group; and

[0911] n is an integer of 0, 1, 2 or 3;

[0912] L 1 、L 2 、L 3 、ring A, ring C, R 1 ~R 3 、x and y are as described in general formula (I).

[0913] The present invention also relates to a preferred embodiment, the compound represented by general formula (I), its stereoisomers or its pharmaceutically acceptable salts, which are the compound represented by general formula (IIIA), its stereoisomers or its pharmaceutically acceptable salts:

[0914]

[0915] Wherein:

[0916] R 5 is selected from a hydrogen atom, a halogen, a cyano group, an alkyl group, an alkoxy group, a hydroxyalkyl group, a haloalkyl group, -(CH 2 ) n1 OR aa 、-(CH 2 ) n1 C(O)NR aa R bb 、a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkyl group, alkoxy group, hydroxyalkyl group, haloalkyl group, cycloalkyl group, heterocyclic group, aryl group and heteroaryl group are optionally further selected from a hydrogen atom, a deuterium atom, a substituted or unsubstituted alkyl group, a halogen, a hydroxyl group, a substituted or unsubstituted amino group, an oxo group, a nitro group, a cyano group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aryl group and a substituted or unsubstituted heteroaryl group, -(CH 2 ) n1 -、-(CH 2 ) n1 R cc 、-(CH 2 ) n1 OR cc 、-(CH 2 ) n1 SR cc 、-(CH 2 ) n1 C(O)R cc 、-(CH 2 ) n1 C(O)OR cc 、-(CH 2 ) n1S(O) m1 R cc 、-(CH 2 ) n1 S(O) m1 NR cc R dd 、-(CH 2 ) n1 NR cc R dd 、-(CH 2 ) n1 C(O)NR cc R dd 、-(CH 2 ) n1 C(O)NR cc S(O) m1 R dd 、-(CH 2 ) n1 NR cc S(O) m1 R dd or -(CH 2 ) n1 NR cc S(O) m1 R dd is substituted by one or more substituents;

[0917] R 6 is selected from hydrogen, halogen, cyano, alkyl, alkoxy, hydroxyalkyl, haloalkyl, cycloalkyl, heterocyclic or -(CH 2 ) n1 C(O)NR aa R bb ;

[0918] L 1 , L 2 , L 3 , Ring A, Ring B, R 1 , R 2 and x are as described in the general formula (I).

[0919] The present invention also relates to a preferred embodiment, wherein the compound represented by the general formula (I), its stereoisomer or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (III), its stereoisomer or a pharmaceutically acceptable salt thereof:

[0920]

[0921] in:

[0922] R 10 and R 11Same or different, each independently selected from a hydrogen atom, a halogen, a cyano group, an alkyl group, an alkoxy group, a hydroxyalkyl group, a haloalkyl group, -(CH 2 ) n1 OR aa 、-(CH 2 ) n1 C(O)NR aa R bb 、-(CH 2 ) n1 S(O) m1 NR aa R bb -, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkyl group, alkoxy group, hydroxyalkyl group, haloalkyl group, cycloalkyl group, heterocyclic group, aryl group and heteroaryl group are optionally further selected from a hydrogen atom, a deuterium atom, a substituted or unsubstituted alkyl group, a halogen, a hydroxy group, a substituted or unsubstituted amino group, an oxo group, a nitro group, a cyano group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aryl group and a substituted or unsubstituted heteroaryl group, -(CH 2 ) n1 -、-(CH 2 ) n1 R cc 、-(CH 2 ) n1 OR cc 、-(CH 2 ) n1 SR cc 、-(CH 2 ) n1 C(O)R cc 、-(CH 2 ) n1 C(O)OR cc 、-(CH 2 ) n1 S(O) m1 R cc 、-(CH 2 ) n1 S(O) m1 NR cc R dd 、-(CH 2 ) n1 NR cc R dd 、-(CH 2 ) n1 C(O)NR cc R dd 、-(CH 2 ) n1 C(O)NRcc S(O) m1 R dd 、-(CH 2 ) n1 NR cc S(O) m1 R dd or -(CH 2 ) n1 NR cc S(O) m1 R dd is substituted by one or more substituents;

[0923] L 1 , L 2 , L 3 , Ring A, Ring B, R 1 , R 2 and x are as described in the general formula (I).

[0924] The present invention also relates to a preferred embodiment, wherein the compound represented by the general formula (I), its stereoisomer or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (IV), its stereoisomer or a pharmaceutically acceptable salt thereof:

[0925]

[0926] in:

[0927] Ring D is selected from heterocyclyl, aryl or heteroaryl; preferably 5-6 membered heterocyclyl, 6-10 membered aryl or 5-6 membered heteroaryl;

[0928] E 1 、E 2 and E 3 The same or different, each independently selected from nitrogen atom or -CR aa -;

[0929] R 4 is selected from a hydrogen atom, a halogen, a cyano group, an alkyl group, an alkenyl group, an alkynyl group or an alkoxy group;

[0930] R 7 is selected from a hydrogen atom, a halogen, a cyano group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an oxo group or a thio group; and

[0931] z is an integer of 0, 1, 2 or 3;

[0932] L 1 , L 3 , Ring C, R 1 , R 3 , R aa , y and n are as described in the general formula (I).

[0933] The present invention also relates to a preferred embodiment, the compound of formula (I), its stereoisomers or its pharmaceutically acceptable salts, which are the compound of formula (V), its stereoisomers or its pharmaceutically acceptable salts:

[0934]

[0935] Wherein:

[0936] Ring G is selected from heterocyclic group, aryl or heteroaryl; preferably 5-6 membered heterocyclic group, 6-10 membered aryl or 5-6 membered heteroaryl;

[0937] R 8 is selected from hydrogen atom, halogen, cyano, alkyl, alkenyl, alkynyl, alkoxy, oxo or thio group; and

[0938] p is an integer of 0, 1, 2 or 3;

[0939] R 5 and R 6 are as defined herein;

[0940] L 1 、E 1 、E 2 、E 3 、R 4 and n are as described in formula (IV).

[0941] The present invention also relates to a preferred embodiment, the compound of formula (I), its stereoisomers or its pharmaceutically acceptable salts, which are the compound of formula (VI), its stereoisomers or its pharmaceutically acceptable salts:

[0942]

[0943] Wherein:

[0944] Ring K is selected from heterocyclic group, aryl or heteroaryl; preferably 5-6 membered heterocyclic group, 6-10 membered aryl, 5-6 membered heteroaryl;

[0945] R 9 is selected from hydrogen atom, halogen, cyano, alkyl, alkenyl, alkynyl, alkoxy, oxo or thio group; and

[0946] q is an integer of 0, 1, 2 or 3;

[0947] R 5 and R 6 are as defined herein;

[0948] E 1 、E 2 、E 3 and R 4As described in General Formula (IV).

[0949] The present invention also relates to a preferred embodiment, the compound represented by General Formula (I), its stereoisomers or its pharmaceutically acceptable salts, which are the compound represented by General Formula (VII), its stereoisomers or its pharmaceutically acceptable salts:

[0950]

[0951] Wherein:

[0952] n is an integer of 0, 1 or 2;

[0953] L 2 , ring A, R 2 , R 5 , R 6 and x are as described in General Formula (IIIA).

[0954] The present invention also relates to a preferred embodiment, the compound represented by General Formula (III), its stereoisomers or its pharmaceutically acceptable salts, which are the compound represented by General Formula (VIII), its stereoisomers or its pharmaceutically acceptable salts:

[0955]

[0956] Wherein:

[0957] M 1 is selected from a nitrogen atom or -CR aa -;

[0958] R 12 is selected from a hydrogen atom, a cyano group, a halogen, an alkyl group or an alkoxy group; and

[0959] z is an integer of 0, 1 or 2;

[0960] L 1 , L 2 , ring C, R 1 , R 3 , R 7 , R aa and y are as described in General Formula (IV).

[0961] The present invention also relates to a preferred embodiment, the compound represented by General Formula (I), its stereoisomers or its pharmaceutically acceptable salts, which are the compound represented by General Formula (IX), its stereoisomers or its pharmaceutically acceptable salts:

[0962]

[0963] Wherein:

[0964] ring C, R 3 , R12 and R 7 , y and z are as described in general formula (VII).

[0965] The present invention also relates to a preferred embodiment, the compound represented by general formula (I), its stereoisomers or its pharmaceutically acceptable salts, which are the compound represented by general formula (X), its stereoisomers or its pharmaceutically acceptable salts:

[0966]

[0967] Wherein:

[0968] R 5 ~R 6 are as described in general formula (IIIA);

[0969] R 12 , R 7 and z are as described in general formula (VII).

[0970] The present invention also relates to a preferred embodiment, the compound represented by general formula (I), its stereoisomers or its pharmaceutically acceptable salts, which are the compound represented by general formula (XI), its stereoisomers or its pharmaceutically acceptable salts:

[0971]

[0972] Wherein:

[0973] L 1 , L 2 , ring B, ring C, R 3 and R 12 are as described in general formula (I)

[0974] R 7 , y and z are as described in general formula (IX).

[0975] The present invention also relates to a preferred embodiment, each general formula, its stereoisomers or its pharmaceutically acceptable salts described in any one of the above, characterized in that

[0976] Ring A is selected from the following groups:

[0977]

[0978]

[0979] Ring B is selected from the following groups:

[0980]

[0981] Ring C is selected from the following groups:

[0982]

[0983] The present invention also relates to a preferred embodiment, each general formula, its stereoisomers or its pharmaceutically acceptable salts as described in any one of the preceding claims, characterized in that,

[0984] L 1 is a C 3-8 cycloalkyl group, a C 3-8 heterocycloalkyl group, -(CH 2 ) n1 -, -NR aa (CH 2 ) n1 -, -(CH 2 ) n1 S(O) m1 -, or -(CH 2 ) n1 S(O) m1 NR aa -;

[0985] L 2 is selected from a bond, an oxygen atom, -CR aa R bb -, -(CH 2 ) n1 C(O)-, -NR 4 -, or -(CH 2 ) n1 S(O) m1 -;

[0986] L 3 is selected from a bond, -NR aa -, or -C(O)NR aa -;

[0987] R 1 is selected from a cyano group, -(CH 2 ) n1 R aa a C 3-8 cycloalkyl group or a 3- to 10-membered heterocyclic group, wherein the cycloalkyl group and the heterocyclic group are optionally further substituted by one or more substituents selected from a hydrogen atom or a cyano group;

[0988] R 2 is a hydrogen atom, a halogen, a cyano group, a hydroxyl group, an oxo group, a C 1-6 alkyl group, a C 1-6 alkoxy group or a 3- to 10-membered heterocyclic group; preferably a hydrogen atom, a halogen, a cyano group, a hydroxyl group, an oxo group, a C 1-3 alkoxy group, a C 1-3 alkyl group or a 3- to 8-membered heterocyclic group; more preferably a hydrogen atom, fluorine, a cyano group, a hydroxyl group, an oxo group, a methoxy group, a methyl group or a morpholinyl group;

[0989] R3 Selected from a hydrogen atom, a cyano group, a halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 3-8 cycloalkyl, a 3- to 10-membered heterocyclic group, -(CH 2 ) n1 OR aa 、-C(O)NR aa R bb or -(CH 2 ) n1 S(O) m1 R aa , wherein the cycloalkyl and heterocyclic groups are optionally further substituted by one or more substituents selected from a hydrogen atom, C 1-6 alkyl or a hydroxy group;

[0990] R 4 is selected from a hydrogen atom or a methyl group;

[0991] R aa 、R bb 、R cc and R dd are the same or different and are each independently selected from a hydrogen atom, C 1-6 alkyl, a cyano group, a hydroxy group, an amino group or a 3- to 10-membered heterocyclic group; wherein the C 1-6 alkyl, amino group and 3- to 10-membered heterocyclic group are optionally further substituted by one or more substituents selected from a hydrogen atom, a cyano group, a hydroxy group or a 5- to 10-membered heteroaryl group.

[0992] The present invention further relates to any of the compounds of general formula (I) shown, their stereoisomers or pharmaceutically acceptable salts thereof, or the use of the pharmaceutical composition in the preparation of a JAK kinase inhibitor drug.

[0993] The present invention also relates to a method for treating and / or preventing a disease mediated by a JAK kinase inhibitor, which comprises administering to a patient a therapeutically effective dose of a compound of general formula (I) shown, its stereoisomers or pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof.

[0994] The present invention also relates to a pharmaceutical composition, which comprises a therapeutically effective dose of a compound of general formula (I) shown, its stereoisomers or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.

[0995] The present invention also relates to the use of the compound of general formula (I) shown, its stereoisomers or pharmaceutically acceptable salts thereof, or the pharmaceutical composition in the preparation of drugs related to inflammatory diseases and tumor diseases.

[0996] The present invention also relates to a method for treating inflammatory diseases and a method for treating tumor diseases, which comprise administering to a patient a therapeutically effective dose of the pharmaceutical composition, wherein the inflammatory diseases are selected from rheumatoid arthritis, dermatitis, psoriasis, and inflammatory bowel disease; wherein the gastrointestinal inflammatory disease is a chronic intestinal inflammatory disease, more preferably ulcerative colitis and Crohn's disease.

[0997] The present invention also relates to a method for treating tumor diseases, which comprises administering to a patient a therapeutically effective dose of the pharmaceutical composition, wherein the tumor diseases are selected from myelofibrosis, polycythemia vera, essential thrombocythemia, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), ductal carcinoma of the breast, and non-small cell lung cancer (NSCLC).

[0998] The present invention also relates to a pharmaceutical composition, which comprises a compound represented by the above general formula (I), its stereoisomers, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents, or excipients, and the compound represented by the general formula (I), its stereoisomers, or a pharmaceutically acceptable salt thereof may be in a therapeutically effective amount.

[0999] The present invention further relates to the use of any of the compounds represented by the general formula (I), its stereoisomers, or a pharmaceutically acceptable salt thereof, or the above pharmaceutical composition in the preparation of a JAK kinase inhibitor.

[1000] The present invention also relates to the use of the compound represented by the above general formula (I), its stereoisomers, or a pharmaceutically acceptable salt thereof, or the above pharmaceutical composition in the preparation of a drug for preventing and / or treating JAK kinase-related diseases. The JAK kinase-related diseases are preferably inflammatory diseases and / or tumor diseases; the inflammatory diseases are preferably selected from rheumatoid arthritis, dermatitis, psoriasis, and inflammatory bowel disease; wherein the gastrointestinal inflammatory disease is preferably a chronic intestinal inflammatory disease, more preferably ulcerative colitis and Crohn's disease. The tumor diseases are preferably selected from myelofibrosis, polycythemia vera, essential thrombocythemia, acute myeloid leukemia, acute lymphoblastic leukemia, ductal carcinoma of the breast, and non-small cell lung cancer.

[1001] The present invention also relates to the use of the compound of general formula (I), its stereoisomers or its pharmaceutically acceptable salts, or the pharmaceutical composition as described above in the preparation of a drug, and the drug is preferably a drug for treating inflammatory diseases and / or tumor diseases. The inflammatory diseases are preferably selected from rheumatoid arthritis, dermatitis, psoriasis, inflammatory bowel disease; among them, gastrointestinal inflammatory diseases are chronic intestinal inflammatory diseases, and more preferably ulcerative colitis and Crohn's disease. The tumor diseases are preferably selected from myelofibrosis, polycythemia vera and essential thrombocythemia, acute myelocytic leukemia, acute lymphocytic leukemia, ductal carcinoma of the breast and non-small cell lung cancer.

[1002] The present invention also relates to a method for treating inflammatory diseases, which comprises administering to a patient a therapeutically effective dose of the compound of general formula (I) as described above, its stereoisomers or its pharmaceutically acceptable salts, or the pharmaceutical composition as described above, and the inflammatory diseases are selected from rheumatoid arthritis, dermatitis, psoriasis, inflammatory bowel disease; among them, gastrointestinal inflammatory diseases are chronic intestinal inflammatory diseases, and more preferably ulcerative colitis and Crohn's disease.

[1003] The present invention also relates to a method for treating tumor diseases, which comprises administering to a patient a therapeutically effective dose of the compound of general formula (I) as described above, its stereoisomers or its pharmaceutically acceptable salts, or the pharmaceutical composition as described above, and the tumor diseases are selected from myelofibrosis, polycythemia vera and essential thrombocythemia, acute myelocytic leukemia, acute lymphocytic leukemia, ductal carcinoma of the breast and non-small cell lung cancer.

[1004] The present invention also relates to a method for preventing and / or treating a JAK kinase-mediated disorder, which comprises administering to a patient a therapeutically effective dose of the compound of general formula (I) as described above, its stereoisomers or its pharmaceutically acceptable salts, or the pharmaceutical composition as described above. The JAK kinase-mediated disorder is preferably an inflammatory disease and / or a tumor disease; the inflammatory diseases are preferably selected from rheumatoid arthritis, dermatitis, psoriasis, inflammatory bowel disease; among them, gastrointestinal inflammatory diseases are preferably chronic intestinal inflammatory diseases, and more preferably ulcerative colitis and Crohn's disease. The tumor diseases are preferably selected from myelofibrosis, polycythemia vera and essential thrombocythemia, acute myelocytic leukemia, acute lymphocytic leukemia, ductal carcinoma of the breast and non-small cell lung cancer.

[1005] Detailed Description of the Invention

[1006] Unless otherwise stated, the terms used in the specification and claims have the following meanings.

[1007] The term "alkyl" refers to a saturated aliphatic hydrocarbon group, which is a straight-chain or branched-chain group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 8 carbon atoms, more preferably an alkyl group containing 1 to 6 carbon atoms, and most preferably an alkyl group containing 1 to 3 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and various branched isomers thereof. More preferred are lower alkyl groups containing 1 to 6 carbon atoms, and non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, etc. The alkyl group can be substituted or unsubstituted. When substituted, the substituent can be substituted at any available attachment point. The substituent is preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl or carboxylate group. The present invention preferably includes methyl, ethyl, isopropyl, tert-butyl, haloalkyl, deuterated alkyl, alkoxy-substituted alkyl, and hydroxy-substituted alkyl.

[1008] The term "alkylene" means that one hydrogen atom of an alkyl group is further substituted. For example, "methylene" refers to -CH 2 -, "ethylene" refers to -(CH 2 ) 2 -, "propylene" refers to -(CH 2 ) 3 -, "butylene" refers to -(CH 2 ) 4 - etc. The term "alkenyl" refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon double bond, such as vinyl, 1-propenyl, 2-propenyl, 1-, 2- or 3-butenyl, etc. The alkenyl can be substituted or unsubstituted. When substituted, the substituents are preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio.

[1009] The term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, and the cycloalkyl ring contains 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms, more preferably 3 to 8 carbon atoms, and most preferably 3 to 6 carbon atoms. Non-limiting examples of monocyclic cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, etc.; polycyclic cycloalkyl includes spiro, fused and bridged cycloalkyl, preferably cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl and cycloheptyl, more preferably cyclopropyl, cyclobutyl and cyclopentyl.

[1010] The term "spiroalkyl" refers to a polycyclic group in which a 5- to 20-membered monocyclic ring shares a carbon atom (called a spiro atom), which may contain one or more double bonds, but no ring has a completely conjugated π electron system. It is preferably 6 to 14 members, more preferably 7 to 10 members. The spiroalkyl is classified into monospiroalkyl, dispiroalkyl or polyspiroalkyl according to the number of spiro atoms shared between rings, preferably monospiroalkyl and dispiroalkyl. More preferably, it is 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 5-membered or 5-membered / 6-membered monospiroalkyl. Non-limiting examples of spiroalkyl include:

[1011]

[1012] It also includes spiroalkyl in which a monospiroalkyl shares a spiro atom with a heterocycloalkyl. Non-limiting examples include:

[1013]

[1014]

[1015] The term "fused cycloalkyl" refers to a fully carbon polycyclic group having 5 to 20 ring members, wherein each ring in the system shares an adjacent pair of carbon atoms with another ring in the system, and one or more of the rings may contain one or more double bonds, but none of the rings has a fully conjugated π-electron system. Preferably it has 6 to 14 ring members, more preferably 7 to 10

[1016] ring members. It can be classified into bicyclic, tricyclic, tetracyclic or polycyclic fused cycloalkyl according to the number of constituent rings, preferably bicyclic or tricyclic, more preferably 4 / 4, 5 / 5 or 5 / 6 bicyclic alkyl. Non-limiting

[1017] examples of fused cycloalkyl include:

[1018]

[1019] The term "bridged cycloalkyl" refers to a fully carbon polycyclic group having 5 to 20 ring members, wherein any two rings share two non-directly connected carbon atoms, and it may contain one or more double bonds, but none of the rings has a fully conjugated π-electron system. Preferably it has 6 to 14 ring members, more preferably 7 to 10 ring members. It can be classified into bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl according to the number of constituent rings, preferably bicyclic, tricyclic or tetracyclic, more preferably bicyclic or tricyclic. Non-limiting examples of bridged cycloalkyl include:

[1020]

[1021] The cycloalkyl ring may be fused to an aryl, heteroaryl or heterocycloalkyl ring, wherein the ring connected to the parent structure is cycloalkyl. Non-limiting examples include indanyl, tetrahydronaphthyl, benzocycloheptyl, etc.

[1022] The cycloalkyl may be optionally substituted or unsubstituted. When substituted, the substituent is preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl or carboxylate group.

[1023] The term "heterocyclic group" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent containing 3 to 20 ring atoms, wherein one or more of the ring atoms are selected from nitrogen, oxygen, boron, phosphorus, S(O) m (where m is an integer from 0 to 2) or P(O) nheteroatoms (where n is an integer from 0 to 2), but excluding ring moieties of -O-O-, -O-S- or -S-S-, and the remaining ring atoms are carbon. It preferably contains 3 to 12 ring atoms, among which 1 to 4 are heteroatoms; more preferably contains 3 to 10 ring atoms; most preferably contains 3 to 8 ring atoms. Non-limiting examples of monocyclic heterocyclic groups include oxetanyl, azetidinyl, pyrrolidinyl, imidazolidinyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydrothienyl, dihydroimidazolyl, dihydrofuryl, dihydropyrazolyl, dihydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, pyranyl, etc., preferably oxetanyl, azetidinyl, tetrahydrofuryl, tetrahydropyranyl, pyrazolidinyl, morpholinyl, piperidinyl, piperazinyl and pyranyl. More preferably azetidinyl, oxetanyl, pyrrolidinyl, tetrahydropyranyl, morpholinyl, piperidinyl and piperazinyl. Polycyclic heterocyclic groups include spiro, fused and bridged heterocyclic groups; the spiro, fused and bridged heterocyclic groups involved are optionally connected to other groups by a single bond, or further fused to other cycloalkyl groups, heterocyclic groups, aryl groups and heteroaryl groups through any two or more atoms on the ring.

[1024] The term "spiroheterocyclic group" refers to a polycyclic heterocyclic group with 3 to 20 membered monocyclic rings sharing one atom (called the spiro atom), where one or more ring atoms are nitrogen, oxygen, boron, phosphorus, S(O) m (where m is an integer from 0 to 2) or P(O) n heteroatoms (where n is an integer from 0 to 2), and the remaining ring atoms are carbon. It may contain one or more double bonds, but none of the rings has a completely conjugated π electron system. It is preferably 6 to 14 membered, more preferably 7 to 10 membered. According to the number of spiro atoms shared between rings, spiroheterocyclic groups are classified into monospiroheterocyclic groups, bisspiroheterocyclic groups or polyspiroheterocyclic groups, preferably monospiroheterocyclic groups and bisspiroheterocyclic groups. More preferably 3-membered / 5-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 5-membered or 5-membered / 6-membered monospiroheterocyclic groups. Non-limiting examples of spiroheterocyclic groups include:

[1025]

[1026] The term "fused heterocyclic group" refers to a polycyclic heterocyclic group with 5 to 20 membered rings, where each ring in the system shares an adjacent pair of atoms with other rings in the system, and one or more rings may contain one or more double bonds, but none of the rings has a completely conjugated π electron system, and one or more ring atoms are selected from nitrogen, oxygen or S(O) ma heteroatom (where m is an integer from 0 to 2), and the remaining ring atoms are carbon. It is preferably 6 to 14 membered, more preferably 7 to 10 membered. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclic groups, preferably bicyclic or tricyclic, more preferably 3 - membered / 5 - membered, 4 - membered / 5 - membered or 5 - membered / 6 - membered bicyclic fused heterocyclic groups. Non - limiting examples of the fused heterocyclic group include:

[1027]

[1028] The term "bridged heterocyclic group" refers to a polycyclic heterocyclic group having 5 to 14 members, in which any two rings share two non - directly - connected atoms. It may contain one or more double bonds, but no ring has a completely conjugated π - electron system, and one or more ring atoms are heteroatoms selected from nitrogen, oxygen or S(O) m (where m is an integer from 0 to 2), and the remaining ring atoms are carbon. It is preferably 6 to 14 membered, more preferably 7 to 10 membered. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged heterocyclic groups, preferably bicyclic, tricyclic or tetracyclic, more preferably bicyclic or tricyclic. Non - limiting examples of the bridged heterocyclic group include:

[1029]

[1030] The heterocyclic group ring can be fused to an aryl, heteroaryl or cycloalkyl ring, where the ring connected to the parent structure is the heterocyclic group. Non - limiting examples include:

[1031]

[1032] The heterocyclic group can be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl or carboxylate group.

[1033] The term "aryl" refers to a 6 - to 14 - membered all - carbon monocyclic or fused polycyclic (i.e., rings sharing adjacent carbon atom pairs) group having a conjugated π - electron system, preferably 6 to 10 membered, such as phenyl and naphthyl. More preferably phenyl. The aryl ring can be fused to a heteroaryl, heterocyclic or cycloalkyl ring, where the ring connected to the parent structure is the aryl ring. Non - limiting examples include:

[1034]

[1035] The aryl group can be substituted or unsubstituted. When substituted, the substituents are preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate group.

[1036] The term "heteroaryl" refers to a heteroaromatic system containing 1 to 4 heteroatoms and 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur and nitrogen. The heteroaryl group is preferably 5 to 10 membered, more preferably 5 or 6 membered, such as imidazolyl, furyl, thienyl, thiazolyl, pyrazolyl, oxazolyl, pyrrolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, thiadiazole, oxadiazole, pyrazinyl and pyridazinyl, etc., preferably pyrazinyl, pyridazinyl, oxazolyl, oxadiazole, tetrazolyl, triazolyl, thienyl, imidazolyl, pyridyl, pyrimidinyl, pyrazolyl, thiazolyl, thiadiazole, pyrazolyl and pyrimidinyl; more preferably pyrazinyl, pyridyl, pyridazinyl, pyrimidinyl, imidazolyl, triazolyl, pyrazolyl and thiazolyl.

[1037] The term "fused heteroaryl" refers to a heteroaromatic system containing 1 to 6 heteroatoms and 4 to 20 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur and nitrogen. The fused heteroaryl group is preferably 6 to 14 membered, more preferably 6 or 10 membered. The fused heteroaryl ring means that a heteroaryl group is fused to an aryl, heterocyclic or cycloalkyl ring. Non-limiting examples thereof include:

[1038]

[1039]

[1040] The said heteroaryl or fused heteroaryl group can be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate group.

[1041] The term "alkoxy" refers to -O-(alkyl) and -O-(unsubstituted cycloalkyl), wherein the alkyl is defined as above. Non-limiting examples of alkoxy include: methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy. The alkoxy group can be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate group.

[1042] "Halogenated alkyl" refers to an alkyl group substituted by one or more halogen atoms, where the alkyl group is as defined above.

[1043] "Halogenated alkoxy" refers to an alkoxy group substituted by one or more halogen atoms, where the alkoxy group is as defined above.

[1044] "Hydroxyalkyl" refers to an alkyl group substituted by a hydroxyl group, where the alkyl group is as defined above.

[1045] "Alkenyl" refers to an alkenyl group, also known as an olefinic group, where the alkenyl group can be further substituted by other relevant groups, such as: alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate group.

[1046] "Alkynyl" refers to (CH≡C- or -C≡C-), where the alkynyl group can be further substituted by other relevant groups, such as: alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate group.

[1047] "Hydroxyl" refers to the -OH group.

[1048] "Halogen" refers to fluorine, chlorine, bromine or iodine.

[1049] "Amino" refers to -NH 2 。

[1050] "Cyano" refers to -CN.

[1051] "Nitro" refers to -NO 2 。

[1052] "Carboxyl" refers to -C(O)OH.

[1053] "THF" refers to tetrahydrofuran.

[1054] "EtOAc" refers to ethyl acetate.

[1055] "MeOH" refers to methanol.

[1056] "DMF" refers to N,N-dimethylformamide.

[1057] "DIPEA" refers to diisopropylethylamine.

[1058] "AN" refers to acrylonitrile.

[1059] "TFA" refers to trifluoroacetic acid.

[1060] "MeCN" refers to acetonitrile.

[1061] "DMA" refers to N,N-dimethylacetamide.

[1062] "Et 2 O" refers to diethyl ether.

[1063] "DCE" refers to 1,2-dichloroethane.

[1064] "DIPEA" refers to N,N-diisopropylethylamine.

[1065] "NBS" refers to N-bromosuccinimide.

[1066] "NIS" refers to N-iodosuccinimide.

[1067] "Cbz-Cl" refers to benzyl chloroformate.

[1068] "Pd 2 (dba) 3 " refers to tris(dibenzylideneacetone)dipalladium.

[1069] "Dppf" refers to 1,1'-bis(diphenylphosphino)ferrocene.

[1070] "HATU" refers to 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate.

[1071] "KHMDS" refers to potassium hexamethyldisilazide.

[1072] "LiHMDS" refers to lithium bis(trimethylsilyl)amide.

[1073] "MeLi" refers to methyllithium.

[1074] "n-BuLi" refers to n-butyllithium.

[1075] "NaBH(OAc) 3 " refers to sodium triacetoxyborohydride.

[1076] Different expressions such as "X is selected from A, B, or C", "X is selected from A, B, and C", "X is A, B, or C", "X is A, B, and C" all express the same meaning, that is, X can be any one or more of A, B, and C.

[1077] Any hydrogen atom in the compounds of the examples involved in the present invention can be replaced by its isotope deuterium.

[1078] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and this description includes instances where the event or circumstance occurs or does not occur. For example, "a heterocyclic group optionally substituted by an alkyl group" means that the alkyl group may but need not be present, and this description includes the case where the heterocyclic group is substituted by an alkyl group and the case where the heterocyclic group is not substituted by an alkyl group.

[1079] "Substituted" means that one or more, preferably up to 5, more preferably 1 - 3 hydrogen atoms in a group are independently replaced by the corresponding number of substituents. It goes without saying that the substituents are only at their possible chemical positions, and those skilled in the art can determine (by experiment or theory) what substitutions are possible or impossible without undue effort. For example, an amino or hydroxyl group with a free hydrogen may be unstable when bonded to a carbon atom with an unsaturated (such as olefinic) bond.

[1080] "Pharmaceutical composition" means a mixture containing one or more compounds described herein or their physiologically / pharmaceutically acceptable salts or prodrugs and other chemical components, as well as other components such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of the pharmaceutical composition is to facilitate administration to an organism, facilitate absorption of the active ingredient and thereby exert biological activity.

[1081] "Pharmaceutically acceptable salt" refers to a salt of the compound of the present invention, which has safety and effectiveness when used in mammals and has the appropriate biological activity. Detailed Description of the Invention

[1082] The present invention will be further illustrated by the following examples, but the present invention is not limited to the scope of the described examples. For the experimental methods without specific conditions in the following examples, they are carried out according to conventional methods and conditions, or selected according to the product specifications.

[1083] Examples

[1084] The structure of the compound of the present invention is determined by nuclear magnetic resonance (NMR) or / and liquid chromatography - mass spectrometry (LC - MS). The NMR chemical shift (δ) is given in parts per million (ppm). The NMR measurement is carried out using a Bruker AVANCE - 400 nuclear magnetic resonance instrument, and the solvents for measurement are deuterated dimethyl sulfoxide (DMSO - d 6 ), deuterated methanol (CD 3 OD) and deuterated chloroform (CDCl 3 ), and the internal standard is tetramethylsilane (TMS).

[1085] For the determination by liquid chromatography-mass spectrometry (LC-MS), an Agilent 1200 Infinity Series mass spectrometer was used. For the determination by HPLC, an Agilent 1200 DAD high-performance liquid chromatograph (Sunfire C18 150×4.6 mm chromatographic column) and a Waters 2695-2996 high-performance liquid chromatograph (Gemini C18 150×4.6 mm chromatographic column) were used.

[1086] For thin-layer chromatography silica gel plates, Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plates were used. The specifications for TLC were 0.15 mm to 0.20 mm, and the specifications for separating and purifying products by thin-layer chromatography were 0.4 mm to 0.5 mm. For column chromatography, silica gel with 200 - 300 mesh from Yantai Huanghai was generally used as the carrier.

[1087] The starting materials in the examples of the present invention are known and can be purchased on the market, or can be synthesized by methods known in the art or according to such methods.

[1088] Unless otherwise specified, all reactions of the present invention were carried out under continuous magnetic stirring in a dry nitrogen or argon atmosphere. The solvent was a dry solvent, and the reaction temperature unit was degrees Celsius.

[1089] Example 1

[1090] 3 - ((3-exo)-3 - ((7 - ((5-methylthiazol-2-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile

[1091]

[1092] First step: tert-butyl (3-exo)-3 - ((7-chloro-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate

[1093]

[1094] 5,7-Dichloro-1,6-naphthyridine (100 mg, 0.502 mmol), tert-butyl (3-exo)-3-amino-8-azabicyclo[3.2.1]octane-8-carboxylate (119 mg, 0.527 mmol) and diisopropylethylamine (195 mg, 1.51 mmol) were dissolved in dimethyl sulfoxide (4 mL). The reaction mixture was heated to 110 °C and stirred for 22 h. After the reaction solution was cooled to room temperature, it was diluted with ethyl acetate, washed with saturated aqueous sodium chloride solution, and the organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography to obtain the title compound as a yellowish-white solid (173 mg, 92%).

[1095] 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.89 (dd, J = 4.2, 1.3 Hz, 1H), 8.72 (d, J = 8.3 Hz, 1H), 7.74 (d, J = 7.5 Hz, 1H), 7.48 (dd, J = 8.4, 4.3 Hz, 1H), 6.96 (s, 1H), 4.70 - 4.56 (m, 1H), 4.16 (s, 2H), 2.05 - 1.87 (m, 4H), 1.81 - 1.57 (m, 4H), 1.44 (s, 9H).

[1096] MS m / z (ESI): 389.2 [M + H] + .

[1097] Step 2: Preparation of 3-((3-exo)-3-((7-chloro-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile

[1098]

[1099] tert-Butyl (3-exo)-3-((7-chloro-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate (100 mg, 0.257 mmol) was dissolved in dichloromethane (1 mL). Trifluoroacetic acid (0.5 mL) was added under stirring at room temperature. The resulting reaction mixture was stirred at room temperature for 30 min, concentrated under reduced pressure to remove the solvent, dissolved in anhydrous methanol, and then diisopropylethylamine (332 mg, 2.57 mmol) and acrylonitrile (16 mg, 0.31 mmol) were added successively. The reaction mixture was stirred at room temperature for 26.5 h, and the solvent was removed under reduced pressure. The residue was separated and purified by silica gel column chromatography to obtain the title compound as a white powder (81 mg, 92%).

[1100] 11H NMR (400 MHz, DMSO-d 6 ) δ 8.90 - 8.87 (m, 1H), 8.72 (d, J = 8.3 Hz, 1H), 7.76 (d, J = 7.7 Hz, 1H), 7.47 (dd, J = 8.4, 4.3 Hz, 1H), 6.94 (s, 1H), 4.51 - 4.35 (m, 1H), 3.34 (s, 2H), 2.69 - 2.58 (m, 4H), 1.98 - 1.88 (m, 2H), 1.84 - 1.62 (m, 6H).

[1101] MS m / z (ESI): 342.1 [M+H] + .

[1102] Step 3: Preparation of 3 - ((3-exo)-3 - ((7 - ((5 - (methylthio)azol - 2 - yl)amino)-1,6 - naphthyridin - 5 - yl)amino)-8 - azabicyclo[3.2.1]octan - 8 - yl)propanenitrile

[1103]

[1104] 3 - ((3-exo)-3 - ((7 - chloro - 1,6 - naphthyridin - 5 - yl)amino)-8 - azabicyclo[3.2.1]octan - 8 - yl)propanenitrile (50 mg, 0.146 mmol), 5 - (methylthio)azol - 2 - amine (25 mg, 0.219 mmol), chloro(2 - (dicyclohexylphosphino)-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (7 mg, 0.009 mmol) and cesium carbonate (86 mg, 0.263 mmol) were added to ultradry 1,4 - dioxane (5 mL). The reaction mixture was saturated with dry nitrogen, sealed in a tube and heated to 110 °C with stirring for 24 h. Then it was cooled to room temperature, filtered, and the filtrate was concentrated under reduced pressure. The title compound was obtained as a yellow - green solid (14 mg, 23%) by preparative TLC.

[1105] 1 1H NMR (400 MHz, DMSO-d 6 ) δ 10.77 (s, 1H), 8.71 - 8.63 (m, 1H), 8.55 (d, J = 8.3 Hz, 1H), 7.47 (d, J = 8.6 Hz, 1H), 7.10 (dd, J = 8.3, 4.3 Hz, 1H), 7.02 (d, J = 1.1 Hz, 1H), 6.46 (s, 1H), 4.96 - 4.77 (m, 1H), 3.36 (s, 2H), 2.65 (s, 4H), 2.32 (s, 3H), 2.04 - 1.72 (m, 8H).

[1106] MS m / z (ESI): 420.2 [M+H] + .

[1107] Example 2

[1108] 3-(3-exo)-3-((7-((5-(hydroxymethyl)thiazol-2-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile

[1109]

[1110] 3-((3-exo)-3-((7-chloro-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile (50 mg, 0.146 mmol), (2-aminothiazol-5-yl)methanol (38 mg, 0.292 mmol), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (58 mg, 0.073 mmol) and cesium carbonate (143 mg, 0.438 mmol) were added to ultradry 1,4-dioxane (5 mL). The reaction mixture was saturated with dry nitrogen to remove oxygen, then heated to 140 °C with stirring using a microwave reactor for 2.5 h and then cooled to room temperature. The reaction solution was filtered, and the filtrate was concentrated under reduced pressure. The title compound (8.6 mg, 14%) was obtained by silica gel column chromatography and reverse-phase HPLC separation and purification in sequence.

[1111] 1 H NMR (400 MHz, DMSO-d 6 ) δ 10.85 (s, 1H), 8.70 - 8.65 (m, 1H), 8.60 - 8.53 (m, 1H), 7.47 (d, J = 8.6 Hz, 1H), 7.18 (s, 1H), 7.11 (dd, J = 8.3, 4.3 Hz, 1H), 6.50 (s, 1H), 5.16 (t, J = 5.2 Hz, 1H), 4.86 (dd, J = 16.7, 8.2 Hz, 1H), 4.56 (d, J = 5.2 Hz, 2H), 3.33 (s, 2H), 2.65 (s, 4H), 1.99 - 1.86 (m, 4H), 1.81 (d, J = 7.4 Hz, 4H).

[1112] MS m / z (ESI): 436.1 [M+H] + .

[1113] Example 3

[1114] 3-((3-exo)-3-((4-((5-methyl-1H-pyrazol-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile

[1115]

[1116] Step 1: Preparation of 2,4-dichloro-5-tosyl-7H-pyrrolo[2,3-d]pyrimidine

[1117]

[1118] To a solution of 2,4-dichloropyrrolo[3,2-D]pyrimidine (200 mg, 1.06 mmol) in dichloromethane (5 mL), TsCl (242 mg, 1.27 mmol) and DIPEA (273 mg, 2.12 mmol) were added successively, and then the mixture was stirred overnight at room temperature. After completion of the reaction, the reaction solution was extracted with DCM (15 mL x 3), washed with saturated aqueous sodium chloride solution (15 mL x 3), the organic phase was collected, dried over anhydrous sodium sulfate, filtered, and the organic solvent was concentrated under reduced pressure. The obtained product was separated and purified by silica gel column chromatography (PE:DCM from 0 to 70:30) to obtain the title compound as a white solid (360 mg, 99%).

[1119] MS m / z (ESI): 343.0 [M+H] + .

[1120] Step 2: Preparation of 2-chloro-N-(5-methyl-1H-pyrazol-3-yl)-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine

[1121]

[1122] To a solution of 2,4-dichloro-5-tosyl-7H-pyrrolo[2,3-d]pyrimidine (171 mg, 0.5 mmol) in MeCN (10 mL), 3-amino-5-methylpyrazole (53 mg, 0.55 mmol) and DIPEA (129 mg, 1 mmol) were added successively, and then the mixture was stirred under microwave conditions at 100 °C for 2 hours. After completion of the reaction, the reaction solution was extracted with EA (15 mL x 3), washed with saturated aqueous sodium chloride solution (15 mL x 3), the organic phase was collected, dried over anhydrous sodium sulfate, filtered, and the organic phase was concentrated under reduced pressure. The obtained product was separated and purified by silica gel column chromatography (DCM:MeOH from 0 to 95:5) to obtain the title compound as a pale yellow solid (185 mg, 92%).

[1123] MS m / z (ESI): 402.1 [M+H]+ .

[1124] Step 3: Preparation of tert-butyl-(3-exo)-3-((4-((5-methyl-1H-pyrazol-3-yl)amino)-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylic acid

[1125]

[1126] To a solution of 2-chloro-N-(5-methyl-1H-pyrazol-3-yl)-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (100 mg, 0.25 mmol) in n-BuOH (5 mL), N-Boc-exo-3-aminotropane (85 mg, 0.375 mmol) and DIPEA (64.5 mg, 0.5 mmol) were added successively, and then the mixture was stirred under microwave conditions at 150 °C for 12 hours. After the reaction was completed, the reaction solution was extracted with EA (15 mL x 3), washed with saturated aqueous sodium chloride solution (15 mL x 3), the organic phase was collected, dried over anhydrous sodium sulfate, filtered, and the organic solvent was concentrated under reduced pressure to obtain the title compound as a pale yellow solid (100 mg, 68%).

[1127] MS m / z(ESI): 593.1[M+H] + .

[1128] Step 4: Preparation of 3-((3-exo)-3-((4-((5-methyl-1H-pyrazol-3-yl)amino)-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile

[1129]

[1130] tert-Butyl-(3-exo)-3-((4-((5-methyl-1H-pyrazol-3-yl)amino)-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylic acid (100 mg, 0.17 mmol) was dissolved in hydrochloric acid ethyl acetate solution (4.0 N, 2 mL), and the reaction solution was rotary evaporated after stirring at room temperature for 30 minutes; then MeOH (10 mL) was added to dissolve it, DIPEA (88 mg, 0.68 mmol) was slowly added dropwise, and the mixture was stirred at room temperature for 10 minutes. After acrylonitrile (14 mg, 0.26 mmol) was added, the mixture was stirred for another 2 hours. The reaction solution was concentrated under reduced pressure and purified by silica gel column chromatography (DCM:MeOH = 10:1) to obtain the title compound as a yellow solid (52.6 mg, 57%).

[1131] MS m / z (ESI): 546.1 [M+H] + .

[1132] Step 5: Preparation of 3-((3-exo)-3-((4-((5-methyl-1H-pyrazol-3-yl)amino)-7H-pyrrolo[2,3-d]

[1133] pyrimidin-2-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile

[1134]

[1135] To a mixed solution of 3-((3-exo)-3-((4-((5-methyl-1H-pyrazol-3-yl)amino)-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile (50 mg, 0.09 mmol) in 1,4-dioxane (10 mL) and methanol (5 mL), an aqueous solution (0.2 mL) of sodium hydroxide (36 mg, 0.9 mmol) was added, and then the mixture was heated with stirring at 55 °C overnight. After the reaction was completed, the reaction solution was concentrated under reduced pressure, and the title compound as a white solid (10 mg, 29%) was obtained by prep-HPLC.

[1136] 1 1H NMR (400 MHz, DMSO) δ 11.85 (s, 1H), 10.72 (s, 1H), 9.38 (s, 1H), 6.67 (s, 3H), 5.92 (s, 1H), 4.11 (s, 1H), 3.29 (s, 2H), 2.62 (s, 4H), 2.20 (s, 3H), 1.90 (s, 2H), 1.82 - 1.47 (m, 6H).

[1137] MS m / z (ESI): 392.2 [M+H] + .

[1138] Example 4

[1139] 3-((3-exo)-3-((4-((5-methyl-1H-pyrazol-3-yl)amino)quinazolin-2-yl)amino)-8-azabicyclo

[1140] [3.2.1]octan-8-yl)propanenitrile

[1141]

[1142] Step 1: Preparation of 2-chloro-N-(5-methyl-1H-pyrazol-3-yl)quinazolin-4-amine

[1143]

[1144] 2,4-Dichloroquinazoline (199 mg, 1.0 mmol), 5-methyl-1H-pyrazol-3-amine (99 mg, 1.02 mmol), and triethylamine (213 mg, 2.1 mmol) were added to anhydrous ethanol (5 mL), and the mixture was stirred at room temperature for 18 h. The reaction solution was concentrated under reduced pressure, and the resulting solid was suspended in water-ethanol (v / v = 9:1, 20 mL). The solid obtained after filtration was washed with petroleum ether and dried to give the title compound (240 mg, 92%).

[1145] MS m / z (ESI): 260.1, 262.1 [M+H] + .

[1146] Step 2: tert-Butyl (3-exo)-3-((4-((5-methyl-1H-pyrazol-3-yl)amino)quinazolin-2-yl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate

[1147]

[1148] 2-Chloro-N-(5-methyl-1H-pyrazol-3-yl)quinazolin-4-amine (40 mg, 0.154 mmol) and tert-butyl (3-exo)-3-amino-8-azabicyclo[3.2.1]octane-8-carboxylate (70 mg, 0.308 mmol) were added to n-butanol (3 mL). After stirring evenly at room temperature, the mixture was reacted at 150 °C by microwave for 4 h. The solvent was removed by concentration under reduced pressure, and the residue was separated and purified by silica gel column chromatography to obtain the crude title compound (120 mg), which was directly used in the next step of the reaction.

[1149] MS m / z (ESI): 450.2 [M+H] + .

[1150] Step 3: Preparation of 3-((3-exo)-3-((4-((5-methyl-1H-pyrazol-3-yl)amino)quinazolin-2-yl)amino)-8-azabicyclo[3.2.1]octane-8-yl)propanenitrile

[1151]

[1152] The crude product of tert-butyl (3-exo)-3-((4-((5-methyl-1H-pyrazol-3-yl)amino)quinazolin-2-yl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate (120 mg, 0.154 mmol) was dissolved in methanol (3 mL), and added to a 1,4-dioxane solution of 4 M HCl (10 mL) under stirring at room temperature. The resulting reaction solution was stirred at room temperature for 30 minutes, and the solvent was removed by concentration under reduced pressure. The residue was dissolved in anhydrous methanol (10 mL), and diisopropylethylamine (0.51 mL, 3.08 mmol) and acrylonitrile (10 mg, 0.154 mmol) were added successively under stirring at room temperature. The resulting reaction mixture was stirred at room temperature for 2.5 hours, and the solvent was removed by concentration under reduced pressure. The residue was separated and purified by silica gel column chromatography and reverse-phase HPLC to obtain the title compound (6.0 mg, 10%).

[1153] 1 H NMR(400MHz,CD 3 OD)δ8.04(d,J=8.1Hz,1H),7.58(t,J=7.5Hz,1H),7.39(s,1H),7.16(t,J=7.5Hz,1H),6.62(s,1H),4.35(s,1H),3.37(s,2H),2.76(t,J=6.9Hz,2H),2.62(t,J=6.9Hz,2H),2.31(s,3H),2.16-1.74(m,6H),1.67(t,J=11.7Hz,2H).

[1154] MS m / z(ESI):403.2[M+H] + .

[1155] Example 5

[1156] 3-(cis-5-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)propanenitrile

[1157]

[1158] Step 1: Preparation of tert-butyl (3aR,5r,6aS)-5-((7-chloro-1,6-naphthyridin-5-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate

[1159]

[1160] tert-Butyl cis-5-aminohexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate (100 mg, 0.442 mmol), 5,7-dichloro-1,6-naphthyridine (83 mg, 0.42 mmol), and diisopropylethylamine (0.208 mL, 1.26 mmol) were dissolved in DMSO (2 mL), heated to 110 °C and stirred for 15 h. The reaction mixture was diluted with ethyl acetate, and the ethyl acetate layer was washed with saturated aqueous sodium chloride. The organic layer was collected, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting product was purified by silica gel column chromatography to give the title compound (142 mg, 87%).

[1161] MS m / z (ESI): 389.4 [M+H] + .

[1162] Step 2: Preparation of 3-(cis-5-((7-chloro-1,6-naphthyridin-5-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-yl)propanenitrile

[1163]

[1164] tert-Butyl cis-5-((7-chloro-1,6-naphthyridin-5-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate (142 mg, 0.365 mmol) was dissolved in methanol (2 mL). 4M HCl in 1,4-dioxane (10 mL) was added under stirring at room temperature, and the mixture was stirred at room temperature for 30 min. The reaction mixture was concentrated under reduced pressure, and the residue was redissolved in anhydrous methanol (10 mL). Diisopropylethylamine (1.2 mL, 7.3 mmol) and acrylonitrile (0.03 mL, 0.438 mmol) were added successively. The resulting reaction mixture was stirred at room temperature for 2 h and then concentrated under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography to give the title compound (123 mg, 98%).

[1165] MS m / z (ESI): 342.1 [M+H] + .

[1166] Step 3: Preparation of 3-(cis-5-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-yl)propanenitrile

[1167]

[1168] 3-(cis-5-((7-chloro-1,6-naphthyridin-5-yl)amino)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)propanenitrile (50 mg, 0.146 mmol), tert-butyl 3-amino-5-methyl-1H-pyrazole-1-carboxylate (44 mg, 0.219 mmol), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (7 mg, 0.009 mmol), and cesium carbonate (86 mg, 0.263 mmol) were added to ultradry 1,4-dioxane (5 mL). The reaction mixture was saturated with dry nitrogen, sealed in a tube, heated to 100 °C, stirred for 17 h, cooled to room temperature, filtered, and the filtrate was concentrated under reduced pressure. It was redissolved in 1,4-dioxane (10 mL) containing 4 M HCl, stirred at room temperature for 30 min, the solvent was concentrated under reduced pressure, and the residue was separated by prep-HPLC to give the title compound (2.6 mg, 4%).

[1169] 1 H NMR(400MHz,CD 3 OD)δ8.54(dd,J=9.0,5.7Hz,1H),8.43-8.24(m,1H),7.06(d,J=5.8Hz,1H),6.66(d,J=5.2Hz,1H),6.12(s,1H),4.63-4.48(m,1H),3.06-2.56(m,8H),2.55-2.34(m,4H),2.28(s,3H),1.57(s,2H).

[1170] MS m / z(ESI):403.2[M+H] + .

[1171] Example 6

[1172] 3-((3-exo)-3-((7-((1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile

[1173]

[1174]

[1175] 3-((3-exo)-3-((7-chloro-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile (50 mg, 0.146 mmol), tert-butyl 3-(1H-pyrazol-1-yl)piperidine-1-carboxylate (40 mg, 0.219 mmol), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (7 mg, 0.009 mmol), and cesium carbonate (86 mg, 0.263 mmol) were added to ultradry 1,4-dioxane (5 mL). The reaction mixture was saturated with dry nitrogen to remove oxygen and then sealed in a tube and heated to 110 °C with stirring for 16 h. After cooling to room temperature, the mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was redissolved in dichloromethane (2 mL), trifluoroacetic acid (1 mL) was added, and the mixture was stirred at room temperature for 30 min and then concentrated under reduced pressure. The residue was separated by prep-HPLC to give the title compound (17 mg, 31%).

[1176] 1 H NMR(400MHz,DMSO-d 6 )δ12.07(s,1H),8.81(s,1H),8.58(d,J=3.3Hz,1H),8.42(d,J=8.6Hz,1H),7.58(s,1H),7.14(dd,J=6.2,2.8Hz,1H),6.97(dd,J=7.9,4.2Hz,1H),6.75(s,1H),6.34(s,1H),4.59-4.42(m,1H),3.33(s,2H),2.63(s,4H),1.97-1.86(m,2H),1.78(ddt,J=24.7,23.4,7.2Hz,6H).

[1177] MS m / z(ESI):389.2[M+H] + .

[1178] Example 7

[1179] 3-((3-exo)-3-((7-((5-(difluoromethyl)-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile

[1180]

[1181] The preparation of 3-((3-exo)-3-((7-((5-(difluoromethyl)-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile was carried out with reference to Example 1.

[1182] MS m / z(ESI):439.2[M+H] + .

[1183] Example 8

[1184] 3-((3-exo)-3-((7-((5-(trifluoromethyl)-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile

[1185]

[1186] The preparation of 3-((3-exo)-3-((7-((5-(trifluoromethyl)-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile was carried out with reference to Example 1.

[1187] MS m / z(ESI):457.2[M+H] + .

[1188] Example 9

[1189] 3-((3-exo)-3-((7-((5-fluoro-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile

[1190]

[1191] The preparation of 3-((3-exo)-3-((7-((5-fluoro-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile was carried out with reference to Example 1.

[1192] 11H NMR (400 MHz, DMSO-d6) δ 11.61 (d, J = 1.5 Hz, 1H), 9.35 (s, 1H), 8.65 (dd, J = 4.3, 1.2 Hz, 1H), 8.49 (d, J = 8.8 Hz, 1H), 7.40 (d, J = 7.8 Hz, 1H), 7.07 (dd, J = 8.4, 4.3 Hz, 1H), 6.25 (s, 1H), 5.77 (dd, J = 6.0, 2.1 Hz, 1H), 4.47 - 4.39 (m, 1H), 3.32 (s, 2H), 2.62 (t, J = 4.2 Hz, 4H), 1.95 - 1.86 (m, 2H), 1.83 - 1.70 (m, 6H).

[1193] MS m / z (ESI): 407.2 [M + H] + .

[1194] Example 10

[1195] 3 - ((5 - ((((3 - exo)-8-(2 - cyanoethyl)-8 - azabicyclo[3.2.1]octan - 3 - yl)amino)-1,6 - naphthyridin - 7 - yl)amino)-1H - pyrazole - 5 - carbonitrile

[1196]

[1197] The preparation of 3 - ((5 - ((((3 - exo)-8-(2 - cyanoethyl)-8 - azabicyclo[3.2.1]octan - 3 - yl)amino)-1,6 - naphthyridin - 7 - yl)amino)-1H - pyrazole - 5 - carbonitrile was referred to Example 1.

[1198] MS m / z (ESI): 414.2 [M + H] + .

[1199] Example 11

[1200] 3 - ((3 - exo)-3 - ((7 - ((5 - ethyl - 1H - pyrazol - 3 - yl)amino)-1,6 - naphthyridin - 5 - yl)amino)-8 - azabicyclo[3.2.1]octan - 8 - yl)propanenitrile

[1201]

[1202] 3-((3-exo)-3-((7-chloro-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile (100 mg, 0.292 mmol), 5-ethyl-1H-pyrazol-3-amine (65 mg, 0.584 mmol), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (115 mg, 0.146 mmol), and cesium carbonate (286 mg, 0.876 mmol) were added to ultradry 1,4-dioxane (10 mL). The reaction mixture was saturated with dry nitrogen and heated to 150 °C in a microwave synthesizer for 8 h. After cooling to room temperature, the mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was separated by silica gel column chromatography and reversed-phase HPLC to give the title compound (2.2 mg, 2%).

[1203] 1 H NMR(400MHz,DMSO-d 6 )δ11.77(s,1H),8.71(s,1H),8.57(dd,J=4.1,1.4Hz,1H),8.40(d,J=7.1Hz,1H),7.12(d,J=8.4Hz,1H),6.95(dd,J=8.1,4.4Hz,1H),6.68(s,1H),6.16(s,1H),4.53(dd,J=12.8,5.6Hz,1H),3.33(s,2H),2.63(ddd,J=24.2,9.2,4.8Hz,6H),1.92(dd,J=8.1,4.4Hz,2H),1.85-1.66(m,6H),1.20(t,J=7.6Hz,3H).

[1204] MS m / z(ESI):417.2[M+H] + .

[1205] Example 12

[1206] 3-((3-exo)-3-((7-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile

[1207]

[1208] 3-((3-exo)-3-((7-chloro-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile (100 mg, 0.292 mmol), 5-cyclopropyl-1H-pyrazol-3-amine (72 mg, 0.585 mmol), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (115 mg, 0.146 mmol) and cesium carbonate (285 mg, 0.876 mmol) were added to ultradry 1,4-dioxane (5 mL). The reaction mixture was saturated with dry nitrogen and heated to 150 °C by microwave irradiation and stirred for 3 h, then cooled to room temperature. The mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography and reversed-phase HPLC to give the title compound (20 mg, 16%).

[1209] 1 H NMR(400MHz,DMSO-d 6 )δ11.75(s,1H),8.67(s,1H),8.57(d,J=3.2Hz,1H),8.44-8.36(m,1H),7.12(ddd,J=12.4,9.6,3.9Hz,1H),6.96(dd,J=8.0,3.9Hz,1H),6.70(s,1H),6.06(s,1H),4.53(d,J=4.9Hz,1H),3.33(s,2H),2.63(s,4H),2.01-1.63(m,9H),0.91(d,J=7.5Hz,2H),0.70(d,J=4.3Hz,2H).

[1210] MS m / z(ESI):429.2[M+H] + .

[1211] Example 13

[1212] 3-((3-exo)-3-((7-((5-(oxetan-3-yl)-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile

[1213]

[1214] The preparation of 3-((3-exo)-3-((7-((5-(oxetan-3-yl)-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile was carried out according to Example 12.

[1215] MS m / z(ESI): 445.2 [M+H] + .

[1216] Example 14

[1217] 3-((3-exo)-3-((7-((5-(1-methylazetidin-3-yl)-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile

[1218]

[1219] The preparation of 3-((3-exo)-3-((7-((5-(1-methylazetidin-3-yl)-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile was referred to Example 12.

[1220] MS m / z(ESI): 458.3 [M+H] + .

[1221] Example 15

[1222] 3-((3-exo)-3-((7-((4,5-dimethyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-

[1223] azabicyclo[3.2.1]octan-8-yl)propanenitrile

[1224]

[1225] The preparation of 3-((3-exo)-3-((7-((4,5-dimethyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile was referred to Example 12.

[1226] 11H NMR (400 MHz, DMSO-d6) δ 8.76 (dd, J = 4.2, 1.3 Hz, 1H), 8.60 (d, J = 8.2 Hz, 1H), 7.44 (d, J = 8.4 Hz, 1H), 7.24 (dd, J = 8.3, 4.4 Hz, 1H), 7.10 (s, 1H), 4.97 (s, 2H), 4.52 (dd, J = 16.9, 8.1 Hz, 1H), 3.33 (s, 2H), 2.66 (dd, J = 10.4, 2.9 Hz, 7H), 1.92 (ddd, J = 5.9, 3.4, 1.8 Hz, 2H), 1.85 (s, 3H), 1.72 (ddd, J = 20.9, 11.4, 4.3 Hz, 6H).

[1227] MS m / z (ESI): 417.1 [M+H] + .

[1228] Example 16

[1229] 3 - ((3-exo)-3 - ((7 - ((4-fluoro-5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile

[1230]

[1231] The preparation of 3 - ((3-exo)-3 - ((7 - ((4-fluoro-5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile was carried out with reference to Example 12.

[1232] MS m / z (ESI): 421.2 [M+H] + .

[1233] Example 17

[1234] 3 - ((3-exo)-3 - ((7 - ((5-methoxy-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-

[1235] azabicyclo[3.2.1]octan-8-yl)propanenitrile

[1236]

[1237] The preparation of 3 - ((3-exo)-3 - ((7 - ((5-methoxy-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile was carried out with reference to Example 12.

[1238] MS m / z (ESI): 419.2 [M+H] + .

[1239] Example 18

[1240] 3-((3-exo)-3-((7-((5-(Methoxymethyl)-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile

[1241]

[1242] 3-((3-exo)-3-((7-chloro-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile (72 mg, 0.21 mmol), 2-(2-aminothiazol-5-yl)propan-2-ol (54 mg, 0.42 mmol), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (83 mg, 0.105 mmol) and cesium carbonate (205 mg, 0.63 mmol) were added to ultradry 1,4-dioxane (10 mL). The reaction mixture was saturated with dry nitrogen and heated to 150 °C with stirring in a microwave synthesizer for 7 h. It was cooled to room temperature, filtered, and the filtrate was concentrated under reduced pressure. The title compound was obtained by prep-HPLC separation (22.4 mg, 25%).

[1243] 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.57 (d, J = 3.5 Hz, 1H), 8.50 (d, J = 8.6 Hz, 1H), 7.07 (dd, J = 8.0, 4.7 Hz, 1H), 6.74 (s, 1H), 6.35 (s, 1H), 4.63 (td, J = 10.8, 6.1 Hz, 1H), 4.43 (s, 2H), 3.71 - 3.48 (m, 2H), 3.35 (s, 3H), 2.93 (s, 2H), 2.75 (s, 2H), 2.23 - 1.75 (m, 8H).

[1244] MS m / z (ESI): 433.2 [M+H] + .

[1245] Example 19

[1246] 3-((3-exo)-3-((7-((5-(Hydroxymethyl)-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile

[1247]

[1248] 3-((3-exo)-3-((7-Chloro-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile (100 mg, 0.292 mmol), (3-Amino-1H-pyrazol-5-yl)methanol (66 mg, 0.584 mmol), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (115 mg, 0.146 mmol), and cesium carbonate (286 mg, 0.877 mmol) were added to ultradry 1,4-dioxane (15 mL). The reaction mixture was saturated with dry nitrogen and heated to 150 °C with stirring in a microwave synthesizer for 6 h. It was cooled to room temperature, filtered, and the filtrate was concentrated under reduced pressure. The title compound was obtained by separation on prep-HPLC (15.7 mg, 13%).

[1249] 1 H NMR(400MHz,DMSO-d 6 ) δ 11.94 (s, 1H), 8.77 (s, 1H), 8.58 (d, J = 3.3 Hz, 1H), 8.41 (d, J = 8.1 Hz, 1H), 7.13 (s, 1H), 6.97 (dd, J = 7.9, 4.4 Hz, 1H), 6.72 (s, 1H), 6.24 (s, 1H), 5.20 (d, J = 1.8 Hz, 1H), 4.53 (dd, J = 6.8, 4.2 Hz, 1H), 4.45 (d, J = 5.2 Hz, 2H), 3.33 (s, 2H), 2.63 (s, 4H), 1.95 - 1.87 (m, 2H), 1.80 (dd, J = 13.3, 7.7 Hz, 4H), 1.75 - 1.67 (m, 2H).

[1250] MS m / z(ESI): 419.2 [M + H] + .

[1251] Example 20

[1252] 3-((3-exo)-3-((7-((5-(2-Hydroxypropan-2-yl)-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile

[1253]

[1254] The preparation of 3 - ((3 - exo) - 3 - ((7 - ((5 - (2 - hydroxypropan - 2 - yl) - 1H - pyrazol - 3 - yl)amino) - 1,6 - naphthyridin - 5 - yl)amino) - 8 - azabicyclo[3.2.1]octan - 8 - yl)propanenitrile was referred to Example 2.

[1255] MS m / z(ESI): 447.3[M + H] + .

[1256] Example 21

[1257] 3 - ((5 - (((3 - exo) - 8 - (2 - cyanoethyl) - 8 - azabicyclo[3.2.1]octan - 3 - yl)amino) - 1,6 - naphthyridin - 7 - yl)amino) - 1H - pyrazole - 5 - carboxamide

[1258]

[1259] The preparation of 3 - ((5 - (((3 - exo) - 8 - (2 - cyanoethyl) - 8 - azabicyclo[3.2.1]octan - 3 - yl)amino) - 1,6 - naphthyridin - 7 - yl)amino) - 1H - pyrazole - 5 - carboxamide was referred to Example 2.

[1260] MS m / z(ESI): 432.2[M + H] + .

[1261] Example 22

[1262] 3 - ((5 - (((3 - exo) - 8 - (2 - cyanoethyl) - 8 - azabicyclo[3.2.1]octan - 3 - yl)amino) - 1,6 - naphthyridin - 7 - yl)amino) - N - methyl - 1H - pyrazole - 5 - carboxamide

[1263]

[1264] The preparation of 3 - ((5 - (((3 - exo) - 8 - (2 - cyanoethyl) - 8 - azabicyclo[3.2.1]octan - 3 - yl)amino) - 1,6 - naphthyridin - 7 - yl)amino) - N - methyl - 1H - pyrazole - 5 - carboxamide was referred to Example 2.

[1265] MS m / z(ESI): 446.2[M + H] + .

[1266] Example 23

[1267] 3-((3-exo)-3-((7-((2-methyl-1H-imidazol-4-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile

[1268]

[1269] The preparation of 3-((3-exo)-3-((7-((2-methyl-1H-imidazol-4-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile was carried out with reference to Example 6.

[1270] MS m / z(ESI):403.2[M+H] + .

[1271] Example 24

[1272] 3-((3-exo)-3-((7-((5-methyl-1H-1,2,4-triazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile

[1273]

[1274] ...

Claims

1. A compound of formula (VIII) or a pharmaceutically acceptable salt thereof: Wherein ： M 1 is CH; R 12 is a hydrogen atom; L 1 Selected from C 1-4 alkylene or -(CH 2 ) n1 C(O)(CH 2 ) m1 -; L 2 selected from -NR 4 ; Ring C is selected from R 1 a 4- to 6-membered monocyclic heteroaryl group selected from a fluorine atom, a cyano group, and one or more heteroatoms selected from N and O, having 1 to 3 heteroatoms; R 3 selected from a hydrogen atom, a cyano group, C 1-3 alkyl, C 1-3 hydroxyalkyl or -C(O)NH 2 ; R 4 selected from a hydrogen atom; R 7 selected from a hydrogen atom; m 1 is 0, 1 or 2; n 1 is 0, 1, or 2; y is an integer of 0, 1 or 2; and z is an integer of 0, 1 or 2.

2. The compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein, R 1 The 4- to 6-membered monocyclic heteroaryl group described in 3. A compound or a pharmaceutically acceptable salt thereof as shown below, and the compound structure is as follows:

4. A compound or a pharmaceutically acceptable salt thereof as shown below, and the compound structure is as follows:

5. A pharmaceutical composition comprising a therapeutically effective dose of the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1-4 and one or more pharmaceutically acceptable carriers, diluents or excipients.

6. Use of the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1-4, or the pharmaceutical composition according to claim 5 in the preparation of a JAK inhibitor drug.

7. Use of the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1-4, or the pharmaceutical composition according to claim 5 in the preparation of a drug for treating inflammatory diseases and tumor diseases, wherein the inflammatory diseases are selected from rheumatoid arthritis, dermatitis, psoriasis, inflammatory bowel disease, and the tumor diseases are selected from myelofibrosis, polycythemia vera and essential thrombocythemia, acute myelocytic leukemia, acute lymphocytic leukemia, ductal carcinoma of the breast and non-small cell lung cancer, and the inflammatory bowel disease is a chronic intestinal inflammatory disease.

8. The use according to claim 7, wherein, The chronic intestinal inflammatory disease is selected from ulcerative colitis and Crohn's disease.

Images